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UABSTRACT 
 
Characterisation of pathogenic markers in acute myeloid leukaemia (AML) may benefit 
patients through refinement of risk stratification, application of molecularly targeted 
therapy and improved understanding of AML biology. Whilst the presence of an 
internal tandem duplication (ITD) within the fms-like tyrosine kinase-3 (FLT3) gene is 
known to predict adverse outcome in young adults with AML, the clinical significance 
of activating mutations in the tyrosine kinase domain (TKD) of FLT3 is unclear. 
Therefore, a highly sensitive and specific denaturing-HPLC technique was developed to 
screen for FLT3/TKDs in 1339 young adult patients with AML. Mutations were 
detected in 161 (12%) cases, with a high incidence in patients with inv(16) (24%; 
P=.009), a group in which FLT3/ITDs are uncommon. Unlike FLT3/ITDs, FLT3/TKDs 
were associated with a favourable long-term outcome with a 10-year overall survival 
(OS) of 36% for FLT3 WT, 51% for FLT3/ITD
-TKD
+ and 24% for FLT3/ITD
+TKD
- 
patients (P<.001). The relative FLT3/TKD mutant level was highly variable with the 
favourable prognosis residing in those patients with greater than 25% mutant alleles 
(10-year OS of 59%), possibly reflecting the stage at which the mutation is acquired. 
The mechanism of FLT3 activation also influenced sensitivity to FLT3-inhibitor 
induced cytotoxicity, with FLT3/ITD
+ blast cells more sensitive than FLT3/TKD
+ cells. 
Following lentiviral transduction, FLT3/ITD-transduced 32Dcl3 and Ba/F3 cells 
demonstrated more rapid proliferation than FLT3/TKD-transduced cells. In an NB4 cell 
line model of ATRA-induced myeloid differentiation, the presence of a FLT3/ITD 
inhibited differentiation unlike a FLT3/TKD mutation which increased differentiation. 
Furthermore, FLT3/ITD-transduced CD34 positive haematopoietic stem cells showed 
greater cytokine-free survival of colony forming cells than FLT3/TKD-transduced cells. 
Signalling studies also revealed that a FLT3/ITD induced stronger STAT5 activation 
than a FLT3/TKD mutation. This unexpected genotype-phenotype relationship is of 
direct relevance to current clinical decision making in AML, and may also provide 
insights into mechanisms of chemoresistance. 
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12BUCHAPTER 1: INTRODUCTION 
 
Acute myeloid leukaemia (AML) is a malignant disease of haematopoietic cells 
characterised by the accumulation of a clonal population of abnormal myeloid cells in 
the bone marrow (BM).  The defining feature of AML is an increase in myeloid blast 
cells, which have failed to mature into normal haematopoietic cells due to a block in 
differentiation. These blast cells expand within the BM, frequently resulting in failure of 
normal haematopoiesis and spillage of leukaemic cells into the peripheral blood (PB) 
leading to a leukocytosis. AML affects patients of all ages with an overall annual 
incidence of 3.5 per 100,000. The incidence increases with age, and consequently the 
majority of cases of AML occur in elderly patients (>60 years) with a median age of 
presentation of 65 years. One of the most striking features of AML is the heterogeneity 
of this disease both in terms of the disease biology and clinical presentation. It may, 
therefore, be more accurate to describe AML as a group of related disorders rather than 
a single disease entity. The study of clinical and biological features of large cohorts of 
patients has allowed different subtypes of AML to be more clearly defined, with 
important clinical implications.  
 
The work presented in this thesis addresses the clinical and biological implications of 
different types of mutation of the fms-like tyrosine kinase 3 (FLT3) gene in AML. In 
order to understand this work in an appropriate context, this chapter will provide an 
overview of the demographics, diagnosis, treatment, prognosis and the cellular and 
molecular pathogenesis of AML. Discussion of the specific biology and clinical 
relevance of FLT3 mutations is provided in the introductions to Chapters 3 to 7.  
 
1.1  21BUClinical presentation of AML 
 
The clinical features of AML at presentation are diverse and relate to the consequences 
of PB cytopenias or direct leukaemic cell infiltration. Patients may present with 
lethargy, bleeding or infection relating to anaemia, thrombocytopenia and neutropenia 
respectively. Leukaemic infiltration may occur in any organ, but most commonly affects 
the spleen, liver, gums, skin or central nervous system, leading to a wide variety of 
possible symptoms or clinical signs. There is also a variable rapidity of disease onset, 
with some patients presenting with a relatively indolent disease over many months and  
19
others presenting with a very rapidly progressive disease with hyperleukocytosis and 
consequent leukostasis with neurological and pulmonary consequences. These various 
clinical manifestations are likely to reflect the heterogeneity of AML at a biological 
level. 
 
1.2  22BUDiagnosis and classification of AML 
 
Historically, the diagnosis of AML was based purely on the appearance of the 
leukaemic blast cells in the PB or BM under light microscopy using a variety of 
different cytochemical stains. Current classification systems use the presence of over 
20% leukaemic blast cells in the bone marrow as the defining feature of AML. The 
initial diagnosis of AML is still largely dependent on morphology and cytochemistry, 
although flow cytometry, cytogenetic and molecular techniques are becoming 
increasingly important in sub-classification. These different techniques have formed the 
basis of different classification systems to stratify cases of AML into defined subtypes. 
 
1.2.1  54BFrench American British (FAB) classification 
At a morphological level, the heterogeneity of AML is evidenced by a marked variation 
in the degree and lineage type of haematopoietic differentiation seen. Since 1976, AML 
has been classified according to the criteria of the FAB group which defines subgroups 
on the basis of the morphological appearance in combination with cytochemical stains 
and, to a certain extent, immunological methods (Bennett et al, 1976, Bennett et al, 
1985). The FAB system of classification of AML is shown in Table 1.1. 
 
1.2.2  55BSecondary and therapy related AML 
Whilst the majority of cases of AML occur sporadically, some arise on a background of 
a previous bone marrow disorder such as myelodysplasia (MDS) or a myeloproliferative 
disease (MPD), these cases are known as secondary AML (sAML), as opposed to de 
novo AML. A third group arise as a result of previous chemotherapy or radiotherapy 
and these cases are known as therapy related AML (tAML). The FAB classification 
system takes no account of de novo, sAML or tAML.  
 
1.2.3  56BRecurrent cytogenetic abnormalities in AML 
Following the development of the FAB classification of AML, metaphase cytogenetic 
analysis of leukaemic blasts led to recognition of a number of recurrent cytogenetic  
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abnormalities in a substantial proportion of patients with AML (Table 1.2). Using 
conventional cytogenetic analysis, approximately 50% of patients have an abnormal 
karyotype (Grimwade et al, 1998). These abnormalities often correlate with specific 
morphological subgroups and, as discussed below, have become an essential component 
of AML classification, as the presence of some abnormalities can lead to modification 
of therapy. There has consequently been a move towards classification systems that 
incorporate these cytogenetic abnormalities. In view of the importance of the detection 
of some of these abnormalities, reverse transcriptase polymerase chain reaction (RT-
PCR) and fluorescent in situ hybridization are now routinely used to improve the rates 
of detection of the t(8;21) (AML1/ETO, AML1 and eight twenty-one), inv(16) 
(CBFβ/MYH11, core binding factor beta/myosin heavy chain 11) and t(15;17) 
(PML/RARα, promyelocytic leukaemia and retinoic acid receptor α) fusion genes above 
that of conventional cytogenetic analysis alone (Grimwade et al, 1997, Langabeer et al, 
1997a, Langabeer et al, 1997b).  
 
1.2.4  57BWorld health organisation (WHO) classification 
The WHO classification has updated and largely superseded the FAB classification 
system through a number of important modifications (Harris et al, 1999). The blast 
percentage required for the diagnosis of AML is now defined as 20%, as opposed to the 
previous cut-off of 30%. Some non-random cytogenetic abnormalities have been 
included as separate subtypes of AML, irrespective of the morphological appearance or 
blast percentage. Other changes include separate categories for patients with sAML, 
tAML, associated multilineage dysplasia and novel morphologic categories. The full 
WHO classification is shown in Table 1.3. These changes represent an attempt to define 
specific biological and clinical entities within AML by correlating clinical, 
morphological, immunological and genetic information. These approaches are at a 
relatively early stage and it is likely that such classification systems will be 
continuously refined as additional information on other molecular genetic information is 
accumulated and incorporated into them (see section 1.3.4).  
 
1.3  23BUPrognostic factors in patients with AML 
 
The majority of cases of AML occur in patients greater than 60 years of age, and in this 
group of patients the prognosis is dismal, with 5-year overall survival (OS) rates 
generally less than 10%. Furthermore, there has been little improvement in outcome for   
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 Table 1.1: The French-American-British (FAB) classification of AML 
FAB subtype  Name  Cytochemistry  Immunology 
   MPO  SB  NSE   
M0  AML with minimal 
differentiation  - -  - 
Cells are positive for MPO 
or other myeloid markers by 
flow cytometry 
M1  AML without 
maturation  + +  -  N/A 
M2 AML  with  maturation  +  +  -  N/A 
M3  Acute promyelocytic 
leukaemia  + +  -  N/A 
M4 
Acute 
myelomonocytic 
leukaemia 
+ +  +  N/A 
M4 (Eo) 
Acute 
myelomonocytic 
leukaemia with 
abnormal eosinophils 
+ +  +  N/A 
M5  Acute monocytic 
leukaemia  - - +  N/A 
M6 Erythroleukaemia  +  +  -  N/A 
M7  Acute megakaryocytic 
leukaemia  - - +  Cells express CD41, CD42b 
or CD61 
MPO indicates myeloperoxidase; SB, sudan black; NSE, non-specific esterase; 
N/A, not applicable. 
 
 
Table 1.2: Recurrent, non-random cytogenetic abnormalities in AML, underlying 
molecular defect and correlation with morphology 
Cytogenetic 
abnormality 
Molecular defect  Incidence in the UK 
MRC AML10 trial 
Morphology 
t(15;17)  PML-RARα fusion gene  12% Acute  promyelocytic 
leukaemia (M3) 
+ 8  Unknown  9%  Various 
t(8;21)  AML1-ETO fusion gene  8%  AML with differentiation 
(M2) 
inv(16)  CBFβ-MYH11 fusion 
gene 
4% Acute  myelomonocytic 
leukaemia with abnormal 
eosinophils (M4Eo) and 
AML with differentiation 
(M2) 
11q23 abnormalities  Various MLL fusion 
genes 
4% Various 
-7 Unknown  4%  Various 
+21 Unknown  3%  Various 
abn(3q) Unknown  3%  Various 
del(7q) Unknown  2% Various 
del(5q) Unknown  2% Various 
+22 Unknown  1%  Various 
t(6;9) DEK-CAN  <1%  Acute  myeloblastic 
leukaemia with abnormal 
basophils 
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Table 1.3: The WHO classification of AML 
AMLs with recurrent cytogenetic translocations 
      AML with t(8;21)(q22;q22), AML1(CBF-alpha)/ETO 
      Acute promyelocytic leukaemia (AML with t(15;17)(q22;q11-12) 
          and variants, PML/RAR-alpha) 
      AML with abnormal bone marrow eosinophils (inv(16)(p13q22) 
          or t(16;16)(p13;q11), CBFb/MYH11) 
      AML with 11q23 (MLL) abnormalities 
AML with multilineage dysplasia 
      With prior myelodysplastic syndrome 
      Without prior myelodysplastic syndrome 
AML and myelodysplastic syndromes, therapy-related 
      Alkylating agent–related 
      Epipodophyllotoxin-related (some may be lymphoid) 
      Other types 
AML not otherwise categorized 
      AML minimally differentiated 
      AML without maturation 
      AML with maturation 
      Acute myelomonocytic leukaemia 
      Acute monocytic leukaemia 
      Acute erythroid leukaemia 
      Acute megakaryocytic leukaemia 
      Acute basophilic leukaemia 
      Acute panmyelosis with myelofibrosis 
Acute biphenotypic leukaemias 
 
 
this group of patients using conventional cytotoxic agents over the last few decades 
(Burnett and Mohite 2006). This adverse prognosis relates to a combination of innate  
drug resistance of the leukaemic cells combined with frequent co-morbidities. 
Improving outcome for elderly patients is therefore a major challenge. However, in 
view of the very poor outcome associated with older age alone, the identification of 
further prognostic factors is unlikely to be helpful in the vast majority of cases. The 
only exception to this would be the rare cases of elderly patients who have favourable 
cytogenetics (see below) which may allow the identification of patients who may be 
more likely to respond well to therapy. 
 
In contrast to the lack of improvement of outcome for elderly patients with AML, 
treatment in young adults with AML (age 18 to 60 years) has improved considerably 
over the last few decades such that 80% to 90% of young adults currently diagnosed 
with AML will enter complete remission (CR, defined as a normocellular BM aspirate  
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with normal trilineage maturation and less than 5% blasts) with conventional 
chemotherapeutic approaches (Burnett 2002a, Hann et al, 1997). Despite this success, 
however, over half of the patients who enter CR will suffer a relapse of their disease. 
Consequently, only approximately 50% of young adults diagnosed with AML will 
achieve long-term disease free survival (DFS). In view of the clinical and biological 
heterogeneity of AML, there has been considerable interest in identifying prognostic 
factors that may be useful in order to risk stratify patients and modify therapy 
accordingly. As the toxicity of conventional therapy in AML is considerable, it is 
possible that outcome could be improved by reducing the treatment intensity for 
patients with a favourable prognosis. Conversely, for patients with a predicted high 
relapse rate (RR), the intensity of treatment could be increased, or more experimental 
approaches used. This concept forms the basis of ‘risk-adapted therapy’ whereby the 
intensity of treatment is tailored to the specific prognosis of an individual case of AML. 
This thesis is focused on the group of young adult (<60 years) patients with AML and 
the following discussion of disease biology, prognostic factors and treatment in this 
chapter will be restricted to this group of patients. 
 
1.3.1  58BClinical Prognostic Factors 
Analysis of the UK Medical Research Council (MRC) AML 10 and 12 trials 
demonstrated that the percentage of blasts in the BM after the first course of 
chemotherapy is an important prognostic factor (Wheatley et al, 1999). For example, in 
the UK MRC AML 12 trial, patients with >15% blasts in the bone marrow after the first 
course of chemotherapy have a poor prognosis (OS at 5 years 26%) compared to 
patients with 5-15% blasts (OS 44%) or <5% blasts (OS 56%). Other clinical prognostic 
factors predicting adverse outcome include increasing age, male sex, secondary AML 
and high white blood cell count (WBC) at diagnosis (Wheatley et al, 1999).  
 
1.3.2  59BCytogenetic Risk Groups 
Given the frequency of recurrent cytogenetic abnormalities in AML, the prognostic 
implications of these abnormalities was of considerable interest but required large 
cohorts of patients for statistically robust conclusions to be drawn. The UK MRC AML 
trials allowed such analysis and showed that presentation cytogenetics is a major 
prognostic factor in AML (Grimwade et al, 1998). Consequently, patients are now 
routinely classified into favourable, intermediate or adverse cytogenetic risk groups. 
Favourable genetic abnormalities are t(8;21), inv(16), t(15;17). Patients with acute  
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promyelocytic leukaemia (APL) associated with the t(15;17) translocation have a 
particularly favourable prognosis and are now widely regarded as a biologically and 
clinically separate entity to non-APL AML. These patients are now treated with 
different protocols, including all-trans retinoic acid (Sanz 2006). Adverse genetic 
abnormalities are -5, -7, del(5q), abn (3q), t(9;22) or complex karyotype (five or more 
abnormalities). Intermediate risk karyotypes constitute all other patients not in the 
favourable or adverse risk groups.  
 
In the UK MRC AML 10 trial, of the 83% of patients with karyotype data available, 
24% showed translocations associated with a good prognosis, 59% fell into the 
intermediate and 17% into the adverse cytogenetic category. In the UK MRC AML12 
trial, the 5-year overall survival of patients in each of these three groups was 73% for 
patients with a favourable karyotype, 44% for those with intermediate cytogenetics and 
17% in the adverse cytogenetic group. If other cytogenetic abnormalities occur in 
addition to one of the favourable cytogenetic markers, these patients still fall into the 
favourable cytogenetic category. A major limitation of cytogenetic risk classification, 
however, is that a large proportion (approximately 50%) of patients with non-APL 
AML fall into an intermediate-risk cytogenetic group and karyotype is therefore not 
informative. 
 
1.3.3  60BCombining different prognostic factors 
Using a combination of cytogenetics and response to the first induction chemotherapy 
course, a prognostic index has been devised for use in risk stratification in the MRC 
AML trials (Table 1.4) (Wheatley et al, 1999). Essentially, this prognostic index 
changes the status of intermediate cytogenetic patients with >15% blasts after course 1 
into a poor prognostic group. The 5-year OS in the AML 12 trial in these risk groups 
was 76%, 48% and 21% in the good, standard and poor risk groups respectively with 
RR of 25%, 52% and 73%. 
 
This prognostic index has been updated as additional data has been acquired through the 
MRC trials. The new index planned for use in the UK MRC AML17 trial takes into 
account patient age, sex, de novo versus secondary AML, cytogeneic risk group, white 
blood cell count at diagnosis and BM blast percentage following cycle 1.  
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Table 1.4: Prognostic risk groups in AML 
Good risk      Any patient with favourable genetic abnormalities 
                           t(8;21), inv(16), t(15;17), irrespective of other genetic 
                           abnormalities or marrow status after course 1 
 
Standard        Any patient not in either good or poor risk groups 
 
Poor risk        Any patient with more than 15% blasts in the bone  
                           marrow after course 1 or with adverse genetic 
                           Abnormalities: -5, -7, del(5q), abn (3q), t(9;22) 
                           or complex (five or more abnormalities) 
                           and without favourable genetic abnormalities 
 
1.3.4  61BMolecular Prognostic Factors 
Given the limitations of conventional cytogenetics for prognostic stratification in AML, 
one of the key questions when a novel molecular abnormality is identified in AML is 
whether it is associated with a specific prognostic impact, particularly in the crucial 
group of patients with intermediate cytogenetics. Over the last few years, a number of 
these molecular markers have emerged as candidate additional prognostic factors. The 
most prominent of these, mutations of FLT3 are the subject of this thesis and discussed 
in more detail in Chapters 3, 4 and 5. However, other markers have been identified. For 
example, nucleophosmin-1 (NPM1) gene mutations are associated with a relatively 
favourable prognosis in patients with a normal karyotype (NK) (Falini et al, 2007, Gale 
et al, 2007). CCAAT/enhancer binding protein-α (CEBPA) gene mutations may also be 
associated with a relatively favourable prognosis in this group (Frohling et al, 2004, 
Preudhomme et al, 2002). Indeed, the recent update of the WHO classification system 
has included cases of AML with mutations of NPM1 or CEBPA as provisional entities 
(Swerdlow et al, 2008). Conversely, mixed lineage leukaemia (MLL) gene partial 
tandem duplications (Basecke et al, 2006, Dohner et al, 2002, Schnittger et al, 2000) 
and mutations in the Wilms Tumour-1 gene (WT1) (Paschka et al, 2008, Summers et al, 
2007, Virappane et al, 2008) are associated with an adverse prognosis. Interest in 
molecular markers has not only focused on somatic mutations but also over-expression 
of candidate genes. For example, high levels of expression of BAALC, WT1, EVI1 and 
ERG have all been shown to confer an adverse prognosis in young adults with AML 
(Baldus et al, 2003, Baldus et al, 2006, Barjesteh van Waalwijk van Doorn-Khosrovani 
et al, 2003, Barragan et al, 2004, Bergmann et al, 1997, Marcucci et al, 2005, Marcucci 
et al, 2007).  
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With such an abundance of different molecular markers of potential prognostic 
relevance, concerted efforts are required in order to determine which of these have 
actual clinical utility. As a number of these markers are relatively uncommon, to 
robustly determine their prognostic significance in AML is challenging, and this is 
complicated by the need to demonstrate that a marker acts independently of other 
known prognostic factors in a multivariate analysis.  Furthermore, in order to justify 
incorporation of a prognostic marker into a prospective, risk-adapted therapy approach 
to the treatment of AML, it is necessary to demonstrate that modification of therapy on 
the basis of the detection of one of these markers improves outcome for patients. 
Therefore, in order to translate this wealth of molecular information into actual benefit 
for patients, the challenge is to gather sufficient information from very large cohorts 
with long follow up, availability of diagnostic material for analysis and sufficient 
numbers of patients in different treatment groups to allow statistically sound 
comparisons.  
 
1.4  24BUConventional Chemotherapeutic Approaches in AML 
 
Whilst there has been a gradual improvement in outcome for young adults with AML 
over the last 3 decades, this has occurred despite the use of very similar therapeutic 
agents during this period. The key agents in the management of AML are cytarabine 
and anthracyclines, both of which are cell-cycle dependent. It is likely that much of this 
improved outcome relates to better standards of supportive care allowing the use of 
more intensive chemotherapy with a lower risk of treatment-related mortality (TRM) 
(Burnett 2002a). Therapy of young adults is generally divided into two phases, 
remission induction therapy followed by consolidation therapy. 
 
1.4.1  62BInduction Chemotherapy for non-APL AML 
The goal of induction therapy is to achieve a CR with recovery of normal 
haematopoiesis. For the UK MRC AML 10 and 12 trials, this was defined as a 
normocellular BM aspirate with normal trilineage maturation and less than 5% blasts 
without a requirement for regeneration of peripheral counts. In practice, 97% of patients 
who achieved the protocol prescribed definition of CR had peripheral regeneration of 
neutrophils to 1.0 x 10
9/L and platelets to 100 x 10
9/L. Standard induction 
chemotherapy in AML consists of cytarabine in combination with anthracyclines or  
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purine analogues. The use of different anthracyclines has not consistently affected 
outcome (Milligan et al, 2006).  Using this approach, up to 80% to 90% of patients will 
enter CR. Details of the induction regimens used in the MRC AML 10 and 12 trials are 
given in Chapter 4. 
 
1.4.2  63BConsolidation Chemotherapy 
Once a patient has achieved CR, further treatment to consolidate this remission is 
necessary as, due to the presence of residual leukaemic cells, the median DFS for 
patients who receive no additional therapy is only 4-8 months (Cassileth et al, 1998). 
High dose cytarabine is widely accepted to be the consolidation chemotherapy of choice 
in AML. The number of courses, dose of cytarabine and combinations with other 
agents, however, remains uncertain (Milligan et al, 2006). Whether a total of 4 or 5 
courses of chemotherapy are required is also uncertain. Details of the induction 
regimens used in the MRC AML 10 and 12 trials are given in Chapter 4. 
 
1.4.3  64BAutologous stem cell transplantation (SCT) 
The high RR associated with patients with non-APL AML who enter CR led to 
enthusiasm for the use of high dose therapy, usually a combination of total body 
irradiation and cyclophosphamide, followed by autologous transplantation with stem 
cell support, thereby allowing higher doses of chemotherapy or radiotherapy to be 
administered than could otherwise be tolerated. This approach has been shown to reduce 
the RR in a number of different trials. However, due to the additional toxicity of the 
procedure, an OS advantage has not been shown. Autologous transplantation has now 
therefore been largely abandoned as a consolidation therapy in current clinical trials. 
 
1.4.4  65BAllogeneic SCT 
Myeloablative, allogeneic SCT from a sibling or unrelated matched donor combines 
high dose chemotherapy with an additional graft versus leukaemia (GvL) effect. Most 
clinical trials have shown a clear benefit in terms of a reduction in RR using this 
approach. However the OS benefit, if any, is modest due to the increased toxicity 
associated with the procedure (Burnett 2002b) with TRM of between 15-35% in most 
clinical trials. Furthermore, the toxicity of this procedure increases with age and 
therefore myeloablative allogeneic SCT is generally restricted to adults less than 40 
years of age. By reducing the intensity of conditioning therapy prior to allogeneic SCT 
(RIC-SCT) the GvL effect can be harnessed without the toxicity associated with  
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myeloablative regimes. Preliminary data suggests that RIC-SCTs are a promising new 
treatment in AML, worthy of further evaluation in ongoing clinical trials (Tauro et al, 
2005, Taussig et al, 2003).  
 
1.4.5  66BAcute Promyelocytic Leukaemia (APL) 
It is now widely accepted that APL is a biologically and clinically distinct disease with 
specific diagnostic criteria and treatment protocols that are markedly different from 
those of non-APL AML (Sanz 2006).  As discussed above, the outcome for this group 
of patients using modern treatment approaches is favourable compared to non-APL 
AML. It is therefore extremely important to identify patients with APL using molecular 
techniques as well as conventional cytogenetics in order that they can be treated 
appropriately. Combination of all-trans retinoic acid (ATRA) with standard 
chemotherapy regimes during induction and/or consolidation results in high rates of CR 
and OS (70-75% at 5 years) in APL. It is not clear if high doses of myelosuppressive 
drugs are required to achieve such high rates of DFS as a Spanish trial group have 
shown that a combination of anthracycline and ATRA without other myelosuppressive 
drugs can achieve similar rates of remission (Sanz et al, 2004). A comparison of the two 
approaches was the purpose of the MRC AML 15 trial for patients with APL. This 
randomisation is now closed and the current recommendation is that patients are treated 
according to the Spanish protocol.  
 
1.5  25BURisk-adapted therapy 
 
A limited degree of risk-adapted therapy has been introduced into current AML 
treatment using the above prognostic factors (Table 1.4), although different approaches 
have been adopted by different groups. For example, the UK MRC approach is to 
exclude good risk patients from receiving an allogeneic SCT. Standard risk patients 
receive an allogeneic SCT if they have a matched sibling donor available and poor risk 
patients should receive a sibling or matched unrelated donor allogeneic SCT if a 
matched donor can be found. This approach is supported by a recent meta-analysis 
which used a ‘genetic randomisation’ to demonstrate that patients with favourable 
cytogenetics did not benefit from availability of a sibling donor, as opposed to those 
with non-favourable cytogenetics, i.e. standard and poor risk patients who had a 
survival advantage if a sibling donor was available (Cornelissen et al, 2007). In this  
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analysis, patients greater than 35 years did not benefit from the availability of a donor, 
although these data were accrued largely before the advent of RIC-SCTs.  
 
A major limitation of current risk stratification strategies is demonstrated by this 
analysis as only 15% of patients fell into the favourable cytogenetic category and 55% 
had intermediate risk cytogenetics, i.e. in the majority of patients, cytogenetics is not 
informative with regards to prognosis. This highlights the unmet need for additional 
prognostic factors that will help to stratify these heterogeneous intermediate risk 
patients into good and poor prognostic groups so that their therapy can be tailored 
appropriately. 
 
1.5.1  67BMonitoring for minimal residual disease (MRD) 
As relapse is the major cause of treatment failure in AML, the identification of markers 
for the detection of MRD in patients who are in morphological CR may also provide 
important prognostic information and allow a degree of response-adapted therapy. This 
approach has been used with a great deal of success in paediatric acute lymphoblastic 
leukaemia (ALL) treatment protocols (Coustan-Smith et al, 2000). There is also 
increasing evidence that monitoring for MRD in APL reliably identifies patients who 
would relapse in the absence of additional therapy (Lo-Coco et al, 2003). Whilst there is 
some evidence that earlier treatment at molecular rather than haematological relapse in 
APL may improve outcome (Esteve et al, 2007), this data remains controversial. At 
present, however, monitoring for MRD in non-APL AML remains an experimental tool 
for use in the context of clinical trials. It is important to recognise, however, that for any 
given MRD marker to be of clinical use the marker must be stable through the course of 
the disease i.e. present both at diagnosis and relapse. 
 
1.6  26BUMolecular and cellular pathogenesis of AML 
 
Understanding the biology of malignant diseases at the cellular and molecular level is 
essential to refine diagnostic and/or classification strategies, improve risk stratification 
approaches, detect novel markers for MRD analysis and develop novel therapies. In 
view of this, major efforts have been made over the last 2 decades to identify genes that 
are mutated in malignancies, including AML. A key group of genes that are 
dysregulated in cancers are known as oncogenes.  
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1.6.1  68BOncogenes 
An oncogene can broadly be defined as a protein encoding gene which, when 
deregulated, participates in the onset and development of cancer. The landmark 
description of oncogene-induced cancer growth was made through the study of Rous 
Sarcoma Virus-transformed cells (Martin 1970). The subsequent characterisation of the 
retroviral oncogene v-src and its normal cellular counterpart c-src by J. Michael Bishop 
and Harold E. Varmus led to the award of the Nobel Prize in Medicine in 1989 (Marx 
1989). Oncogenes encode proteins that are involved at any stage of the control of cell 
cycle and/or apoptosis regulation, thus dysregulation leads to increased cell proliferation 
and/or survival signals. They can be categorised into six main groups:  
 
•  Growth factors e.g. INT2 in breast cancer 
•  Growth factor receptors (GFRs) e.g. FLT3 in AML 
•  Signal transduction proteins e.g. H-RAS in colon cancer 
•  Transcription factors e.g. MYC in Burkitt lymphoma 
•  Chromatin remodelers e.g. MLL in AML or ALL 
•  Apoptosis regulators e.g. BCL2 in lymphomas 
 
Dysregulation of oncogenes in human malignant diseases usually occurs through 
somatic genetic events or mutations, although it may also occur on the background of a 
germ-line genetic predisposition to cancer or through epigenetic events (Croce 2008). 
Early evidence that human cancer arises due to somatic genetic events arose from 
studies of Burkitt lymphoma. It was shown that translocation of the MYC oncogene to 
enhancer regions of the immunoglobulin gene loci led to overexpression of the MYC 
protein (Croce et al, 1983, Dalla-Favera et al, 1982). Furthermore, transgenic mice 
overexpressing MYC developed fatal lymphomas with a short latency (Adams et al, 
1985). Overexpression of oncogenes can also arise through a number of different 
mechanisms in addition to oncoretroviral or chromosomal translocation related events 
including gene amplification indirectly through mutation of a gene involved in 
regulation of expression of the protein. Oncogenes can also be activated by somatic 
mutation of the gene, abnormal expression of isoforms or gene fusion leading to 
constitutive activation of the protein product. An early example of an activating 
mutation of a human oncogene was the H-RAS and K-RAS oncogenes, as demonstrated 
by transfecting mouse fibroblasts with genetic material from bladder and colon cancer 
cell lines respectively (Capon et al, 1983, McCoy et al, 1983). When mutated in codons  
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12, 13 or 61, these RAS signal transduction genes encoded a protein that was 
constitutively activated, irrespective of the normal cellular control mechanisms. This, in 
turn, led to continuous activation of downstream signalling proteins, with the end result 
of an increased rate of cell proliferation and survival signalling. The recognition of the 
central role of mutated oncogenes in human malignancy, and their potential diagnostic 
and therapeutic importance, subsequently induced major efforts to identify dysregulated 
oncogenes in a wide range of different malignancies. 
 
1.6.2  69BMutations in growth factor receptors in AML 
Despite extensive efforts to identify activated oncogenes in AML, by the mid-1990s, 
these remained largely unknown. Mutations in N-RAS and K-RAS  had been identified, 
but these were relatively uncommon in AML, occurring in less than 20% of cases (Bos 
et al, 1985, Bowen et al, 2005). Therefore, aside from the recurrent cytogenetic 
translocations described above, the somatic events leading to oncogene activation in the 
majority of cases of AML remained unknown. As haematopoiesis is controlled by 
haematopoietic growth factors binding to their respective receptors, many studies 
attempted to identify GFRs that may be aberrantly activated in AML. Such 
haematopoietic GFRs fall into two main categories. Firstly, receptor tyrosine kinases 
(RTKs) such as c-Fms, c-Kit and FLT3 with intrinsic tyrosine kinase activity. Secondly, 
haemopoietin receptors such as erythropoietin receptor (EPO-R), thrombopoietin 
receptor, interleukin-3 receptor (IL-3R), IL-5R, granulocyte colony stimulating factor 
receptor (G-CSFR) and granulocyte macrophage colony stimulating factor receptor 
(GM-CSFR). This latter group do not have intrinsic tyrosine kinase activity and 
associate non-covalently with intracellular tyrosine kinases. 
 
However, despite biological evidence of a possible role for GFR mutations in AML 
(Longmore and Lodish 1991), up to the mid-1990s, screening of the haemopoietin 
receptors GM-CSF (Decker et al, 1995, Freeburn et al, 1998), EPO-R (Le Couedic et al, 
1996) and G-CSF (Forbes et al, 2002) as well as the RTKs c-Fms and c-Kit (Arland et 
al, 1994) suggested that such activating mutations were rare events in AML. However, 
the detection of activating mutations in the RTK FLT3 in one quarter of young adults 
with AML (Nakao et al, 1996) heralded a new era in the understanding of genetic 
events underlying AML pathogenesis. The subsequent characterisation of these FLT3 
mutations are discussed in more detail in the introductions of Chapters 3 to 7. 
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1.6.3  70BCooperating genetic events in leukaemogenesis 
Transformation of a normal haematopoietic cell into a leukaemic cell requires not only 
an abnormal proliferative or survival signal, which may arise from an activated 
oncogene, but also an abnormal capacity for haematopoietic differentiation as well as 
maintenance of self-renewal capacity (Kelly and Gilliland 2002). Therefore, unless a 
single genetic event is sufficient to confer all of the above properties to a 
haematopoietic cell, a number of cooperating genetic events are necessary for the 
development of AML. This has been simplified as a ‘two-hit’ model of 
leukaemogenesis with class I mutations conferring a proliferative and/or survival 
advantage and class II mutations impairing haematopoietic cell differentiation (Kelly 
and Gilliland 2002).  
 
Cloning of the chromosomal translocation breakpoints associated with AML has 
identified, in many cases, fusion genes that are directly implicated in leukaemogenesis 
(Kelly and Gilliland 2002). The fusion genes involve transcription factors or 
coactivators of transcription in the majority of cases. Some genes are involved in 
multiple different chromosomal translocations, e.g. the CBF complex and RARα, which 
are both important in the regulation of normal haematopoiesis. Dysregulation of these 
genes leads to impairment of haematopoietic differentiation and/or increased self-
renewal capacity but may not confer a marked proliferative advantage to a cell, i.e. they 
are type II mutations. Experimental evidence for this derives from a number of animal 
models of leukaemia where artificial expression of PML/RARα, AML1/ETO or inv(16) 
alone leads to impairment of haematopoietic differentiation and expansion of the stem 
cell pool but not an overt leukaemic phenoptype (Castilla et al, 1999, Grisolano et al, 
1997, He et al, 1997, Higuchi et al, 2002). Leukaemia only developed if the animals 
were exposed to chemical mutagens such as n-ethyl-n-nitrosourea, suggesting that 
additional genetic events (type I mutations) are required for a leukaemic phenotype. 
Similarly, expression of an activated RAS or FLT3 in a mouse model leads to a 
myeloproliferative phenotype but not acute leukaemia (Kelly et al, 2002b, MacKenzie 
et al, 1999). Expression of both activated FLT3 and PML/RARα leads to the 
development of acute leukaemia with high penetrance and short latency (Kelly et al, 
2002a).  
 
Further supporting evidence for the concept of collaborating genetic events in AML 
derives from the observation in humans that germline mutation of AML1 alone is  
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insufficient for the development of AML and further mutations later in life are required 
for the development of leukaemia (Song et al, 1999). This is in keeping with 
observations in ALL that the TEL/AML1 fusion gene is present at birth in children who 
went on to develop ALL later in life as assessed by polymerase chain reaction (PCR) 
analysis of genomic DNA (gDNA) from Guthrie cards (Wiemels et al, 1999). Studies in 
syngeneic twins have also shown that a ‘pre-leukaemic’ TEL/AML1 positive clone is 
likely to predate the development of ALL, again suggesting that a second mutation is 
required for development of leukaemia (Hong et al, 2008).  
 
In view of these multiple lines of evidence, it is now widely accepted that the majority 
of cases of AML are caused by cells which have acquired a series of genetic ‘hits’ over 
time. Exactly how many ‘hits’ are required for leukaemia development, however, 
remains uncertain (Rangarajan et al, 2004). A particular exception to this, however, 
may occur with MLL fusion genes that may be sufficient alone to cause acute 
leukaemia (Barabe et al, 2007).  
 
1.6.4  71BLeukaemic stem cells 
Understanding the cellular as well as genetic basis of AML is also important with 
regards to improving diagnosis and therapy. This is because AML not only 
demonstrates heterogeneity between cases, but also cells within a particular leukaemic 
clone can have different biological characteristics. For example, an early study using 
tritiated thymidine incorporation in two adults with leukaemia showed that only a small 
proportion (5.6% and 6.1% respectively) of the blast cells in the bone marrow were 
actively proliferating (Clarkson et al, 1967). This may have important implications for 
the therapy of AML which mostly relies on cell cycle-dependent agents. One of the 
most important questions with regards to this heterogeneity within a particular 
population of leukaemic cells is whether all cells are capable of propagating and 
renewing the leukaemia. It has become increasingly apparent that this is not the case 
and that leukaemic cells form a hierarchy, in a similar way to normal tissues, with stem 
cells giving rise to progenitor cells, in turn giving rise to more mature, blast cells.  
Consequently, only a certain fraction of the leukaemic cells, leukaemic stem cells 
(LSCs), are capable of renewing the complete leukaemic hierarchy. These LSCs are 
likely to be similar to the target cell of transformation and also, importantly, in patients 
who enter CR, LSCs are likely to be the cells that are responsible for relapse. 
Identifying the cellular phenotype of these cells may therefore allow their specific  
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targeting with therapeutic agents. The definitive studies with regards to this used non-
obese diabetic mice with severe combined immunodeficiency (NOD-SCID) to 
demonstrate that only approximately 1 in 10
6 cells within a leukaemic population are 
capable of initiating a leukaemia in this transplantation model (Bonnet and Dick 1997). 
Using fluorescence activated cell sorting (FACS) these studies demonstrated that these 
NOD-SCID leukaemia initiating cells (SL-ICs) have a CD34+CD38- cell surface 
phenotype. These SL-ICs share a number of biological features associated with stem 
cells in that they have extensive proliferative and self-renewal capacity but differ in that 
they have an impaired capacity to differentiate into normal, mature haematopoietic 
cells. There is, however, still considerable uncertainty as to whether these LSCs are 
formed by damage to normal haematopoietic stem cells (HSCs) or whether 
haematopoietic progenitor cells (HPCs) acquire the genetic hits that therefore confer 
stem cell-like properties. There is some evidence for the latter in mouse models 
(Kirstetter et al, 2008, Krivtsov et al, 2006) but this needs to be recapitulated in human 
model systems. The frequency of LSCs is also controversial with some mouse models 
suggesting that LSCs are relatively frequent within the leukaemic hierarchy (Kelly et al, 
2007, Krivtsov et al, 2006, Somervaille and Cleary 2006) and that the apparent very low 
frequency of SL-ICs in previous studies may have been due to inefficiencies of 
xenotransplantation.  
 
Despite the controversy with regards to the frequency of LSC, there is wide acceptance 
that these LSCs exist and that they have a very high self-renewal capacity combined 
with impaired differentiation capability. Due to their lack of proliferative capacity, 
current cell-cycle dependent therapeutic strategies are unlikely to target this type of cell 
and therefore the current challenge is to identify novel therapeutic agents that may 
selectively target these LSCs. In order to achieve this, it is essential to understand how 
individual oncogenes disrupt the process of differentiation, proliferation and self-
renewal in leukaemia. 
 
1.7  27BUNovel Therapeutic Approaches in AML 
 
The importance of different cytogenetic abnormalities in predicting the response to 
therapy suggests that an increased understanding of the underlying molecular defects in 
AML may in turn provide insights into the mechanisms of chemoresistance in AML. 
Furthermore, the identification of some of the molecular defects underlying recurrent  
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cytogenetic abnormalities may have more direct therapeutic benefits. For example, the 
identification of the PML-RARα fusion gene in over 95% of cases of APL with t(15;17) 
led to the use of ATRA in this disorder with profound therapeutic benefits (Lo-Coco 
and Ammatuna 2006, Mistry et al, 2003). RARα is a member of the RA nuclear receptor 
family and is a ligand-inducible transcriptional activator through histone acetylation. 
The PML-RARα fusion protein acts as an aberrant receptor leading to altered DNA-
binding affinities and repression of normal RA signalling. This leads to the 
differentiation block in haematopoiesis that characterises APL. Administration of supra-
physiological levels of ATRA leads to a conformational change in the PML-RARα 
fusion protein and consequent activation of previously repressed RARα target genes. 
Furthermore, ATRA induces the degradation of the PML-RARα fusion protein through 
the ubiquitin/proteasome system. Thus, ATRA is directly targeting the underlying 
molecular defect in AML. The dramatically improved rates of DFS using ATRA-based 
therapeutic approaches in APL has led to enthusiasm for the development of other such 
therapeutic approaches targeting other recurrent molecular defects in AML.  
 
1.7.1  72BTargeted inhibitors 
Oncogenic proteins in cancer cells can be targeted using small molecules which 
specifically inhibit an activated oncogene. The remarkable success of imatinib in the 
treatment of chronic myeloid leukaemia (CML) is the paradigm for this approach, and 
this is discussed in more detail in Chapter 6. 
 
1.7.2  73BOther novel therapies 
Whilst the addition of higher doses or more courses of conventional chemotherapy is 
effective at reducing the risk of relapse in AML, this has to be balanced against the 
additional toxicity that arises as a result. Monoclonal antibody therapy is an alternative 
to conventional cytotoxic agents in that the specificity of the antibody allows the 
leukaemic cells to be targeted whilst minimising toxicity. A humanised anti-CD33 
monoclonal antibody conjugated to calicheamicin has demonstrated considerable 
efficacy in the treatment of high-risk relapsed or refractory patients with AML and is 
currently being assessed in large phase 3 clinical trials (Pagano et al, 2007). Other 
approaches aim to modify drug resistance mechanisms, epigenetic changes, 
angiogenesis and apoptotic mechanisms (Stone 2007).  
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1.8  28BUAims of this thesis 
 
FLT3 mutations in AML are heterogeneous with 2 main classes of mutation, internal 
tandem duplications (ITDs) and  tyrosine kinase domain (TKD) mutations. The 
objective of the studies described in this thesis was to compare and contrast the 
incidence (Chapter 3), clinical implications (Chapters 4 and 5) and biological impact 
(Chapter 7) of these different types of mutation in AML as well as the impact of FLT3 
inhibitors according to FLT3 mutations status (Chapter 6). 
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2   13BUCHAPTER 2: MATERIALS AND METHODS 
 
Specific methods are discussed in the relevant results chapter (Chapters 3-7).  
 
2.1  29BUCell Culture 
 
2.1.1  74BCell lines 
•  293T   human embryonal kidney line, adherent, growth factor 
independent 
•  32Dcl3   murine myeloid line, non-adherent, growth factor dependent 
•  Ba/F3    murine pro-B line, non-adherent, growth factor dependent 
•  HeLa   human cervical carcinoma line, adherent, growth factor 
independent 
•  NB4   human promyelocytic leukaemia line, non-adherent, growth 
factor independent 
 
2.1.2  75BCell culture general reagents 
•  0.25% Trypsin-EDTA (Invitrogen, Paisley, UK) 
•  0.4% Trypan Blue (Sigma Aldrich, Poole, UK) 
•  Antibiotic-Antimycotic Solution (Sigma Aldrich, Poole, UK) 
•  Calibration beads for flow cytometry (Dako, Glostrup, Denmark) 
•  Dimethyl sulfoxide (Sigma Aldrich, Poole, UK) 
•  Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Paisley, UK) 
•  Ficoll-Paque™ gradient (Amersham Biosciences, Bucks, UK) 
•  Foetal calf serum (FCS), heat inactivated for 30 minutes at 56°C (PAA 
Laboratories, Pasching, Austria) 
•  MACS® Cell Separation Columns and Reagents (Miltenyi Biotec, Germany) 
•  Methocult™ (Stem Cell Technologies, Vancouver, Canada) 
•  MTS tetrazolium compound (Promega, Southampton, UK) 
•  Phosphate buffered solution (PBS) (Invitrogen, Paisley, UK) 
•  Polybrene (Sigma Aldrich, Poole, UK) 
•  Propidium iodide (Invitrogen, Paisley, UK) 
•  RPMI-1640 medium with L-glutamine (Invitrogen, Paisley, UK) 
•  StemPro-34 (Invitrogen, Paisley, UK)  
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•  X-vivo10 medium (Cambrex, Bath, UK) 
 
2.1.3  76BTyrosine Kinase Inhibitors 
•  Lestaurtinib (CEP701) (Cephalon, West Chester, PA, USA)  
•  PKC412 (Novartis, Basel, Switzerland) 
 
2.1.4  77BOther therapeutic agents 
•  All-trans retinoic acid (ATRA) (Sigma Aldrich, Poole, UK) 
•  Cytarabine arabinoside (Ara-C) (David Bull Laboratories, Victoria, Australia) 
 
2.1.5  78BRecombinant growth factors 
•  Human G-CSF (PeproTech, London, UK) 
•  Human FLT3-ligand (PeproTech, London, UK) 
•  Human IL3 (PeproTech, London, UK) 
•  Human thrombopoietin (PeproTech, London, UK) 
•  Murine IL-3 (PeproTech, London, UK) 
•  Human SCF (PeproTech, London, UK) 
 
2.1.6  79BCell culture plastics 
•  80 cm
2 and 175 cm
2 flasks (Nalge Nuc, Rochester, NY, USA) 
•  6, 12, 24 and 96 well tissue culture plates (Nalge Nunc, Rochester, NY, USA) 
 
2.1.7  80BFicoll-Hypaque centrifugation 
Cells were washed in RPMI containing 2% FCS (R2) and resuspended in R2 at a 
density of 10-20 x 10
6/L. Cells were then layered onto an equal volume of Ficoll-
Paque™Plus (Amersham, Bucks, UK), and centrifuged at 800g for 20 minutes. Cells 
from the interface were removed, washed twice in R2 and resuspended to the required 
concentration in R10 (RPMI-1640 cotaining 10%FCS). 
 
2.1.8  81BCell cryopreservation and thawing 
82BPrimary cells and cell lines in R10 were frozen at a density of 10x10
6/mL by adding an 
equal volume of freezing mix (RPMI [30%], FCS [50%] and DMSO [20%]) and stored 
in liquid nitrogen until required. Cells were thawed at room temperature and very 
slowly resuspended in 10mLs of R10 by the addition of small volumes of pre-warmed  
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R10 with regular and thorough mixing. Then, cells were pelleted and washed in R10 
and viability assessed by trypan blue exclusion. If the viability was less than 90%, 
viable cells were selected by Ficoll-Hypaque centrifugation. 
 
2.1.9  83BTrypan blue exclusion 
Trypan blue exclusion was used to determine the density of viable cells in a cell 
suspension. It is based on the priniciple that viable cells have an intact cell membrane 
and are therefore able to exclude the trypan blue, unlike non-viable cells. Viable cells 
therefore can be identified as they retain a clear cytoplasm, unlike non-viable cells 
which have a blue cytoplasm when visualised by light microscopy. The cell suspension 
to be tested was mixed with an equal volume of 0.4% trypan blue and incubated at room 
temperature for 2-5 minutes. The trypan blue cell suspension was then transferred to a 
haemacytometer and the number of viable and non-viable cells counted under a light 
microscope. 
 
2.1.10  84BPropidium iodide staining 
Propidium iodide (PI) is a DNA intercalating agent and a fluorescent molecule that can 
be used to stain DNA in order to differentiate between necrotic, apoptotic and normal 
cells. When bound to nucleic acids, the absorption maximum for PI is at 535 nm and the 
fluorescence emission maximum is 617 nm. As PI is not able to cross the cell 
membrane, it is excluded from viable cells and therefore the fluorescence of viable cells 
is lower than that of dead cells. Cells were incubated for 5 minutes at 4°C with 2μg/mL 
of PI and then analysed on a flow cytometer. 
 
2.2  30BUMolecular Biology 
 
2.2.1  85BReagents 
•  γ-[
32P]-ATP (3000 Ci/mmol, Amersham Pharmacia Biotech, Little Chalfont, 
UK) 
•  3MM Chr chromatography paper (Sigma Aldrich, Poole, UK) 
•  Acetonitrile (Transgenomic Ltd, Glasgow, UK) 
•  Acrylamide/NN’methylene bis-acrylamide 30%:0.8% (National Diagnostics, 
Hull, UK) 
•  Agar (Calbiochem, UK) 
•  Agarose (Sigma Aldrich, Poole, UK)  
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•  Ammonium persulphate (APS) (Sigma Aldrich, Poole, UK) 
•  Bioline buffer and magnesium chloride (Bioline, London, UK) 
•  BIOTAQ™ polymerase (Bioline, London, UK) 
•  Bromophenol blue (VWR International Ltd, Lutterworth, UK) 
•  Carbenicillin (Invitrogen, Paisley, UK) 
•  Chloroform (VWR International Ltd, Lutterworth, UK) 
•  DH5α competent bacteria  (Invitrogen, Paisley, UK) 
•  DNA size standard kit – 400 (Beckman Coulter UK Ltd., Buckinghamshire, 
UK) 
•  dNTPs (Bioline, London, UK) 
•  DTAB (dodecyl-trimethyl ammonium bromide) (Sigma Aldrich, Poole, UK) 
•  DTCS Quick Start kit (Beckman Coulter UK Ltd., Buckinghamshire, UK) 
•  EDTA (ethylenediaminetetraacetic acid disodium salt) (Sigma Aldrich, Poole, 
UK) 
•  Ethanol 100% (VWR International Ltd, Lutterworth, UK) 
•  Ethidium Bromide  (Invitrogen, Paisley, UK) 
•  Glycerol (VWR International Ltd, Lutterworth, UK) 
•  HEPES (Sigma Aldrich, Poole, UK) 
•  IPTG (Sigma Aldrich, Poole, UK) 
•  KCl (VWR International Ltd, UK) 
•  Luria-Bertani (LB) broth (Anachem, Luton, UK) 
•  Low melting point agarose (Invitrogen, Paisley, UK) 
•  N’N’N’N-tetra-methylethylenediamine (TEMED) (Biorad, CA, USA) 
•  Na acetate (VWR International Ltd, Lutterworth, UK) 
•  NaCl (VWR International Ltd, Lutterworth, UK) 
•  Optimase buffer and magnesium sulphate (Transgenomic Ltd, Glasgow, UK) 
•  Optimase™ polymerase (Transgenomic Ltd, Glasgow, UK) 
•  Orthoboric acid (VWR International Ltd, Lutterworth, UK) 
•  Primers (Invitrogen, Paisley, UK) 
•  Promega T4 DNA Ligase (Promega, Southampton, UK) 
•  QIAGEN Plasmid Mini- and Mega-prep kits (Qiagen, Crawley, UK) 
•  QIAquick Gel Extraction Kit (Qiagen, Crawley, West Sussex, UK) 
•  QIAquick PCR Purification kit (Qiagen, Crawley, UK) 
•  Restriction enzymes and buffers (New England Biolabs, Hitchin, UK)  
41
•  Sample loading solution (SLS) (Beckman Coulter UK Ltd., Buckinghamshire, 
UK) 
•  SDS (sodium dodecyl sulphate) (Sigma Aldrich, Poole, UK) 
•  SOC medium (Invitrogen, Paisley, UK) 
•  T4 polynucleotide kinase (Promega, Southampton, UK) 
•  TOPO TA Cloning Kit (Invitrogen, Paisley, UK) 
•  Tri-ethylene ammonium acetate (TEAA) (Transgenomic Ltd, Glasgow, UK) 
•  Tris (Hydroxymethyl) methylamine (VWR International Ltd, Lutterworth, UK) 
•  X-Gal (Sigma Aldrich, Poole, UK) 
 
2.2.2  86BBuffers 
2 x HBS: 50mM HEPES, pH 7.05; 10 mM KCl; 12 mM Dextrose; 280 mM NaCl; 1.5 
mM Na2HPO4 (FW 141.96). The final pH of the solution was adjusted to 7.05 +/- 0.05. 
Filtered through a 0.2 µM filter, aliquoted, and stored at -20°C. 
 
DNA lysis buffer: 20g  DTAB (final concentration 8%), 22g NaCl (final concentration 
1.5 M), 25 mLs of 1M Tris Cl pH 7.8 (100 mM). Made up to 250 mLs with dd H20 
(double distilled H20). 
 
10x TBE (pH8.3), for 1 litre: Tris 108.9g, orthoboric acid 55.7g, EDTA 7.4g. 
 
Loading buffer: 30% glycerol, 0.025% bromophenol blue in 1xTBE. 
 
2.2.3  87BDNA Extraction 
Cells were suspended in PBS at a concentration of 1 x 10
6 cells per 100 μL, double the 
volume of DNA lysis buffer added, mixed well and incubated at 68°C for 5 minutes. 
The sample was then cooled, mixed with an equal volume of chloroform and 
centrifuged at 2000g for 20 minutes. The upper layer, containing the DNA in solution, 
was carefully decanted, added to an equal volume of 100% ethanol and gently mixed 
until the DNA precipitated. The DNA was transferred to a clean tube and washed twice 
in 70% ethanol, then dissolved by end-over-end rotation at 4°C in an appropriate 
volume of ddH20. Samples were stored at 4°C. 
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2.2.4  88BPolymerase chain reaction (PCR) 
The PCR was used to amplify specific regions of genomic and complementary DNA. 
The DNA is amplified by successive cycles of denaturation, sequence-specific forward 
and reverse primer annealing and DNA polymerisation. Two different Taq polymerases 
were used during this work, BIOTAQ™ and Optimase™, each with specific conditions 
as recommended by the manufacturer. For BIOTAQ™ these were: 1x reaction buffer 
(160mM (NH4)2SO4, 67mM Tris-HCl, 0.1% Tween-20), 2mM MgCl2, 200 μM of each 
dNTP, 200 nM of each forward (5’) and reverse (3’) oligonucleotide primer and water 
to the required volume prior to the addition of DNA template. In order to ensure 
uniformity of conditions in each reaction tube, a master mix containing the necessary 
reagents was made prior to the addition of DNA template or ddH2O for the negative 
control. For BIOTAQ™ the cycling conditions were denaturation at 95°C for 30 
seconds followed by primer-annealing step for 30 seconds (temperature dependent on 
the composition of the primers) and a primer extension step at 72°C for 30 seconds. 
These 3 steps were repeated for a variable number of cycles as specified in the specific 
materials and methods section of each chapter. Following this, a final extension step 
was carried out at 72°C for 5 minutes to ensure complete extension of all primers. For 
Optimase™ the conditions were as specified by the manufacturer; concentrations of 
dNTPs and primers were as used for BIOTAQ™. An initial denaturation step was added 
(95°C for 5 minutes) and the primer extension step was longer (1 minute at 72°C rather 
than 30 seconds). 
 
2.2.5  89BAgarose gel electrophoresis 
Agarose gels (1.0% - 3.5%) were used to confirm the presence of PCR products of 
appropriate size and purity as well as to identify bands of different sizes following 
restriction enzyme digestion of PCR products or plasmid DNA. The required amount of 
agarose was added to 35mL of 1xTBE, dissolved by heating in a microwave oven and 
cooled before the addition of 5 μL ethidium bromide (1mg/mL). The gel was then 
poured into a mould and allowed to set. Appropriate volumes of PCR product or 
restriction enzyme digest were mixed with loading buffer, loaded into the wells and 
electrophoresed in 1xTBE (containing 200ng/mL ethidium bromide) using an 
appropriate voltage. PCR products were visualised under a UV transilluminator and 
digital and/or Polaroid images were made. 
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2.2.6  90BEnd-labelling of primers 
One primer from a given primer pair was labelled with a radioactive isotope to allow 
visualisation and quantification of digested bands as detailed in Chapter 5. To do this, 
10pmol of primer was incubated with 10 units of T4 polynucleotide kinase in 1x 
reaction buffer (70mM Tris-HCl, 10mM MgCl2, 50mM 1,4-dithiothreitol) and 3 μl γ-
[
32P]-ATP (3000 Ci/mmol) for 30 minutes at 37°C which resulted in the exchange of the 
5’ phosphate of the primer with γ-[
32P]-ATP. Following the incubation, samples were 
incubated at 95°C for 5 minutes to inactivate the enzyme. The labelled primer was then 
used for PCR as above. 
 
2.2.7  91BPolyacrylamide gel electrophoresis 
Polyacrylamide gels were used for quantitative analysis of digested PCR products as 
detailed in Chapter 5. Denaturing polyacrylamide gels consisted of 7 M urea, 6% 
polyacrylamide (cross-linker ratio 37.5:1) and 1 x Tris-borate-EDTA. To catalyse 
acrylamide polymerisation, 50 μL TEMED and 250 μL 10% APS were added to 50mLs 
of gel solution immediately prior to pouring. The gel was poured into a cast of 33cm x 
40cm with 0.4mm spacers and allowed to polymerise. Before loading, PCR products 
were mixed with loading solution (95% formamide, 20mM EDTA, 0.05% 
Bromophenol blue, 0.05% xylene cyanol), incubated for 5 minutes at 95°C to denature 
and quenched on ice. Following sample loading they were electrophoresed in 0.5xTBE 
at 1500V until the xylene cyanol ran about two thirds of the way down the plate 
(approximately 3.5 hours). The gels were transferred to 3MM Chr chromatography 
paper, dried and exposed to a Fuji BAS-IIIs imager plate overnight. 
 
2.2.8  92BRestriction enzyme digestion 
All restriction enzymes used were obtained from New England Biolabs and PCR 
products or plasmid DNA were digested overnight according to the manufacturers 
specified conditions. 
 
2.2.9  93BDNA Sequencing protocol 
PCR products were purified using the QIAquick PCR purification kit with the 
manufacturers’ recommended protocol. Dye-terminator sequencing reaction was then 
performed using the CEQ™ DTCS Quick Start kit (a single reaction mix containing the 
dye terminators, DNA polymerase, MgCl2 and reaction buffer) according to 
manufacturers’ recommended conditions with the addition of approximately 20ng  
44
purified PCR product and 3.2pmol of the required oligonucleotide primer. Twenty-five 
amplification cycles of 96°C for 20 seconds, 50°C for 20 seconds and 60°C for 4 
minutes were performed. The sequencing reaction products were precipitated using 
2.0μL Na acetate (3M, pH 4.6), 1 μL 20mg/mL glycogen and 50μL 95% ethanol and 
incubated at room temperature for 10 minutes. The DNA precipitate was pelleted by 
centrifugation at 15,000 g for 20 minutes. The pellet was washed twice in 75% ethanol 
and allowed to air dry prior to resuspension in 15μL SLS. The sample was then 
sequenced on a CEQ8000 Beckman Coulter DNA Genetic Analysis System. 
 
2.2.10  94BLB broth and plates 
LB broth was made by adding 4 LB tablets to 250mLs of ddH20 followed by 
autoclaving. For LB-agar plates, 3.75g of agar was added to the above mix, again 
followed by autoclaving. Once cool to touch, carbenicillin (final concentration 
50μg/mL) was added, if required. Plates were then poured, dried for 1 hour and stored 
at 4°C until required. 
 
2.2.11  95BCloning of PCR products 
PCR products were cloned using the TA cloning system which utilises the 
polyadenosine overhang at the 3’ end of PCR products generated using a non-
proofreading Taq polymerase. PCR products were ligated with pCR®2.1-TOPO 
plasmid which contains deoxythymidine overhang at the insertion site by incubating 0.5 
- 4μL of PCR product with 1μL vector and 1μL salt solution (200mM NaCl; 10mM 
MgCl2) in a final volume of 6μL at room temperature for 5 minutes. The vector was 
then transformed into DH5α competent bacteria by heatshock at 37°C for 30 seconds 
and the cells were then placed on ice for 2 minutes. LB agar plates (1xLB, 15% agar, 
50μg/mL carbenicillin) were pre-coated with 40μL IPTG (100 mM) and 20 μL X-Gal 
(50mg/mL) which were allowed to absorb for 30 minutes at 37°C. The transformed 
bacteria were plated and incubated overnight at 37°C. The presence of an inserted PCR 
sequence was detected by the presence of white colonies due to disruption of the lacZ 
gene in the pCR®2.1-TOPO plasmid. Colonies without an insertion were blue. 
Transformed colonies were picked and expanded in LB medium containing 50μg/mL 
carbenicillin and products for sequencing obtained either by direct PCR of bacterial 
cells or following preparation of plasmid DNA using the QIAGEN Plasmid Mini-prep 
kits.  
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2.3  31BUSDS-PAGE, Immunoblotting and Flow Cytometry 
 
2.3.1  96BReagents 
•  Aprotinin (Sigma Aldrich, Poole, UK) 
•  Bovine Serum Albumin (BSA) (Sigma Aldrich, Poole, UK) 
•  BD-Perm/Wash™ (BD-Biosciences, Oxford, UK) 
•  DL-Dithiothreitol (DTT) (Sigma Aldrich, Poole, UK) 
•  Enhance chemiluminescence kits (ECL and ECL-plus) (Amersham Life 
Sciences, Bucks, UK) 
•  Hybond-C-Extra nitrocellulose membrane (Amersham Life Sciences, Bucks, 
UK) 
•  Hyperfilm™ high performance autoradiography film (Amersham Life Sciences, 
Bucks, UK) 
•  Leupeptin (Sigma Aldrich, Poole, UK) 
•  Microcystin LR (Sigma Aldrich, Poole, UK) 
•  Non-fat dried milk (MARVEL) 
•  Pefabloc (Boehringer-Mannheim, Mannheim, Germany) 
•  PepstatinA (Sigma Aldrich, Poole, UK) 
•  Prestained molecular weight markers  (Sigma Aldrich, Poole, UK) 
•  Tween-20 (Sigma Aldrich, Poole, UK) 
 
2.3.2  97BBuffers 
Lysis buffer: 50mM HEPES pH 7.5, 100mM NaCl, 1% Triton X100, 1mM EDTA, 
1mM EGTA, 20mM NaF, 1mM Na orthovanadate, Aprotinin 10 μg/mL, Pepstatin 10 
μg/mL, Leupeptin 10 μg/mL, 5μM Microcystin and 1mM Pefabloc. 
 
98BGel running buffer: Tris base 30.3g, Glycine 144.2g, SDS 10g, made up to 1L with dd 
H2O. 
 
99BTransfer buffer: Tris base 30.3g, Glycine 144.2g, Methanol 100mLs, made up to 1L 
with dd H2O. 
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100B4x Loading buffer: 17.5 mLs 1M Tris pH 6.8, SDS 4g, DTT 2.315g, Glycerol 20 mLs, 
Bromophenol blue 50mg, made up to 50 mLs with dd H2O. 
 
2.3.3  101BAcrylamide gel 
10% separating gel: 2.86 mls deionised water, 3.74 mLs 1M Tris pH 8.8, 3.34 mLs 
acrylamide/N’N’-bis-methylene 30%:0.8%, 100 μL 10% SDS, 75 μL 10% APS, 9 μL 
TEMED. 
 
Stacking gel: 3.49 mls deionised water, 0.625 mls 1M Tris pH 6.8, 0.835 mLs 
Acrylamide/NN’methylene bis-acrylamide 30%:0.8%, 50 μL 10% SDS, 38 μL 10% 
APS, 7.5 μL TEMED. 
 
Gels were prepared immediately prior to use. The separating gel was prepared as above 
and poured into a Mighty-Small Hoeffer gel caster (Hoeffer Scientific Instruments, San 
Francisco, USA). Isobutanol was layered on top of the separating gel and the solution 
allowed to polymerise at room temperature. The isobutanol layer was then removed, the 
gel was washed in ddH20 and the stacking gel was layered on top of the separating gel 
and a 10 well comb inserted. Prestained molecular size markers and approximately 20 
μL of sample (boiled for 5 minutes) were loaded onto the gel which was then run at 
150V until adequate separation. The gel was then transferred to a Hybond-C-Extra 
nitrocellulose membrane by electroblotting at 0.8mA/cm
2 for 1 hour. 
 
2.3.4  102BAntibodies 
•  Alpha-Tubulin (Cell Signalling Technology, Hitchin, UK) 
•  Mouse IgG, HRP-linked (Cell Signalling Technology, Hitchin, UK) 
•  Rabbit IgG, HRP-linked (Cell Signalling Technology, Hitchin, UK) 
•  APC conjugated mouse IgG (BD-Biosciences, Oxford, UK) 
•  APC conjugated CD11b (Abcam, Cambridge, UK) 
•  FLT3 (Cell Signalling Technology, Hitchin, UK) 
•  PE conjugated CD34 (BD-Biosciences, Oxford, UK) 
•  Phospho-Akt (Thr 308) (Cell Signalling Technology, Hitchin, UK) 
•  Phospho-p42/44ERK (Thr 202/Tyr204) (New England Biolabs, Hitchin, UK) 
•  Phospho-S6 Ribosomal Protein (Ser235/236) (Cell Signalling Technology, 
Hitchin, UK)  
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•  Phospho-STAT5 (Tyr694) (Cell Signalling Technology, Hitchin, UK) 
 
2.3.5  103BFlow cytometry 
The methods for flow cytometry are describe in the specific materials and methods 
section of Chapter 7.  
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3  14BUCHAPTER 3: SCREENING FOR MUTATIONS IN THE 
TYROSINE KINASE DOMAIN OF FLT3 
 
3.1  32BUIntroduction 
 
Protein tyrosine kinases (TKs) are an important class of enzyme that catalyse the 
transfer of phosphates to tyrosine residues in protein substrates, converting adenosine 
triphosphate (ATP) to adenosine diphosphate in the process. Tyrosine phosphorylation 
is an important mechanism for the regulation of protein function, thereby controlling 
key cellular functions such as proliferation, apoptosis and differentiation. There are over 
90 different TK genes that have been identified in the human genome, with many other 
TK-like genes in addition to this. They can be broadly divided into two groups, receptor 
TKs (RTKs) at the cell surface and intracellular non-receptor TKs.  
 
It is over 25 years since protein TKs were first implicated in oncogenesis, and 
subsequently the identification of aberrant protein TK signaling pathways in many 
different human cancers has led to important diagnostic and therapeutic advances 
(Krause and Van Etten 2005). A classic example is FLT3 (Fms-like tyrosine kinase 3), 
also known as foetal liver kinase-2 (FLK-2) or stem cell kinase-1. FLT3 is a 993 amino 
acid RTK encoded by a 24 exon gene located on chromosome 13 (13q12) which was 
independently cloned by two groups (Matthews et al, 1991, Rosnet et al, 1991). It is a 
class III RTK and is closely related to other members of this family of receptor TKs 
(Table 3.1).  
 
Table 3.1: Members of the class III receptor tyrosine kinase family 
Receptor Alternative  Names  Ligand 
Fms-like tyrosine kinase 3 
(FLT3) 
FLK-2, stem cell kinase-1, 
CD135 
FLT3 ligand 
Steel factor receptor (c-KIT) SCF-1,  CD117  SCF 
Platelet derived growth factor 
receptor (PDGFR) α  
CD140a PDGF-A 
PDGFR β  CD140b PDGF-A,B,C 
Macrophage colony 
stimulating factor receptor 
CSF-1R, c-FMS, CD115  CSF-1 
SCF indicates stem cell factor; PDGF, platelet derived growth factor; and CSF-1R, 
colony stimulating factor 1 receptor  
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3.1.1  104BStructure of FLT3 
The crystal structure of FLT3 has been determined (Griffith et al, 2004). It has all the 
key structural features which are associated with class III RTKs (Figure 3.1A): 
 
•  An extracellular ligand-binding domain composed of 5 immunoglobulin like 
domains. 
•  A transmembrane domain 
•  A juxtamembrane (JM) domain  
•  An activation loop 
•  Two TK domains or lobes linked by a kinase insert 
•  An ATP binding pocket within the first kinase domain. 
 
Amino acid residues 572 to 603 encode the JM domain, whereas 604 to 946 include the 
activation loop, TK domains and insert. The N-lobe or first kinase domain (formed by 
amino acids 604-690) consists of a twisted 5-stranded β-pleated sheet adjacent to an α-
helix. Within this, the ATP binding pocket is formed by residues 610-631. The C-lobe 
or second kinase domain (formed by residues 698-946) consists of 7 α-helices and 3 β-
pleated sheets. The catalytic loop of the kinase is within this second kinase domain 
(residues 805-820). The 2 lobes are joined by a flexible kinase insert domain which 
allows considerable movement of the 2 kinase domains relative to each other. When the 
2 lobes are rotated away from each other, the kinase is held in an inactive state. This 
inactive conformation is stabilised by an activation loop (residues 829-856 within the 
second kinase domain) which sits between the 2 lobes, a conformation that is typical of 
class 3 RTKs. Furthermore, the JM domain also acts to stabilise this conformation by 
making contact with virtually every structural component involved in the 
activation/inactivation cycle of FLT3, and is therefore critical for holding the 
intracellular FLT3 kinase in an inactive state (Griffith et al, 2004). 
 
FLT3 is post-translationally modified and is found in two main forms, an 
unglycosylated 130-143 kDa non-membrane bound form and a 158-160 kDa 
glycosylated membrane bound form. FLT3 is expressed on the surface of normal HPCs 
within the BM, thymus and liver, on the surface of more mature blood cells such as 
monocytes, in lymph nodes and the thymus as well is in the brain, gonads and placenta. 
Within the BM, it is unclear whether FLT3 is expressed on the earliest HSCs but is 
expressed at the multipotent progenitor stage. The exact subclass of progenitor cells that   
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Figure 3.1. (A) Diagrammatic representation of the key structural features of the 
class III receptor tyrosine kinase FLT3 and (B) the key abnormalities of the two 
main types of mutation, internal tandem duplications and tyrosine kinase domain 
mutations.  
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express FLT3 and the lineage differentiation capability of these FLT3
+ HPCs remains 
controversial in both humans and mice (Adolfsson et al, 2005, Luc et al, 2007). 
 
3.1.2  105BFLT3 ligand 
FLT3-ligand (FL) is a 235 amino acid type I transmembrane protein that is widely 
expressed as a membrane-bound and soluble form (Lyman et al, 1993, Stirewalt and 
Radich 2003). The highest expression level of FL is found in peripheral blood 
mononuclear cells. Ligand binding to the FLT3 protein leads to receptor 
homodimerisation and results in a change in the normal autoinhibitory configuration of 
the JM domain and activation loop. This leads to exposure of the phosphoryl acceptor 
sites in the kinase domains and consequent autophosphorylation of a number of key 
regulatory intracellular tyrosine residues in FLT3. These changes lead to a reorientation 
of critical amino acids, thereby increasing the catalytic activity of the enzyme and 
generating binding sites for protein substrates. The activated receptor is rapidly 
internalised and degraded.  
 
3.1.3  106BMutations in the JM domain of FLT3 
Interest in FLT3 in AML was initially generated by the demonstration of expression of 
the receptor on the surface of blast cells from the majority of cases of AML (Drexler 
1996, Rosnet et al, 1996). It is also expressed in acute lymphoblastic leukaemia (ALL) 
and blast crisis of chronic myeloid leukaemia (CML). The crucial role for FLT3 in 
AML leukaemogenesis became apparent when a study screening AML samples for 
expression of FLT3 using reverse-transcriptase polymerase chain reaction (PCR) noted 
that a number of samples had unexpectedly long transcripts in the JM domain (Nakao et 
al, 1996). It was subsequently shown that these long transcripts were due to a region of 
duplicated genomic DNA within the JM domain, excluding aberrant splicing as an 
explanation for this finding. The duplications were always in-frame and located in the 
JM domain, but varied considerably in length and exact location from patient to patient. 
The mutations are somatic mutations as demonstrated by the absence of the FLT3/ITD 
in remission samples from patients who were FLT3/ITD positive at diagnosis. 
Screening of larger cohorts of patients demonstrated that these internal tandem 
duplications (ITDs) of FLT3 occur in approximately one quarter of cases of AML in 
young adults (Kottaridis et al, 2003, Levis and Small 2003, Stirewalt and Radich 2003). 
Interestingly, 9-23% of FLT3/ITD mutant positive patients have been reported to carry 
more than one duplication, and up to 5 have been reported in a single patient (Kottaridis  
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et al, 2003). The presence of FLT3/ITDs is generally restricted to cases of AML, 
although occasional cases in myelodysplasia, chronic myelomonocytic leukaemia and 
ALL have been reported (Lee et al, 2007, Xu et al, 1999, Yokota et al, 1997).  
 
As shown in Figure 3.1B, the ITDs interfere with the normal autoinhibitory role of the 
JM domain (Griffith et al, 2004), and functional studies have shown that the presence of 
a FLT3/ITD leads to constitutive activation of the receptor (Stirewalt and Radich 2003). 
The clinical and functional consequences of FLT3/ITDs in AML are discussed in more 
detail in chapters 4, 5 and 7 respectively. Interestingly, two studies have also identified 
point mutations within the JM domain in primary AML samples and myeloid cell lines 
(Reindl et al, 2006, Stirewalt et al, 2004) that were shown to lead to constitutive 
activation of FLT3 in a murine cell line model (Reindl et al, 2006). These types of 
mutation are, however, uncommon in AML, occurring in <1% of the patients studied. 
 
3.1.4  107BMutations in the TK domains of FLT3 
Subsequent to the identification of FLT3/ITDs in AML, it was noted that primary AML 
blasts from a number of patients had constitutively phosphorylated FLT3 in the absence 
of a FLT3/ITD (Fenski et al, 2000) raising the possibility of other mechanisms of 
aberrant FLT3 activation. Shortly afterwards, two groups independently reported 
activating mutations affecting codons D835 and I836 in the second TK domain (TKD) 
of FLT3 in approximately 7% of AML patients (Abu-Duhier et al, 2001, Yamamoto et 
al, 2001). These FLT3/TKD mutations also occur at a lower frequency in ALL and 
myelodysplasia (Yamamoto et al, 2001). This part of the molecule was screened as 
mutations have been reported to occur in the highly conserved homologous region of 
the closely related receptors c-KIT and FMS. For example, D816 mutations of c-KIT 
had been reported to occur in AML, mast cell lines and systemic mastocytosis (Furitsu 
et al, 1993, Kitayama et al, 1995, Longley et al, 1999, Sotlar et al, 2000, Sperr et al, 
1998). Mutations of FMS at codon D802 had also previously been shown to be 
constitutively activating (Figure 3.1B) (Sotlar et al, 2000). Interestingly, one group had 
already shown that substitution of aspartate with valine at position 838 of the murine 
FLT3 kinase (the equivalent to human FLT3 codon 835) led to constitutive activation 
(Fenski et al, 2000). Similar to FLT3/ITDs, the TKD mutations of FLT3 were shown to 
be somatic mutations as they were absent in remission samples. Furthermore, screening 
of normal controls did not detect any TKD mutations. It is thought that TKD mutations  
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disrupt key amino acids which stabilise the activation loop in a closed configuration, 
although the exact mechanism of this disruption remains unclear (Griffith et al, 2004).  
 
The presence of FLT3/TKD mutations within the second TK domain in AML has been 
confirmed in a number of other studies (Table 3.2). The overall incidence in AML has 
been reported to be approximately 7%, ranging between 5% and 22% depending on the 
technique used and the specific inclusion criteria of the study with regards to patient 
age, cytomorphology and karyotype. A number of different mutations have been 
reported. Most are point mutations such as substitution of asparate residue 835 with a 
tyrosine (D835Y, the most frequent mutation), histidine, valine or glutamate; other 
alterations include small deletions (∆835, ∆836) and insertions. All mutations initially 
described disrupted an EcoRV restriction enzyme cutting site that facilitated a simple 
screening technique using digestion of PCR products, an approach which has been 
employed in most studies (Table 3.2). Subsequently, however, using different 
techniques to screen the whole of exon 20 of FLT3, a number of other point mutations 
have been reported at codons 839, 841 and 842 (Jiang et al, 2004, Kindler et al, 2005, 
Smith et al, 2005) as well as a two amino acid insertion between codons 840 and 841 
(Spiekermann et al, 2002). All of these mutations occur outside of the EcoRV 
restriction digest site and would therefore have been missed using this technique. 
Interestingly, a single case of a constitutively activating point mutation in the first TK 
domain has also been described (K663Q) (Schittenhelm et al, 2006). Further studies 
will be required in order to determine the frequency of such mutations. 
 
3.1.5  108BScreening techniques for the detection of FLT3/TKD mutations 
In order to study the clinical consequences of these relatively infrequent FLT3/TKD 
mutations, screening of large cohorts of patients with AML is required. A number of 
different techniques have been used for the detection of FLT3/TKD mutations and each 
has specific limitations. For example, direct sequencing lacks sensitivity for the 
detection of somatic mutations which may only be present in a subclone of cells. 
Techniques depending on the EcoRV restriction digest are limited by the failure to 
detect mutations occurring within the TKD but outside of the digest site. Other 
techniques such as SSCP and CSGE are technically demanding and therefore 
impractical for large scale screening programmes. Lightcycler melting curve analysis 
depends on the exact sequence of the sensor and anchor probes used, for example, in the  
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Table 3.2: Published studies reporting TKD mutations of FLT3 in AML 
Reference  No. 
patients  Method 
No. TKD 
Mutant 
(%) 
Mutation, No.  Multiple 
Mutants, No. 
(Abu-Duhier 
et al, 2001) 
97 Sequencing, 
EcoRV, and CSGE 
7 (7.2)  D835Y, 5 
Δ835, 1 
D835H, 1 
None 
(Yamamoto et 
al, 2001) 
429  EcoRV and 
sequencing 
30 (7.0)  D835Y, 23 
D835V, 5 
D835E, 2 
D835H, 1 
D835E + D835Y, 
1 
(Thiede et al, 
2002) 
979  EcoRV and 
sequencing 
75 (7.7)  D835Y, 34 
D835H, 18 
D835V, 5 
D835E, 8 
D835N, 2 
D835G, 4 
D835LK, 1 
Δ836, 13 
I836MR, 1 
I836T, 1 
dual mutants, 8 
triple mutants, 1 
(Noguera et 
al, 2002) 
90 
(APL 
only) 
EcoRV and 
sequencing 
7 (7.8)  D835Y, 3 
D835E, 1 
NR, 3 
None 
(Frohling et 
al, 2002) 
224  EcoRV and 
sequencing 
32 (14.3)  D835Y, 17 
D835E, 6 
D835V, 2 
D835H, 2 
D835A, 1 
Δ836, 2 
NR, 1 
1, D835Y + Δ836 
(Spiekermann 
et al, 2002) 
359 PCR  and 
sequencing 
N/A Ins840GS,  2  N/A 
(Sheikhha et 
al, 2003) 
80  EcoRV and 
Sequencing 
6 (7.5)  D835Y, 4 
D835E, 2 
None 
(Bianchini et 
al, 2003) 
34  EcoRV, 
Sequencing and 
dHPLC 
2 (5.9)  D835E, 2  None 
(Shih et al, 
2003) 
107 
(APL 
only) 
EcoRV and 
sequencing 
20 (18.7)  D835Y, 13 
D835H, 5 
D835V, 1 
D835E, 1 
None 
(Moreno et al, 
2003) 
208  EcoRV and 
sequencing 
20 (9.6)  D835Y, 5 
D835H, 3 
D835V, 1 
D835A, 1 
NR, 10 
None 
(Jiang et al, 
2004) 
53 Sequencing,  mass 
spectometry 
NR N841I,  2 
N841Y, 1 
1, N841I and 
D835 point 
mutation 
(Andersson et 
al, 2004) 
109  EcoRV and 
sequencing 
11 (10.1)  D835Y, 3 
D835V, 2 
D835H, 2 
D835N, 1 
D835E, 1 
Δ834 and 835, 1 
NR, 1 
None 
(Au et al, 
2004) 
82 
(APL 
only) 
EcoRV and 
sequencing 
18 (22.0)  D835Y, 11 
D835V, 4 
D835H, 3 
D835A, 1 
None  
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Table 3.2: continued 
Reference  No. 
patients  Method 
No. TKD 
Mutant 
(%) 
Mutation, No.  Multiple 
Mutants, No. 
(Shih et al, 
2004) 
120  EcoRV and 
sequencing 
13 (10.8)  D835Y, 9 
D835V, 2 
D835E, 1 
D835H, 1 
None 
(Mills et al, 
2005) 
258 Capillary 
electrophoresis 
and sequencing 
35 (13.6)  D835/836 Pt M, 30 
Δ836, 2 
D839, 2 
1, Triple 
mutant 
(Scholl et al, 
2005) 
122  EcoRV, 
Sequencing and 
real-time PCR 
9 (7.4)  D835Y, 5 
D835H, 3 
Δ836, 1 
None 
(Smith et al, 
2005) 
175 SSCP,  EcoRV and 
sequencing 
8 (4.6)  D835 Pt M, 7  
D839G, 1 
NR 
(Kindler et al, 
2005) 
110  Sequencing  9 (8.2)  D835 Pt M, 7 
Y842C, 2 
None 
(Wang et al, 
2005) 
143  EcoRV 9  (6.3)  NR  NR 
(Auewarakul 
et al, 2005) 
256  EcoRV and 
sequencing 
15 (5.9)  D835Y, 7 
D835H, 4 
D835E, 1 
D835A, 1 
Δ835/I836V, 1 
None 
(Mills et al, 
2006) 
N/A Capillary 
electrophoresis 
and sequencing 
N/A D835V/I836F/M837P  N/A 
(Schittenhelm 
et al, 2006) 
109 dHPLC  and 
sequencing 
5 (4.6)  D835Y, 2 
D835H, 1 
Δ836, 1 
N841H 
None 
(Whitman et 
al, 2008) 
217  EcoRV and 
sequencing 
19 (8.8)  NR  NR 
(Bacher et al, 
2008) 
3082 Lightcycler 
melting curve 
analysis 
147 (4.8)  D835Y, 68 
D835H, 20 
D835V, 14 
D835E, 11 
D835A, 3 
D835S, 1 
D835N, 1 
Δ836, 14 
NR, 10 
D835A + 
D835Y, 1 
D835E + 
D835Y, 2 
D835Y + 
D835H, 1 
D835Y + Δ836 
NR, not reported; CSGE, Conformation sensitive gel electrophoresis; SSCP, Single 
strand conformational polymorphism; dHPLC, denaturing high performance liquid 
chromatography; APL, acute promyelocytic leukaemia; and Pt M, point mutation. 
 
 
study by Bacher et al (2007) the probes used would pick up mutations within codons 
821 to 838 but would fail to detect mutations occurring between codons 839 to 842.  
 
The experimental work presented in this chapter evaluated the role of denaturing high 
performance liquid chromatography (dHPLC) for the detection of FLT3/TKD 
mutations. The Transgenomic WAVE
® System of dHPLC is a powerful technique for  
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the detection of mutations based on temperature modulated heteroduplex analysis. It 
was developed in the early 1990s (Xiao and Oefner 2001), and the use of dHPLC for the 
detection of somatic mutations was first reported for the detection of phosphatase and 
tensin homolog (PTEN) mutations in malignant gliomas (Liu et al, 1998). The 
technique involves binding a PCR product to a polystyrene-divinylbenzene copolymer 
column using tri-ethylene ammonium acetate (TEAA) an ion pairing agent. The column 
contains hydrophobic beads that interact with the hydrophobic portion of TEAA, which 
in turn binds to negatively charged DNA via its positively charged phosphate backbone. 
The temperature of the column is carefully calculated in order to partially denature the 
double stranded DNA. Gradually increasing concentrations of acetonitrile elute the 
DNA off the column, an ultraviolet detector measures the DNA absorbance of the eluate 
and a chromatogram is generated. The presence of heteroduplexes in the PCR product 
leads to a higher proportion of the fragment being single stranded which is less strongly 
bound and therefore elutes off the column earlier. The presence of heteroduplexes 
formed by the presence of a somatic mutation will therefore be detected by an abnormal 
chromatogram pattern (Figure 3.2). A major advantage of this technique is that it is 
automated and relatively rapid (approximately 7 minutes per sample).  The accuracy of 
dHPLC for the detection of FLT3/TKD mutations was therefore first evaluated and 
compared with the most commonly used alternative screening technique, EcoRV 
restriction digest analysis, and then applied to a large cohort of samples from adult 
patients with AML. 
 
3.2  33BUPatients, Materials and Methods 
 
3.2.1  109BPatients 
Genomic DNA (gDNA, n=1297) or complementary DNA (cDNA, n = 42) was 
available from blast cells of 1339 adults with AML entered into either the UK MRC 
AML 10 (n=444) or AML12 (n=895) trials (further details on the clinical characteristics 
and treatment of these patients in chapter 4). Ethical approval for the trials and tissue 
collection for research was obtained from the Multi-Centre Research Ethics Committee 
of Wales and local research ethics committees as appropriate and informed consent was 
provided according to the Declaration of Helsinki. 
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Figure 3.2. Schematic representation of FLT3/TKD mutation detection by dHPLC. 
PCR amplification of wild type and heterozygous D835Y mutant (allele A is FLT3/WT, 
B is D835Y mutant) cases generates double stranded DNA fragments containing the 
respective mutant and wild-type alleles. These products are then heated and slowly 
cooled, generating heteroduplexes in the mutant case only. The lower section shows a 
diagram of dHPLC. At too low a temperature, all the fragments are double stranded and 
have a long retention time (time taken to elute off the column). As the temperature 
increases, heteroduplexes are resolved as the PCR products are partially denatured. At 
too high a temperature, all the fragments are single stranded and the retention time is 
therefore short.  
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3.2.2  110BScreening for FLT3/TKD mutations by dHPLC      
For dHPLC analysis to screen for FLT3/TKD mutations, PCR was used to amplify a 
278 base pair (bp) fragment covering FLT3 exon 20 (previously designated exon 17) 
and the flanking intronic regions from approximately 100ng gDNA with Optimase 
polymerase using manufacturer's recommended conditions, primers 20F and 20R (Table 
3.3), 32 cycles of amplification and an annealing temperature of 63°C. For cDNA, a 
290bp fragment covering exon 20 was amplified as above with primers FLT3/F2 and 
FLT3/R (Table 3.3).  Products were denatured and run on dHPLC (Transgenomic 
WAVE) at optimal melting temperatures calculated using WAVEMAKER software: 
59.0°C and 62.0°C for the 278bp fragment from gDNA (Figure 3.3A), 60.2°C and 
62.0°C for the 290bp product from cDNA (Figure 3.3B). The higher temperature was 
required in order to reduce the possibility that a mutation could be missed in the section 
of the PCR product that remains double stranded at the lower temperature (see Figure 
3.3). 
 
In order to determine the sensitivity of dHPLC for the detection of FLT3/TKD 
mutations, dilutions of a D835Y mutant positive case were made with equal amounts of 
DNA (as measured by optical density) from the promyelocytic leukaemia cell line NB4, 
which is FLT3/WT. Dilutions of D835Y:NB4 of 1:1, 1:3, 3:17, 1:9 thereby should lead 
to an estimated percentage of D835Y mutant alleles of 25%, 12.5%, 7.5% and 5% 
respectively. These estimations assume a 50% level of mutant in the D835Y sample and 
that optical density accurately correlates with the number of FLT3 alleles available for 
PCR amplification in each sample. 
 
3.2.3  111BScreening for FLT3/TKD mutations by EcoRV restriction digest 
In order to partially overcome the difficulty in discriminating between a failed or partial 
EcoRV digest and a codon 835/836 FLT3/TKD mutation, a modified method of the 
original PCR EcoRV digestion procedure was used (Gale et al, 2005b, Yamamoto et al, 
2001). Using the original method, EcoRV cuts WT sequence once but does not cut 
alleles with mutations of codons 835 or 836 (Yamamoto et al, 2001). In the modified 
method, a mismatch was introduced into the reverse primer (Table 3.3), thereby creating   
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Figure 3.3. Theoretical melting curves of PCR products generated by 
WAVEMAKER software. (A) 278 bp PCR product generated from genomic DNA run 
at 59.0°C and 62.0°C. Exon 20 includes base pairs 100 to 223 of this PCR fragment. 
The location of codon 835 is shown. (B) 290 bp PCR product generated from cDNA run 
at 60.2°C and 62.0°C. Mutation detection is optimal when the helical fraction of the 
area where the mutations reside is between 75 and 95%. 
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Table 3.3: PCR primers and restriction enzyme digests used for the detection of FLT3/TKD mutations 
 
Primers 
PCR  
Annealing  
Temperature 
RE 
WT PCR 
product 
size 
MT fragment 
lengths post 
digest 
DHPLC         
gDNA 20F:  5’-CATCACCGGTACCTCCTACTG-3’ 
20R: 5’-TAACGACACAACACAAAATAGCCGT-3’  63°C  N/A 278bp  N/A 
cDNA FLT3/F2:  5’-GGAATGGAATTTCTGGAATTTAAGTCG-3’ 
FLT3/R: 5’-ACCGGAATGCCAGGGTAAGGA-3’  63°C  N/A 290bp  N/A 
EcoRV          
gDNA 20F:  5’-CATCACCGGTACCTCCTACTG-3’  63°C  EcoRV 303bp  26  +  277 
 20R2  (mm):  5-CAGTGAGTGCAGTTGTTTACCATGAUTUATCG-3        
Mutation          
D835Y F(mm):  5’-GTGAAGATATGTGACTTTGGATTGGUAUTCGA-3’ 
R: 5’-CAGTGAGTGCAGTTGTTTACCATGATAACG-3’  62°C  ClaI 149bp  27bp  +  122bp 
D835H F(mm):  5’-GTGAAGATATGTGACTTTGGATTGGUGUTCGA-3’ 
R: 5’-CAGTGAGTGCAGTTGTTTACCATGATAACG-3’  64°C  HincII  149bp 28bp  +  121bp 
D835E F:  5’-CATCACCGGTACCTCCTACTG-3’ 
R: 5’-TAACGACACAACACAAAATAGCCGT-3’  63°C  DpnII  278bp 188bp  +  90bp 
D835V F:  5’-CATCACCGGTACCTCCTACTG-3’ 
R(mm): 5’-CCTGACAACATAGTTGGAATCACTCATGUTUT-3’  64°C  HincII  217bp 187bp  +  30bp 
Δ836  F(mm): 5’-AAGATATGTGACTTTGGATTGGCTCGAUCUAT-3’ 
R: 5’-CAGTGAGTGCAGTTGTTTACCATGATAACG-3’  64°C  NdeI  146bp 29bp  +  114bp 
Δ835  F(mm): 5’-GTGAAGATATGTGACTTTGGATTGGUTUTCGA-3’ 
R: 5’-CAGTGAGTGCAGTTGTTTACCATGATAACG-3’  64°C  BstBI  149bp 27bp  +  119bp 
D835N F(mm):  5’-GTGAAGATATGTGACTTTGGATTGGUTUTCGA-3’ 
R: 5’-CAGTGAGTGCAGTTGTTTACCATGATAACG-3’  64°C  BstBI  149bp 27bp  +  122bp 
F indicates forward primer, R reverse primer, WT wild type, MT mutant, mm mismatch primer (mismatch underlined), 
RE restriction endonuclease, N/A not applicable.  
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an additional EcoRV digestion site that would be present in all PCR products, 
irrespective of the presence of the mutation. This allowed discrimination of undigested 
products from FLT3/TKD
+ cases (cut once) and FLT3/WT cases (cut twice). For 
gDNA, 35 cycles of amplification were performed with an annealing temperature of 
63°C. EcoRV digestion of the 180 bp product gave bands of 277 and 26 bp for 
FLT3/TKD mutant alleles and 187 + 90 + 26 bp for WT alleles. Mutation screening on 
cDNA samples using EcoRV digestion was carried out in previous work in the 
department at UCL (Gale et al, 2005b). In total, 430 patients were screened for 
FLT3/TKD mutations by EcoRV restriction digest, including all patients with an 
abnormal WAVE chromatogram. 
 
3.2.4  112BIdentification of TKD Mutations     
PCR products were obtained using 35 cycles of amplification with BIOTAQ DNA 
polymerase (Bioline, London, UK), manufacturer's recommended conditions and 
annealing temperatures as specified (Table 3.3).  They were sequenced using the DTCS 
Quick Start kit and analysed on a CEQ8000 DNA Genetic Analysis System (Beckman 
Coulter). Some mutations were confirmed using mutation-specific restriction enzyme 
digestion of PCR products by designing mismatch primers that discriminated between 
WT and mutant alleles (Table 3.3). For samples where the mutant level was too low to 
be identified by sequencing or restriction digest, PCR products were cloned (TOPO TA 
Cloning, Invitrogen) and sequenced. 
 
3.3  34BUResults 
 
3.3.1  113BSensitivity of dHPLC for the detection of D835Y mutations 
In order to determine the sensitivity of dHPLC for the detection of FLT3/TKD mutants, 
mixtures of gDNA were made from the FLT3/WT cell line NB4 and a known D835Y 
mutant case where approximately half the FLT3 alleles were known to carry a mutation. 
At a melting temperature of 59.0°C, mutations could be detected down to a 9:1 ratio of 
NB4:D835Y heterozygous mutant, consistent with approximately 5% of the FLT3 
alleles carrying a mutation (Figure 3.4A). The higher melting temperature of 62.0°C 
was less sensitive for the detection of the D835Y mutation (Figure 3.4B) as the relevant 
section of the PCR fragment is completely single stranded at this temperature (Figure 
3.3A).  
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Figure 3.4. dHPLC chromatogram traces of PCR products amplified from 
mixtures of genomic DNA from a heterozygous D835Y mutant positive case and 
from the FLT3 wild-type NB4 cell line. (A) 59.0°C and (B) 62.0°C.  
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3.3.2  114BIncidence of FLT3/TKD mutations 
In the total cohort of 1339 patients studied, 161 (12%) had an abnormal chromatogram 
trace, indicative of the presence of a FLT3/TKD mutation (FLT3/TKD
+). As predicted 
from Figure 3.4, when using gDNA the chromatogram trace at 59.0°C was the most 
sensitive for mutation detection and the most robust for the specific patterns associated 
with specific mutants (Figure 3.5A - O). The higher temperature (62.0°C) was useful for 
confirmation of an abnormal trace at the lower temperature. It is also possible that, 
given the melting temperature profiles shown in Figure 3.3, mutations in the region of 
the amplified fragment that remains tightly double stranded at 59.0°C would be missed 
at this temperature. Therefore all samples were run at both temperatures. The 
chromatogram profiles of the 42 cases screened from cDNA samples were more 
difficult to optimise but, nevertheless, picked up all 4 mutants previously detected in 
these cases using EcoRV screening in prior work in the department (Figure 3.5 R, S) 
(Gale et al, 2005b). 
 
3.3.3  115BIdentification of FLT3/TKD mutations 
Mutations were initially determined by direct sequencing, however, it soon became 
apparent that the WAVE chromatogram pattern was often specific to the underlying 
mutation. In many cases therefore the mutation could be confirmed by mutation-specific 
restriction enzyme digest without the need for sequencing (Tables 3.3 and 3.4, Figure 
3.5B, C, D, E, F, I, J). All mutants were identified and confirmed except those in 8 
patients in which the heteroduplex peak was very small, suggesting that the mutant 
present was only a small percentage of the total FLT3 alleles. In four of these patients, 
EcoRV restriction digest screening was positive. In the other four cases the EcoRV 
digest was negative but the chromatogram traces were consistently and reproducibly 
abnormal and these cases were therefore scored as mutant-positive. 
 
Overall, 14 different mutations were identified (Table 3.4, Figure 3.5). D835Y was the 
most common, accounting for 50% of mutant-positive patients; D835H, D835V, D835E 
and ∆836 were all found at a similar frequency of 8%-11% of positive patients. Three 
previously undescribed mutations were detected, each in a single case: S840G (Figure 
3.5L), a 3 bp insertion which replaced aspartate codon 835 with glycine and proline 
(Figure 3.5G), and a 16bp tandem duplication plus 10bp deletion within the kinase 
domain which replaced codons 835 and 836 (DI) with VIPT (Figure 3.5H).   
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Table 3.4: FLT3/TKD mutations detected in total cohort of 1339 patients. 
Where 2 mutations were present, the case is classified according to the 
predominant mutation. 
Mutation 
Total 
(%FLT3/TKD
+ Patients) 
WAVE Pattern 
D835Y  50 (50%)  Figure 3.5B 
D835E  13 (8%)  Figure 3.5C 
D835H  18 (11%)  Figure 3.5D 
D835V  15 (9%)  Figure 3.5E 
D835N  1 (1%)  Figure 3.5F 
D835GP  1 (1%)  Figure 3.5G 
ΔDI + InsVIPT  1 (1%)  Figure 3.5H 
Δ835  1 (1%)  Figure 3.5I 
Δ836  16 (10%)  Figure 3.5J 
D839G  1 (1%)  Figure 3.5K 
S840G  1 (1%)  Figure 3.5L 
N841I  2 (1%)  Figure 3.5M 
N841K  2 (1%)  Figure 3.5N 
N841Y  1 (1%)  Figure 3.5O 
Unknown  8 (5%)  Figure 3.6 
 
Of the 161 cases with an abnormal chromatogram, 155 had a pattern consistent with a 
single mutant and six samples had a pattern suggestive of the presence of two mutants 
(Figure 3.5P). In each of these six cases, there was a predominant mutant which was 
readily identified and a minor mutation that was identified in 4 of the cases. The 
mutation types (predominant followed by the minor mutant) were D835Y and Δ836 
(shown in Figure 3.5P); D835H and D835Y; Δ836 and D835H; N841K and D835Y; 
N841I and unknown (EcoRVpositive); D835V and unknown (EcoRV negative).  
 
A technical issue relating to sample quality and dHPLC analysis is demonstrated in 
Figure 3.5Q. Some of the aliquots of gDNA in the UCL DNA bank are more than 10 
years old. The working DNA solutions were stored as dilutions of a main stock of 
gDNA. In a number of cases the working DNA had degraded and this created an 
abnormal dHPLC chromatogram, however, no mutation could be detected by 
sequencing. In these cases, when a fresh aliquot of the main stock gDNA was made, the 
dHPLC chromatogram was normal.  
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Figure 3.5 (next 4 pages). dHPLC chromatogram traces of different FLT3 TKD 
mutations and their confirmation by specific restriction digest and/or direct 
sequencing. For the specific restriction digests, M represents mutant positive cases and 
W wild type. (A) FLT3 wild type; (B) D835Y with ClaI mismatch digest and relevant 
section of sequence; (C) D835E with  DpnII digest and relevant section of sequence; 
(D) D835H with HincII mismatch digest and sequence; (E) D835V with HincII 
mismatch digest and sequence; (F) D835N with BstBI mismatch digest and sequence; 
(G) D835GP with sequence; (H) ΔDI + InsVIPT with sequence; (I) Δ835 with BstBI 
mismatch digest and sequence; (J) Δ836 with NdeI mismatch digest and sequence; (K) 
D839G with sequence; (L) S840G with sequence;(M) N841I with sequence; (N) N841K 
with sequence; (O) N841Y with sequence; (P) dual mutation with a predominant 
D835Y mutation and a minor Δ836 mutation; (Q) chromatogram trace at 59°C from a 
sample with degraded genomic DNA showing the corresponding agarose gel 
electrophoresis of the 278bp product, with the degraded case shown by the black arrow; 
the chromatogram trace obtained using a fresh aliquot of DNA is normal; (R) D835V 
mutation detected by dHPLC of PCR amplified product from cDNA; (S) D835Y 
mutation detected by dHPLC of PCR amplified product from cDNA.  
66 
67 
68 
69 
70
3.3.4  116BComparison of EcoRV Screening and dHPLC screening for FLT3/TKD 
mutations 
EcoRV digestion and dHPLC analysis were performed in 430 patients, including all 161 
with an abnormal WAVE pattern: 269 were WT by both techniques but 17 (11%) that 
were mutant by dHPLC were WT by EcoRV digestion (Figure 3.6). In total, seven of 
the 161 mutations detected (4%) occurred outside the EcoRV restriction digest site. Five 
of these cases had a markedly abnormal dHPLC chromatogram but were negative by 
EcoRV. Two further mutations that occurred outside the digest site were EcoRV 
positive due to the presence of a second minor mutation within codons 835 and 836 (see 
section 3.3.3). Eight cases had an identified mutation within the digest site but were 
negative by EcoRV screening (Figure 3.6). In these cases, the dHPLC trace was 
suggestive of a minor mutation that was below the level of detection for restriction 
digest analysis. A further four cases were scored as mutant-positive as their dHPLC 
chromatogram trace was reproducibly abnormal but they were negative by EcoRV 
screening and the mutation was not identified. Consequently, approximately one-third 
of the mutants missed by EcoRV digestion were because the mutation did not change 
this cutting site and the remainder were below the detection level of the EcoRV 
technique.  
 
There were two mutant-positive cases that showed only a very slight degree of digestion 
by EcoRV, suggesting that only a small minority of the FLT3 alleles were WT. The 
chromatogram profile on these patients was abnormal in both cases (one example, a 
D835V mutation, is shown in Figure 3.6D) but only due to the presence of a ‘shoulder’ 
on the main peak. These cases with apparent loss of the WT allele are discussed in more 
detail in chapter 5. 
 
3.4  35BUDiscussion 
 
With an ever-increasing number of different molecular abnormalities now being 
described in human malignancies, developing appropriate molecular biology techniques 
to detect them is a major challenge. Even in AML alone, there are many different 
genetic mutations that have been reported (see chapter 1), and it is possible that 
information derived from the detection of some of these mutations will directly 
influence clinical management. In the case of FLT3 mutations, the introduction of FLT3 
inhibitors into large clinical trials (Knapper 2007) has necessitated that the FLT3  
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Figure 3.6. EcoRV restriction digest screening for FLT3/TKD mutations and the 
corresponding dHPLC chromatograms. An undigested PCR product is shown in the 
first lane for comparison. Mutant positive products are only digested once and therefore 
have a band at 277 bp. Wild type (W) FLT3 is digested twice with corresponding bands 
at 187 and 90 bp, as shown. (A) A minor Δ836 mutation detected by dHPLC but missed 
by EcoRV; (B) A heterozygous D835Y mutation detected by both dHPLC and EcoRV; 
(C) A minor D835E mutant detected by both dHPLC and EcoRV; (D) A D835V mutant 
where the EcoRV screen shows very little wild type FLT3 but the dHPLC trace is 
suggestive of only a small amount of heteroduplex; and (E) An unknown mutant with a 
shoulder on the main chromatogram peak that was negative by EcoRV. 
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 mutation status be accurately and rapidly determined within 1-2 weeks of diagnosis. It 
is necessary therefore to develop sensitive and high throughput techniques that are 
capable of detecting these mutations. 
 
The data presented in this chapter reports on a comparison 2 different techniques for the 
screening of a large cohort of younger adult AML patients for the presence of 
FLT3/TKD mutations. Using dHPLC, FLT3/TKD mutations in AML were detected in 
161 of 1339 cases, 12%. This is considerably higher than the 7% reported in most other 
studies, although incidences up to 22% have been reported (Table 3.2). One possible 
explanation for the increased frequency of FLT3/TKD mutations detected in this study 
is that dHPLC is more sensitive than EcoRV restriction digest, a technique that had 
been used in the majority of previous studies. In a comparison of over 400 cases 
screened by both methods, there were no cases where dHPLC showed a normal 
chromatogram but the EcoRV digest suggested the presence of a mutation. Conversely, 
there were 17 cases which were EcoRV negative but dHPLC positive, demonstrating 
the superiority of the dHPLC technique. 
 
One major limitation of restriction digest screening is that it will only detect mutations 
within a very specific region of DNA, usually 4-6 base pairs. Whilst the majority of 
FLT3/TKD mutations occur within codons 835 and 836, a number of mutations in the 
second kinase domain occur outside this region. One advantage of the dHPLC technique 
therefore, is that it will detect mutations across a wider region of DNA. In our cohort, 
there were 7 mutations which occurred outside of the EcoRV restriction digest site 
accounting for 4% of the mutant-positive patients. Other cohorts have reported a higher 
incidence of these mutations occurring between codons 840 and 842 (Jiang et al, 2004, 
Kindler et al, 2005, Spiekermann et al, 2002). Given the potential for the presence of a 
FLT3/TKD mutation to influence clinical management of patients with AML, the are 
clear advantages to the use of dHPLC. 
 
A number of the mutations (n=13) detected by dHPLC but not by EcoRV occurred 
within the EcoRV digest site. As interpretation of EcoRV digestion is greatly dependent 
on the efficiency of the restriction digest, even using the modified approach adopted in 
this analysis, it can be extremely difficult to differentiate between an undigested band 
due to the presence of a lower level mutation or to incomplete digestion of FLT3/WT. 
Using dHPLC however, small heteroduplex peaks were detected in cases where the  
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EcoRV digest was negative or difficult to interpret (Figure 3.6). This observation 
highlights the sensitivity of the dHPLC technique for the detection of mutations that 
may only be present in a small proportion of the amplified alleles. The detection of such 
mutations may be important as somatic mutations only arising in a subclone of 
malignant cells may nevertheless be clinically or biologically important. Furthermore, 
whilst contamination by non-leukaemic cells is not a major problem in AML as the 
majority of samples contain a high percentage of leukaemic cells, many solid tumours 
are characterised by infrequent clonal malignant cells with a polyclonal stromal cell 
infiltrate. Sensitive techniques may therefore be required in order to detect mutations 
within the malignant cells in these cases. 
 
Another advantage of dHPLC is that the chromatogram profile produced by different 
mutations was found to be specific and highly reproducible, in most cases enabling 
direct mutation identification from the WAVE pattern and confirmation using a 
mutation-specific restriction enzyme digest, without the need for sequencing (Figure 
3.5). The distribution of mutations reported in this chapter is similar to that in previous 
studies, with the most frequent mutation, accounting for approximately 50% of 
mutations detected, converting an aspartate residue to a tyrosine at position 835 in the 
coding sequence (D835Y). There were three novel mutations which were detected in the 
present study, each in a single case. In one of these cases, a 16 base pair region of exon 
20 was duplicated, the first report of a tandem duplication within this region of FLT3. 
Functional studies will be required in order to determine whether these mutations lead 
to constitutive activation of the FLT3 kinase.   
 
Whilst the increased frequency of FLT3/TKD mutations in this study can partly be 
explained by the increased sensitivity of the dHPLC technique, this is not the only 
explanation, as even using EcoRV screening alone, the incidence would have been 
10.8%, considerably higher than most other studies using the same method. There are a 
number of possible explanations for this. Firstly, although unlikely, it is possible that 
the modification to the EcoRV screening technique used in this study may have led to 
an increased sensitivity for the detection of lower level mutants. Secondly, it has 
previously been shown that FLT3/TKD mutations are associated with a leukocytosis at 
diagnosis (see chaper 4). It is more likely therefore, that sufficient material would have 
been available from FLT3/TKD
+ cases than cases with FLT3/WT, although why this 
should differ between the present and other cohorts is unclear. Thirdly, as analysis of  
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the EcoRV digest was made in parallel with dHPLC analysis, it is possible that the 
dHPLC increased confidence in identifying difficult cases by EcoRV. Finally, variation 
in inclusion criteria between the studies, for example relating to the age of patients 
studied, may have influenced the overall incidence detected. 
 
One potential disadvantage of the dHPLC technique is that it is dependent on the 
presence of heteroduplexes for the detection of mutant positive cases. Loss of the wild 
type allele has been reported for FLT3/ITDs (Kottaridis et al, 2001, Raghavan et al, 
2005, Thiede et al, 2002, Whitman et al, 2001), if the same occurs in FLT3/TKD
+ cases 
then these may be missed by dHPLC due to the lack of heteroduplexes. In practice, 
however, this is unlikely to be the case as even in samples where there is no FLT3/WT 
in any of the mutant cells, it is likely that there would be small amounts of 
‘contaminating’ gDNA from FLT3/WT non-leukaemic cells sufficient to create some 
heteroduplexes and an abnormal dHPLC chromatogram. In the above study, of 1178 
cases that were negative by dHPLC 269 were also screened by EcoRV digestion, all of 
these cases were WT by both techniques. There were only 2 cases detected by EcoRV 
screening with partial loss of the WT allele, both these cases were detected by dHPLC 
but had the appearance of lower level mutants (Figure 3.6). The measurement and 
significance of FLT3/TKD mutant levels are discussed in more detail in chapter 5. 
 
In conclusion, the data presented in this chapter shows that dHPLC is a sensitive and 
rapid means of screening for FLT3/TKD mutations and is superior to EcoRV restriction 
enzyme screening. This information is significant to ongoing studies where FLT3/TKD 
mutation screening is required. 
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4  15BUCHAPTER 4: CLINICAL CHARACTERISTICS AND 
PROGNOSTIC IMPACT OF FLT3/TKD MUTATIONS AND 
COMPARISON WITH FLT3/ITDs IN YOUNG ADULTS WITH 
AML 
 
4.1  36BUIntroduction 
 
In order to understand the clinical characteristics and outcome of patients with 
FLT3/TKD
+ AML it is important to be able to compare and contrast this with the 
features of patients with FLT3/ITDs in order that the two types of mutation can be 
directly compared. 
 
4.1.1  117BClinical characteristics of AML patients with a FLT3/ITD 
Following the discovery of FLT3/ITDs in patients with AML, an important question to 
address was whether the presence of a FLT3/ITD was associated with particular clinical 
phenotypes. Furthermore, in view of the limitations of current prognostic risk 
stratification in AML (see chapter 1), there was also considerable interest in whether 
FLT3/ITDs were a useful molecular marker for predicting response to therapy and long-
term outcome in patients with AML. These questions have been addressed by screening 
large cohorts of patients for FLT3/ITDs. The results of these studies are summarised in 
Tables 4.1 and 4.2. The incidence reported for FLT3/ITDs in these cohorts is 
approximately 25% but varies considerably, with incidences reported between 13.2% 
and 38.5%, partly relating to heterogeneity in the age and cytogenetic status of the 
patients studied. There are, nevertheless, a number of findings that are reproducible 
across the studies. For example, in terms of the clinical features at presentation, the 
most striking finding is the association between the presence of a FLT3/ITD, a high 
WBC and high BM blast percentage. Consistent with this, a number of studies have also 
shown that FLT3/ITDs are associated with a high serum level of lactate dehydrogenase 
(LDH) at diagnosis, although this data is not available from the majority of studies. 
Some studies have suggested that the incidence of FLT3/ITDs is higher in younger 
compared to older adults with AML (Schnittger et al, 2002, Stirewalt et al, 2001). 
However, this has not been shown in any of the other series, and interestingly, 
paediatric AML cohorts have generally shown a lower incidence of FLT3/ITDs than 
those seen in adult patients (Kottaridis et al, 2003, Meshinchi et al, 2006).   
76
Table 4.1: Studies of the clinical characteristics of adult AML patients with FLT3/ITDs  
FAB Type  Cytogenetics  Reference No.  Median Age 
(range)  ITD
+ (%)  Clinical Characteristics 
Increased Decreased  Increased  Decreased 
(Kiyoi et al, 
1997) 
74 (APL)  NR  15 (20.3)  Leucocytosis (P<.001) 
High LDH (P=.04) 
Low fibrinogen (P=.04) 
NR NR  NR  NR 
(Yokota et al, 
1997) 
112 NR  22  (19.6)  NR NR  NR  NR  NR 
(Kiyoi et al, 
1999) 
201 (non-
APL) 
NR  46 (22.9)  Leucocytosis (P<.001)  M2    NS  t(8;21) 
(Abu-Duhier et 
al, 2000) 
106 Mean  41.2 
(15-74) 
14 (13.2)  NR  NR    NS  Favourable 
(Rombouts et 
al, 2000) 
81  52 (16-88)  18 (22.2)  NS  NS    NS  NS 
(Kottaridis et 
al, 2001) 
854  41 (16-63)  227 (26.6)  Leucocytosis (P<.001) 
High BM Blasts (P<.001) 
M3 (P=.004) 
 
M0 (P=.02) 
M6 (P=.08) 
M7 (P=.04) 
t15;17 (P<.001 
NK (P<.001)          
 
 
inv(16) (P<.001) 
11q23 (P<.006) 
Complex (P<.001) 
Del(5q) (P.006) 
-5 (P.02); -7 (P=.01) 
t(8;21) (P<.001) 
(Stirewalt et al, 
2001) 
140  67 (56-88)  41 (29.3)  Lower age (P=.03) 
High BM Blasts (P=.003) 
Leucocytosis (P<.001) 
NS NS  NS  Adverse    (P<.001) 
(Whitman et al, 
2001) 
82 (de 
novo, NK) 
45 (20-59)  23 (28.0)  Leucocytosis (P=.01)  NS  NS  NR  NR 
(Frohling et al, 
2002) 
523  NR (16-60)  119 (22.8)  NR  NR  NR  NK (P<.001)         
t(15;17) (P<.001)   
inv(16) (P<.001) 
t(11q23) (P<.001) 
Complex (P<.001) 
t(8;21) (P<.001) 
(Frohling et al, 
2002) 
224 (NK)  47 (16-60)  71 (31.7)  De novo AML (P=.002) 
Leucocytosis (P<.001) 
High BM Blasts (P=.002) 
High LDH (P<.001) 
NR NR  N/A  N/A 
(Kainz et al, 
2002) 
53 (de 
novo, NK) 
58 (NR)  16 (30.2)  Leucocytosis (P<.05) 
High LDH (P<.05) 
NS NS  N/A  N/A  
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Table 4.1: continued 
(Kainz et al, 
2002) 
21 (APL)  52 (NR)  8 (38.1)  NS  NS  NS  NS  NS 
(Noguera et al, 
2002) 
90 (APL)  NR  33 (36.7)  Leucocytosis (P<.001) M3v  (P<.001)  NS BCR3  (P=.003)  NS 
(Thiede et al, 
2002) 
979 NR  200  (20.4)  Leucocytosis  (P<.001) 
High BM Blasts (P<.01) 
NS M6  and 
M4Eo 
(P<.05) 
NK (P<.001)  
t(15;17) (P<.001)  
t(6;9) (P<.001)  
Complex (P<.001) 
-7/7q- (P<.001) 
-5/5q- (P<.05) 
(Schnittger et 
al, 2002) 
1003 NR  234  (23.3)  Leucocytosis  (P<.001) 
Younger age (P=.04) 
Females (P=.02) 
De novo AML 
M3v 
M5b 
M5a 
M4Eo 
NK (P<.001)        
t(15;17) (P.01)         
inv16 (P<.001) 
Complex (P<.001) 
-5/-7/7q- (P<.001)  
t(8;21) (P=.006) 
t(11q23) (P=.006) 
(Boissel et al, 
2002) 
159  44 (15-65)  40 (25.2)  Leucocytosis (P=.002) 
Females (P=.04) 
NS NS  NK  (P<.001) 
 
t(8;21) (P<.001) 
inv(16) (P<.001) 
(Moreno et al, 
2003) 
208  NR  36 (17.3)  Leucocytosis (P<.001)  NS  NS  NK (P=.04)  NS 
(Shih et al, 
2003) 
107 (APL)  38 (2-76)  22 (20.6)  NS  M3v (P=.002)  NS  BCR-3 (P=.005)  NS 
(Sheikhha et al, 
2003) 
80  52 (17-74)  8 (10,0)  Leucocytosis (P=.004)  M4  NS  NK  NS 
(Jilani et al, 
2003) 
85  56 (18-84)  18 (21.2)  Leucocytosis (P<.001)  NS  NS  NS  NS 
(Andersson et 
al, 2004) 
109  70 (60-90)  20 (18.3)  Leucocytosis (P<.01)  M4 and M5 
(P<.05) 
NS NS  NS 
(Au et al, 2004)  82 (APL)  39 (7-87)  16 (19.5)  Leucocytosis ( P<.001)  M3v (P=.01)  NS  NS  NS 
(Chillon et al, 
2004) 
176  NR  34 (19.3)  NR (ITDs and TKDs 
grouped together) 
NR NR  NR  NR 
(Gale et al, 
2005b) 
203 (APL)  37 (1-60)  69 (34.0)  Leucocytosis (P<.001)  M3v (P<.001)  NS  t(15;17) alone (P<.001) 
BCR3 (P=.002) 
RARA-PML  
   expression (P=.01) 
NS 
(Wang et al, 
2005) 
143  39 (NR)  37 (25.9)  Leucocytosis (P<.001)  M3 and M5 
(P.01) 
NS NK 
t(15;17) 
NS  
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Table 4.1: continued 
(Auewarakul et 
al, 2005) 
256  NR  70 (27.3)  Leucocytosis (P<.001)  NR  NR  NR  NR 
(Kuchenbauer 
et al, 2005) 
170 (APL)  NR (17-83)  53 (38.4)  Leucocytosis (P=.003)  M3v (P<.001)  NS  BCR3 
High PML-RARA   
  expression level 
NS 
(Callens et al, 
2005) 
117 (APL)  43 (29-55)  45 (38.5)  Leucocytosis (P<.01)  M3v (P<.01)  NS  BCR2 and 3 (P<.05)  NS 
(Mathews et al, 
2007) 
94 (APL)  29 (NR)  20 (21.3)  Leucocytosis (P=.07)  NS  NS  BCR3 (P=.01)  NS 
NK indicates normal karyotype; APL, acute promyelocytic leukaemia; NS, not significant; NR, not reported. 
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Table 4.2: Studies of the clinical outcome of adult AML Patients with a FLT3/ITD 
Reference No.  Median Age 
(range) 
No. Mutants 
(%)  CR RD/DFS/EFS  RR  OS  Multivariate 
(Kiyoi et al, 1999)  201  49 (15-85)  46 (22.9)  ND  DFS Reduced  NR  Reduced (P=.004)  Reduced DFS (P=.006) 
OS NS 
(Kiyoi et al, 1999)  NR  <60 yrs only  NR  NR  NR  NR  NR  OS reduced (P=.008) 
(Abu-Duhier et al, 
2000) 
106 Mean  41.2 
(15-74) 
14 (13.2)  NR  NR  NR  Reduced (P<.001)  NR 
(Rombouts et al, 2000)  70  NR  17 (24.3)  Reduced 
(P=.03) 
Reduced (P=.002)  NR  Reduced (P=.001)  NR 
(Kottaridis et al, 2001)  854  41 (16-63)  227 (26.6)  NS  DFS and EFS 
reduced (P<.001) 
Increased 
(P<.001) 
Reduced (P<.001)  Increased RR (P<.001) 
DFS reduced (P<.001) 
OS reduced (P=.009) 
(Stirewalt et al, 2001)  140  67 (56-88)  41 (29.3)  NS  NS  NS  NS  NS 
(Frohling et al, 2002)  224 (NK)  47 (16-60)  67 (29.9)  NS  RD reduced (P=.007)  NR  Reduced (P<.001)  NR for ITD alone 
(Noguera et al, 2002)  90 (APL)  NR  33 (36.7)  NS  NS  NS  NS  NS 
(Thiede et al, 2002)  640 (Non-APL)  NR  111 (17.3)  NS  DFS Reduced 
(P=.03) 
NR Reduced  (P.09)  NS 
(Thiede et al, 2002)  254 (de novo, IR)  <60yrs  56 (22.0)  NS  Reduced (P=.007)  Increased 
(P=.008) 
NS NS 
(Schnittger et al, 2002)  563  NR  126 (22.4)  NS  EFS reduced (P.007)  NR  NS  NR 
(Kainz et al, 2002)  53 (de novo, NK)  58 (NR)  16 (30.2)  NS  DFS reduced (P=.02)  NR  Reduced (P=.003)  Reduced OS (P=.002) 
(Kainz et al, 2002)  21 (APL)  52 (NR)  8 (38.1)  Improved 
(P=.05) 
NS NS  Improved  (P=.06)  NR 
(Boissel et al, 2002)  159  44 (15-65)  40 (25.2)  NS  NS  NS  NS  NS 
(Moreno et al, 2003)  146  NR  28 (19.2)  NS  DFS reduced (P=.03)  NR  Reduced (P=.003)  NR 
(Shih et al, 2003)  107 (APL)  38 (2-76)  22 (20.6)  NS  NS  NS  NS  NR 
(Sheikhha et al, 2003)  80  52 (17-74)  8 (10,0)  NR  Reduced (P=.04)   NR  Reduced (P=.007)  NR 
(Jilani et al, 2003)  85  56 (18-84)  18 (21.2)  NS  NS  NR  Reduced OS in 
<50yrs (P=.02) 
NR 
(Andersson et al, 2004)  109   70 (60-90)  20 (18.3)  NS  NS  NS  NS  NR 
(Au et al, 2004)  82 (APL)  39 (7-87)  16 (19.5)  NS  Reduced  (P=.05)  NR  NS  NS 
(Gale et al, 2005b)  203 (APL)  37 (1-60)  69 (34.0)  NS  NS  NS  NS  NS 
(Wang et al, 2005)  143  39 (NR)  37 (25.9)  Reduced 
(P=.01) 
NR NR  NR  NR  
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Table 4.2: continued 
(Kuchenbauer et al, 
2005) 
170 (APL)  NR (17-83)  53 (38.4)  NR  NS  NR  Reduced (P=.09)  NS 
(Callens et al, 2005)  117 (APL)  43 (29-55)  45 (38.5)  NS  NR  NS  Reduced (P=.09)  NR 
(Auewarakul et al, 
2005) 
256 NR  70  (27.3)  NR  NR  NR  Reduced  (P=.002)  NR 
(Mathews et al, 2007)  94 (APL)  29 (NR)  20 (21.3)  NS  NS  NR  NS  NR 
IR indicates intermediate risk; NK indicates normal karyotype; APL, acute promyelocytic leukaemia; NS, not significant; NR, not reported.  
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Correlation of FLT3/ITD status with FAB subtypes demonstrated that FLT3/ITDs are 
particularly common in patients with M3 (acute promyelocytic leukaemia, APL), more 
specifically the microgranular variant (M3v), as well as the monocytic leukaemias (M4 
and M5a). Conversely, some studies have shown that FLT3/ITDs are uncommon in 
M4Eo, M5b, M6 and M7. Some, but not all studies, have observed an increased 
frequency of FLT3/ITDs in patients with de novo AML compared to those with 
secondary AML arising as a transformation from myelodysplasia.  
 
Analysis of karyotype of the leukaemic blasts at diagnosis and correlation with 
FLT3/ITD mutation status is of considerable importance as this may provide biological 
insights into cooperating genetic events in AML. These analyses have shown that 
FLT3/ITDs are found at an increased frequency in patients with a normal karyotype 
(NK), a t(15;17) translocation and the rare t(6;9) translocation. Conversely, FLT3/ITDs 
are uncommon in patients with the core binding factor (CBF) leukaemias inv(16) and 
t(8;21), patients with a complex karyotype, patients with 11q23 (mixed lineage 
leukaemia [MLL]) abnormalities and patients with complete or partial deletion of 
chromosomes 5 and 7. In terms of cytogenetic risk groups, FLT3/ITDs are found at a 
reduced frequency in patients with favourable (excluding APL) and adverse 
cytogenetics and are more common in cases with intermediate cytogenetics. 
 
4.1.2  118BClinical outcome of patients with FLT3/ITD
+ AML 
With regards to clinical outcome, Kiyoi et al (1999) were the first group to screen a 
large cohort of adult patients with non-APL, de novo AML. They demonstrated an 
adverse outcome in FLT3/ITD
+ patients, a finding that remained highly significant in 
multivariate analysis and that has been reproduced in most, but not all, studies (Table 
4.2). Consequently, it is now widely accepted that FLT3/ITDs are an adverse prognostic 
marker predicting for reduced OS in comparison with FLT3/WT patients. Importantly, 
patients with an ITD achieve CR at a similar rate to those with FLT3/WT. The presence 
of a FLT3/ITD, however, predicts for a much higher RR, particularly in the crucial 
intermediate cytogenetic risk group where karyotype is not an informative prognostic 
marker as the majority of patients have a NK. For example, in the study from the 
department at UCL it was shown that in the intermediate risk group the RR at 5 years 
was 48% for FLT3/WT patients as opposed to 74% for FLT3/ITD
+ patients (Kottaridis 
et al, 2001). In multivariate analysis in the MRC cohort of patients, the presence of a 
FLT3/ITDs was the single most powerful predictor of RR in young adults with AML.  
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This is particularly relevant for risk stratification as relapse remains the main cause of 
treatment failure in AML. At a biological level, the increased RR associated with 
FLT3/ITDs but lack of difference in CR rate is of interest. It suggests that, whilst the 
presence of a FLT3/ITD does not influence the chemosensitivity of the bulk of 
leukaemic cells, in patients who enter remission, residual leukaemic stem cells are less 
likely to be eradicated by post remission therapies in patients with a FLT3/ITD than 
those without a FLT3/ITD. 
 
4.1.3  119BClinical features and outcome of patients with FLT3/TKD
+ AML 
In view of the highly significant clinical associations of FLT3/ITDs in AML, following 
the discovery of FLT3/TKD mutations there was considerable interest in whether these 
mutations were associated with the same clinical features. The clinical features and 
prognostic implications of FLT3/TKD mutations reported in the literature are 
summarised in Tables 4.3 and 4.4. Like FLT3/ITDs, most studies have demonstrated 
that FLT3/TKDs are associated with a leucocytosis at diagnosis. A number of studies 
have also shown that FLT3/TKD mutations are less common in patients with secondary 
AML. The cytogenetic associations of FLT3/TKD mutations are less clear than for 
FLT3/ITDs. This may partly relate to the reduced frequency of FLT3/TKD mutations, 
necessitating the study of much larger cohorts of patients in order to have the power to 
demonstrate such associations. The largest studies reported to date, excluding the data 
presented in this chapter, have suggested that, like FLT3/ITDs, FLT3/TKD mutations 
are also observed at an increased frequency in patients with a NK (Bacher et al, 2008, 
Thiede et al, 2002). There was also an inverse correlation between the presence of a 
FLT3/TKD mutation and a complex karyotpe or deletion of chromosome 5.  
 
An area of considerable interest in the literature relates to the clinical significance of 
FLT3/TKD mutations in non-APL AML. As FLT3/ITDs may prove to be a clinically 
useful marker for risk stratification in AML, it is important to know whether 
FLT3/TKDs are associated with a similarly adverse prognosis. Many different groups 
have attempted to address this question but all have failed to show a statistically 
significant impact of a FLT3/TKD mutation on OS (Table 4.4). One group observed a 
trend for reduced OS (P=.09) associated with FLT3/TKDs in a study including 37  
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Table 4.3: Clinical characteristics of patients with FLT3/TKD mutations 
Reference No.  Median Age 
(range) 
No. Mutants 
(%) 
Dual TKD/ITD 
mutants (%)  Clinical Characteristics  FAB Type  Cytogenetics 
(Abu-Duhier et al, 2001)  97  NR (16-85)  7 (7)  0 (0)  NS  NS  NS 
(Yamamoto et al, 2001)  429  NR  30 (7)  1 (0.2)  NS  Increased: M5 
(P=.02) 
NS 
(Thiede et al, 2002)  979  NR  75 (7.7)  17 (1.7)  Leucocytosis (P<.001) 
High BM Blasts (P<.01) 
NS Increased:  NK  (P<.01) 
Reduced: -5/5q- (P<.05) 
(Moreno et al, 2003)  208  NR  20 (9.6)  4 (2.2)  NS  NS  NS 
(Frohling et al, 2002)  224 (NK)  47 (16-60)  32 (14.3)  4 (1.8)  De novo AML (P=.002) 
High BM Blasts (P=.002) 
NR N/A 
(Noguera et al, 2002)  90 (APL)  NR  7 (7.8)  NR  NR  NR  NR 
(Sheikhha et al, 2003)  80  52 (17-74)  6 (7.5)  0 (0)  NS  NS  NS 
(Shih et al, 2003)  107 (APL)  38 (2-76)  20 (18.7)  3 (2.8)  NS  NS  NS 
(Shih et al, 2004)  120  42 (15-74)  13 (10.8)  NR  NS  NS  NR 
(Andersson et al, 2004)  109  70 (60-90)  11 (10.1)  3 (2.8)  Leucocytosis (P=.07)  NS  NS 
(Au et al, 2004)  82 (APL)  39 (7-87)  18 (22.0)  1 (1.2%)  NS  NS  NS 
(Chillon et al, 2004)  135  NR  7 (5.2)  NR  NR  NR  NR 
(Gale et al, 2005b)  203 (APL)  37 (1-60)  23 (11.3)  4 (2.0)  Leucocytosis (P=.001)  NS  NS 
(Auewarakul et al, 2005)  256  NR  15 (5.9)  7 (2.7)  NS  NS  NS 
(Kuchenbauer et al, 2005)  170 (APL)  NR (17-83)  8 (5.7)  1 (0.6)  NS  NS  NS 
(Callens et al, 2005)  112 (APL)  43 (29-55)  22 (19.6)  8 (7)  Increased in males (P<.05)  NS  NS 
(Mathews et al, 2007)  94 (APL)  29 (NR)  11 (11.7)  0 (0)  NS  NS  NS 
(Whitman et al, 2008)  217 (NK)  47 (19-59)  16 sole TKD+ 
(7.4) 
3 (1.4) excluded  Leucocytosis (P<.001) 
High BM blast % (P<.001) 
NS N/A 
(Bacher et al, 2008)  3082  63 (18-92)  147 (4.8)  NR  Leucocytosis (P<.001) 
De novo AML (P=.01) 
Increased: 
M3v (P=.02) 
M4 (P<.001) 
M5b (P<.001) 
Reduced: 
M2 (P<.001) 
M6 (P=.01) 
Increased: 
NK 
Reduced: complex 
karyotype (P<.001) 
NK indicates normal karyotype; APL, acute promyelocytic leukaemia; NS, not significant; NR, not reported. 
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Table 4.4: Clinical Outcome of AML Patients with a FLT3/TKD 
Reference No.  Median  Age 
(range) 
No. Mutants (%)  CR  DFS  RR  OS  Multivariate 
(Abu-Duhier et 
al, 2001) 
82 NR  7  (9) NR  NR  NR    NS  NR 
(Yamamoto et 
al, 2001) 
201 NR  8  (4)  NS  NS  NS  NS  NR 
(Thiede et al, 
2002) 
640 (Excluding 
APL) 
NR  37 Sole TKD (5.8)  NS  NS  NR  Reduced (P=.09)  NS 
(Thiede et al, 
2002) 
254 (de novo, 
intermediate risk) 
<60yrs  20 Sole TKD (7.9)  NS  NS  NS  Reduced (P=.015)  NS 
(Frohling et al, 
2002) 
224 (NK only)  47 (16-60)  28 sole TKD (12.5)  NS  NS  NS  NS  NR 
(Moreno et al, 
2003) 
146 NR  14  (9.6)  NS  Reduced  (P=.04)  NR  NS  NR 
(Sheikhha et al, 
2003) 
80 52  (17-74)  6  (7.5)  NS  NS  NS  NS  NS 
(Shih et al, 
2003) 
107 (APL only)  38 (2-76)  20 (18.7)  NS  NS  NS  NS  NR 
(Shih et al, 
2004) 
120  42 (15-74)  13 (10.8)  NR  NR  NS  NS  NR 
(Andersson et 
al, 2004) 
109 (>60 yrs 
only) 
70 (60-90)  11 (10.1)  NS  NS  NS  NS  NR 
(Au et al, 2004)  82 (APL only)  39 (7-87)  18 (22.0)  NS  NS  NR  NS  NS 
(Gale et al, 
2005b) 
203 (APL only)  37 (1-60)  19 TKD only (9.4)  Reduced CR (P=.04) 
Increased ID (P=.04) 
NR NS  Reduced  (P=.05)  NS 
(Auewarakul et 
al, 2005) 
256 NR  15  (5.9)  NR  NR NR  NS  NR 
(Kuchenbauer 
et al, 2005) 
170 (APL only)  NR (17-83)  8 (5.7)  NR  NS  NR  NS  NS 
(Callens et al, 
2005) 
112 (APL only)  43 (29-55)  22 (19.6)  NS  NR  NS  NS  NR 
(Mathews et al, 
2007) 
94 (APL only)  29 (NR)  11 (11.7)  NS  NS  NR  NS  NR  
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Table 4.4: continued 
(Whitman et al, 
2008) 
217 (de novo, NK, 
<60) 
47 (19-59)  16 sole TKD+ (7.4)  NS  Reduced (P=.01)  NR  NS  Reduced  DFS (P=.02)  
OS NS 
(Bacher et al, 
2008) 
1051 NR 69  (6.6)  NS  NS  NS  NS  NS 
Three studies were published after completion of the work presented in this thesis and are included in the table for completion. NK indicates normal 
karyotype; APL, acute promyelocytic leukaemia; NS, not significant; NR, not reported.  
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TKD
+ patients, excluding those with dual FLT3/TKD and FLT3/ITD mutations (Thiede 
et al, 2002). This study also performed a subgroup analysis of patients <60 years old 
with de novo, NK AML that included 20 FLT3/TKD
+ patients. This subgroup analysis 
suggested that FLT3/TKDs were associated with an adverse OS (P.015) although, 
interestingly, there was no impact on RR or DFS. The uncertainty regarding the 
prognostic impact of FLT3/TKDs is partly due to the low incidence of the mutations 
such that relatively small numbers of mutant-positive patients have been investigated. In 
order to address this, a meta-analysis of four studies was performed which concluded 
that the outcome of FLT3/TKD mutations may be similar to that of FLT3/ITDs (Yanada 
et al, 2005). However this meta-analysis only included a total of 83 mutant positive 
patients, with consequently wide confidence intervals. Furthermore, whilst FLT3/TKD 
mutations were suggested to have an adverse DFS, no significant impact on OS was 
observed. Moreover, the amalgamation of these retrospective, observational studies 
with heterogeneous patient age and treatment protocols warrants a degree of caution in 
the interpretation of the data.  
 
A definitive study to determine the prognostic significance of FLT3/TKD mutations is, 
therefore, important for the application of risk-adapted treatment in these patients, 
particularly in view of the debate regarding optimal therapy for FLT3/ITD
+ patients 
(Gale et al, 2005a, Litzow 2005) and the current interest in molecularly targeted therapy 
with FLT3 inhibitors (Sternberg and Licht 2005). The clinical characteristics and 
prognostic impact of FLT3/TKD mutations were therefore examined in a large cohort of 
uniformly treated young adult AML patients with comprehensive clinical follow-up 
data available. 
 
4.2  37BUPatients, Materials and Methods 
 
4.2.1  120BPatients 
As detailed in chapter 3, 1339 adults with AML entered into either the UK MRC AML 
10 (n=444) or AML12 (n=895) trials were screened for FLT3/TKD mutations. 
Demographics and cytogenetic data on the patients included in this analysis were 
available via the MRC Clinical Trial Unit and are shown in Table 4.5. Both these trials 
were also open to children, but the present analysis was only conducted on samples 
from patients ≥15 years of age. Median age at trial entry was 42 years and only 29 were 
over 60 years of age. The majority of patients had de novo AML (n=1246, 93%).  
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Details of FLT3/TKD mutation screening are described in chapter 3. The FLT3/ITD 
status on this cohort of patients was available as a result of previous work in the 
department at UCL (Gale et al, 2005a). 
 
4.2.2  121BTherapy 
The MRC AML 10 trial had two randomisations in patients <56 years of age. The first 
randomisation was between two different induction schedules. One consisted of 2 
courses of DAT chemotherapy (daunorubicin [50 mg/m
2 by slow intravenous push on 
days 1, 3 and 5]; cytarabine [100 mg/m
2 12-hourly by iv push on days 1 to 10 for the 
first course and 1 to 8 for the second course] and thioguanine [100 mg/m
2 12 hourly, 
orally days 1-10 for the first course and 1 to 8 for the second course]). The other 
induction regimen was ADE (cytarabine  [100 mg/m
2 12-hourly by iv push on days 1 to 
10 for the first course and 1 to 8 for the second course]; daunorubicin [50 mg/m
2 by 
slow intravenous push on days 1, 3 and 5] and etoposide [100 mg/m
2 by 1 hour 
intravenous infusion days 1 to 5]). Patients who entered CR then received consolidation 
with MACE (amsacrine [100 mg/m
2 by 1 hourly intravenous infusion days 1 to 5]; 
cytarabine [200 mg/m
2 iv by continuous infusion days 1 to 5] and etoposide [100 mg/m
2 
by 1 hour intravenous infusion days 1 to 5]) and MiDAC (Mitozantrone [10 mg/m
2 by 
short intravenous infusion days 1 to 5]; cytarabine [1.0 g/m
2 by short intravenous 
infusion days 1 to 5]). The second randomisation was open to patients who completed 4 
courses of chemotherapy and compared high-dose therapy with autologous bone 
marrow transplant (BMT) rescue versus no further therapy. Patients who had an HLA-
matched sibling donor were scheduled for allogeneic BMT after 4 courses of 
chemotherapy and were not randomised to receive autologous-BMT or not.  
 
The MRC AML 12 trial also randomised patients between 2 different induction 
schedules. One consisted of 2 cycles of ADE chemotherapy as used in AML 10. The 
other induction regimen consisted of 2 cycles of MAE (mitoxantrone [12 mg/m
2 by 
intravenous infusion on days 1, 3 and 5]; cytarabine  [100 mg/m
2 12-hourly by iv push 
on days 1 to 10 for the first course and 1 to 8 for the second course]; and etoposide [100 
mg/m
2 by 1 hour intravenous infusion days 1 to 5]). After the first course of induction 
therapy, patients were assigned into risk groups (good, standard or poor) on the basis of 
karyotype and response to the first course of induction therapy as detailed in chapter 1. 
Good or standard risk patients (patients who entered CR and who completed both 
courses of induction chemotherapy) received one course of consolidation therapy with  
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MACE (identical to AML 10 schedule). Following this, good risk patients were 
randomised to receive one of two options. One was a further course of consolidation 
chemotherapy (MiDAC, identical to the AML 10 schedule). The other was two courses 
of consolidation chemotherapy (ICE then MiDAC). Standard risk patients were also 
eligible for these two options but in addition were randomised between two further 
options, immediate BMT or ICE followed by BMT. Patients in the transplant groups 
received an allogeneic BMT if an HLA-matched sibling donor was available or 
autologous BMT if a donor was not available. Poor risk patients were treated on a MRC 
relapsed/refractory protocol. 
 
4.2.3  122BEnd Points 
CR was defined as a normocellular BM aspirate with normal trilineage maturation and 
less than 5% blasts without a requirement for regeneration of peripheral counts. In 
practice, 97% of patients who achieved the protocol prescribed definition of CR had 
peripheral regeneration of neutrophils to 1.0 x 10
9/L and platelets to 100 x 10
9/L. 
Remission failures were classified by the clinicians as either partial remission (5%-15% 
blasts or less than 5% blasts but a hypocellular BM), resistant disease (RD) defined as 
greater than 15% blasts in the BM, or induction death (ID) i.e. related to treatment or 
hypoplasia. When a clinician’s evaluation was not available, deaths within 30 days of 
trial entry were classified as IDs and all other failures to achieve remission as RD. OS 
was defined as the time from trial entry to death. For patients entering CR, DFS was the 
time from first CR to an event (death in first CR or relapse). RR was calculated as the 
cumulative incidence of relapse (CIR) for which death during CR was considered a 
competing risk. 
 
4.2.4  123BStatistical methods 
The Mantel Haenszel test for trend (for ordinal data) and Fisher’s exact test (in 2 x 2 
tables) or chi-squared tests (for larger tables) were used to test for differences in clinical 
and demographic data by FLT3/TKD positivity. Kaplan-Meier life-tables were 
constructed for survival data and were compared by means of the log rank test, with 
surviving patients in AML10 censored on 1
st April 2004, and surviving patients in 
AML12 censored on 1
st April 2005. Follow up was up to date for the vast majority of 
patients and the small number of patients lost to follow up were censored at the date 
they were last known to be alive. Analysis of time to event data was using standard 
logrank methods. Odds ratio (OR) plots, with tests for heterogeneity, were used to  
89
investigate whether the prognostic relevance of FLT3/TKD differed between FLT3/ITD 
subgroups and different levels of FLT3/TKD mutant. Multivariate analysis was used to 
find the factors most closely associated with CR rate, and multivariate Cox models were 
used to analyse OS, DFS and CIR. Models were fitted using forward selection, with 
variables added to the model if they reached significance at the P = .01 level in 
univariate analysis. All P values are two-tailed. Statistical analysis was performed by 
Robert Hills (Department of Haematology, Welsh School of Medicine, Cardiff). 
 
4.3  38BUResults 
 
4.3.1  124BDemographics and presenting clinical features of patients with a 
FLT3/TKD mutation 
Details of the demographics and presenting clinical features of the 1339 patients 
stratified according to FLT3/TKD mutation status are given in Table 4.5. The presence 
of a mutation was not related to gender or age. Mutations were found in all FAB 
subtypes except M7, and there was some evidence that they occurred at an increased 
frequency in M4 (P=.04 for heterogeneity). FLT3/TKD mutations were less frequent in 
patients with secondary AML compared to de novo disease (P=.007). There was some 
evidence that the presence of a FLT3/TKD mutation may be correlated with a high 
WBC at presentation. The median WBC was 25.6 x 10
9/L in mutant-positive patients 
versus 18.5 x 10
9/L in WT patients (P=.05).  
 
Information on karyotype was available in 1083 patients (Table 4.6). There was a high 
incidence of FLT3/TKD mutations in patients with inv(16) (13 of 55 patients, 24%, 
P=.009), but a low incidence in patients with t(8;21) although this was not statistically 
significant (5 of 78 patients, 6.4%, P=.15). There was also a low incidence in cases with 
adverse cytogenetics (3 of 107 patients, 3%, P=.003), in particular those with a complex 
karyotype (1 of 62 patients, 2%, P=.007). 
 
4.3.2  125BComparison of presenting clinical characteristics of FLT3/TKD
+ and 
FLT3/ITD
+ patients 
In the total cohort of 1339 patients, 372 (27.8%) were FLT3/ITD
+. Of 967 patients 
without a FLT3/ITD (FLT3/ITD
-), 127 were FLT3/TKD
+ (13%) compared to 34 of 372 
FLT3/ITD
+ patients (9%), a negative correlation that was statistically significant   
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Table 4.5 Clinical and demographic characteristics of 1339 AML patients 
 
Total 
(n) 
FLT3/TKD
-
(% of total 
TKD
-) 
FLT3/TKD
+ 
(% of total 
TKD
+) 
Percent 
FLT3/TKD
+ 
P 
Percent 
FLT3/ITD
+ 
Total  1339 1178  161  12%    28% 
AML10  444 382  (32)  62  (39)  14%  26% 
AML12  895 796  (68)  99  (61)  11% 
.12 
29% 
Type of AML           
De novo  1247  1088 (92)  158 (98)  13%  28% 
Secondary  92 89  (8)  3  (2)  3% 
.007 
25% 
FAB type           
 M0  38 35  (3)  3  (2)  8%  8% 
 M1  215 196  (17)  19  (12)  9%  29% 
 M2  324 295  (26)  29  (19)  9%  24% 
M3  226 194  (17)  32  (21)  14%  38% 
 M4  278 232  (21)  46  (30)  17%  30% 
 M5  130 112  (10)  18  (12)  14%  32% 
 M6  30 24  (2)  6  (4)  20%  7% 
 M7  15 15  (1)  0  0%  7% 
 RAEB-t  19 19  (2)  0  0%  5% 
 Bilineage  1 1  (<.5)  0  0% 
.04 
100% 
 Unknown  63 55  8  0%   20% 
Sex           
Female  667 581  (49)  86  (53)  13%  29% 
Male  672 597  (51)  75  (47)  11% 
.3 
27% 
Age (y)           
15-29  280  242 (21)  38 (24)  14%    25% 
 30-39  297  264 (22)  33 (21)  11%    25% 
 40-49  387  339 (29)  48 (30)  12%  .5  32% 
 50-59  346  308 (26)  38 (24)  11%    27% 
 60 or older  29 25  (2)  4  (2)  14%    38% 
 Median  42 42  41  N/A   N/A 
WBC (x10
9/L)            
 <10  475 429  (37)  46  (30)  10%  16% 
 10-19.9  196 172  (15)  24  (15)  12%  25% 
 20-49.9  276 240  (21)  36  (23)  13%  30% 
 50-99.9  190 161  (14)  29  (18)  15%  38% 
 100 or above  177 153  (13)  24  (15)  14% 
 
.05 
48% 
 Unknown  25 23  2  8%   20% 
 Median  19.1 18.5  25.6  N/A    N/A 
Cytogenetics            
 Favourable  307 262  (27)  45  (35)  15%  27% 
 Intermediate  669 590  (62)  79  (62)  12%  31% 
 Adverse  107  104 (11)  3 (2)  3% 
 
.003 
7% 
 Unknown  256 222  34  13%    30% 
P values relate to the incidence of FLT3/TKD mutations using Mantel-Haenszel 
test for trend in age, WBC count and cytogenetics, otherwise chi-squared or 
Fisher’s exact test used for heterogeneity. N/A indicates not applicable.  
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Table 4.6: Incidence of FLT3/TKD
+ patients in specific cytogenetic risk groups and subgroups 
Cytogenetics  Total 
(n) 
FLT3/TKD
– 
(n) 
FLT3/TKD
+ 
(n) 
FLT3/TKD
+ 
(%)  P  FLT3/ITD
+ 
(%) 
Favourable  307 262  45  15%    27% 
    t(15;17)  174 147  27  16%  .10  38% 
    t(8;21)  78 73  5  6%  .15  17% 
    inv(16)  55 42 13  24%  .009  7% 
           
Intermediate  669 590  79  12%    31% 
    Normal  452 396  56  12%  .6  35% 
    del(7q)  24 22  2  8%  1.0  4% 
    11q23  30 28  2  7%  .6  3% 
    +8  92 78 14  15%  .3  24% 
    +22  16 13  3  19%  .4  6% 
           
Adverse  107 104  3  3%    7% 
    Complex  62 61  1  1%  .007  5% 
    del (5q)  22 20  2  9%  1.0  0 
    -5  21 21  0  0%  .16  0 
    -7  42 40  2  5%  .2  2% 
    abn(3q)  33 32  1  3%  .17  15% 
           
Unknown  256 222  34  13%    30% 
P values are for Fisher exact test for the incidence of TKD mutations in each individual cytogenetic abnormality versus all other known 
karyotypes. 
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(P=.04). There were a number of clinical features which were similar between 
FLT3/ITDs and FLT3/TKDs, for example, both were associated with a high WBC at 
diagnosis. In addition to this, both types of mutation were found at an increased 
frequency in patients with M4 AML and were uncommon in patients with adverse 
cytogenetics. Conversely, there were a number of features associated with FLT3/TKD
+ 
cases that differed markedly from those of FLT3/ITD
+ cases. For example, FLT3/TKD 
mutations were uncommon in patients with secondary AML whereas in this cohort the 
incidence of FLT3/ITDs did not differ significantly between de novo and secondary 
AML. Unlike FLT3/ITDs, which are particularly frequent in patients with t(15;17) and 
normal cytogenetics, the only group in which FLT3/TKD mutations were more 
common were cases with inv(16), a cytogenetic subgroup in which FLT3/ITDs are 
uncommon. 
 
4.3.3  126BRelationship between the presence of a FLT3/TKD mutation and clinical 
outcome in patients with non-APL AML 
APL patients are biologically distinct from non-APL cases of AML and are treated 
according to different regimens. The impact of mutant FLT3 status on clinical outcome 
in patients from this cohort with APL has already been published in previous work from 
the department at UCL (Gale et al, 2005b). Therefore, for the analysis of the impact of 
FLT3/TKD mutations on clinical outcome, APL patients have been excluded. Of 1107 
non-APL cases, 127 were FLT3/TKD
+. Outcome data was available on the whole 
cohort with a median follow up of 7.9 years (range 6 – 193 months). The CR rate for all 
1107 patients was 85%. The presence of a FLT3/TKD mutation did not influence the 
rate of CR, ID or RD (Table 4.7). However, the presence of a FLT3/TKD mutation was 
associated with a reduced CIR at 5 years of 48% for FLT3/TKD
- versus 39% for 
FLT3/TKD
+ cases (P=.03). Furthermore, the DFS was also improved at 35% and 48% 
(P=.008) for FLT3/TKD
- versus FLT3/TKD
+ cases, which translated into an improved 
OS of 37% versus 53% respectively (P=.002). Of the total cohort of 1107 non-APL 
AML patients analysed for the impact of FLT3/TKD mutation status on clinical 
outcome, only 17 of the 127 mutant-positive patients received an allograft. This was an 
insufficient number for a robust analysis of the impact of allogeneic transplant 
according to FLT3/TKD mutation status and this analysis was therefore not performed. 
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4.3.4  127BImpact of cytogenetic subgroup on the prognostic impact of FLT3/TKD 
mutations 
It is possible that the prognostic impact of FLT3/TKDs may be influenced by the 
underlying cytogenetic subgroup. Furthermore, given the high proportion of cases of 
inv(16) that are FLT3/TKD mutant-positive, it is possible that this unequal distribution 
may account for the favourable prognosis associated with FLT3/TKDs. To address this, 
the cohort was stratified according to cytogenetic risk group and specific cytogenetic 
abnormality. There was no heterogeneity or trend in the effect of a FLT3/TKD mutation 
on CIR (Figure 4.2A) or OS between the different subgroups (Figure 4.2B). Kaplan-
Meier analysis also demonstrated that FLT3/TKD
+ patients had an improved survival in 
the favourable and intermediate risk categories (Figure 4.3).  As only 3 patients in the 
adverse cytogenetic risk group were FLT3/TKD
+, survival for these patients is not 
shown. 
 
Table 4.7: Clinical outcome in FLT3/TKD
– and FLT3/TKD
+ non-
APL AML patients 
  TKD
– TKD
+ OR (CI)  P  Adjusted result: OR 
(CI) 
Initial Response to therapy          
      CR  84%  88%  0.73 (0.44-1.21)  .2  0.80 (0.38-1.69); P.6 
      ID  6%  4%  0.68 (0.31-1.50)  .3  0.64 (0.19-2.15); P.5 
      RD  10%  8%  0.79 (0.42-1.48)  .5  0.94 (0.38-2.28); P.9 
          
Outcome at 5 years          
      CIR  48%  39%  0.75 (0.57-0.98)  .03  0.75 (0.53-1.07); P.11 
      DFS  35%  48%  0.74 (0.59-0.93)  .008  0.71 (0.52-0.97); P.03 
      OS  37%  53%  0.72 (0.58-0.89)  .002  0.71 (0.52-0.96); P.03 
P values are for Mantel-Haenszel test for initial response, and log-rank test for long 
term outcomes. Adjusted results show results of multivariate analyses adjusted for 
significant variables in forward selection regression model. OR indicates odds ratio; 
CI, 95% confidence intervals. 
 
 
4.3.5  128BAnalysis of both FLT3/TKD and FLT3/ITD status 
In view of the negative correlation between the presence of a FLT3/ITD and a 
FLT3/TKD mutation, outcome in a greater proportion of the FLT3/TKD mutant-
negative cases would be influenced by the presence of a FLT3/ITD. Therefore, the 
impact of both types of mutation was examined. Of the 1107 non-APL AML patients, 
723 (65%) had WT FLT3, 257 (23%) were FLT3/ITD
+ only, 100 (9%) FLT3/TKD
+ 
only and 27 (2%) had both mutations. The CIR at 10 years was 46% for FLT3 WT   
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Figure 4.1. Clinical outcome for non-APL AML patients stratified according to 
FLT3/ITD and FLT3/TKD status. (A) Cumulative incidence of relapse, (B) overall 
survival, (C) Analysis of overall survival showing effect of  FLT3/TKD status stratified 
by FLT3/ITD. 
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Figure 4.2. Cumulative incidence of relapse (A) and overall survival (B) stratified according to karyotype and cytogenetic category.  
96
 
 
Figure 4.3. Overall survival in non-APL AML patients according to cytogenetic risk 
group. Kaplan-Meier curves stratified according to FLT3/TKD status and cytogenetic 
risk group. As only 3 patients with adverse cytogenetics carried a FLT3/TKD mutation 
this curve is not shown,   
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patients, 37% for FLT3/ITD
-TKD
+ patients, 62% for FLT3/ITD
+TKD
- patients and 68% for 
FLT3/ITD
+TKD
+ patients (Figure 4.1A). OS for these groups was 36%, 51%, 24% and 
37% respectively (Figure 4.1B). A direct comparison of FLT3/TKD mutations and 
FLT3/ITDs demonstrated a highly significant difference in CIR (OR = 0.45, 95%  
confidence intervals [CI] = 0.33-0.61, P<.001) and OS (OR = 0.53, CI = 0.41-0.69, 
P<.001). There was no evidence that the impact of a FLT3/TKD mutation on OS differed 
according to FLT3/ITD status (test for interaction, P=.8), although there were only 27 
patients with both types of mutation (Figure 4.1C).  
 
4.3.6  129BMultivariate analysis 
A Cox multivariate analysis was performed, the variables considered being trial, 
cytogenetic risk group, age, sex, presentation WBC count, de novo or secondary AML, 
WHO performance status, and presence of a FLT3/ITD or TKD mutation. The prognostic 
impact of a FLT3/TKD mutation on OS was of borderline significance (OR = 0.71, CI = 
0.52-0.96, P=.03). Other variables were more powerful, including presence of a FLT3/ITD 
(OR = 1.43, 95% CI = 1.19-1.72, P<.001), cytogenetics (OR = 1.80, 95% CI = 1.51-2.16, 
P<.0001), age (OR = 1.02, 95% CI = 1.01-1.02, P<.001), sex (OR = 0.79, 95% CI = 0.67-
0.94, P=.007) and WHO performance status (OR = 1.13, 95% CI = 1.04-1.22, P=.003). The 
point estimate for the reduction in CIR associated with a FLT3/TKD mutation was of 
similar magnitude to the reduction in OS (OR = 0.75, 95% CI = 0.53-1.07, P=.13). The 
only variables predicting for increased CIR were the presence of a FLT3/ITD (OR = 1.82, 
95% CI = 1.46-2.27, P<.001) and cytogenetic risk group (OR = 1.70, 95% CI = 1.35-2.13, 
P<.001). The OR and CI for clinical outcome analyses of FLT3/TKD mutations adjusted in 
a multivariate analysis including the above variables are shown in Table 4.7. 
 
4.4  39BUDiscussion 
 
The data presented in this chapter describe the associations of FLT3/TKD mutations with 
clinical characteristics and outcome of a large cohort of uniformly treated young adults 
with AML. As the clinical phenotype of FLT3/ITDs has already been well described in the 
literature (Tables 4.1 and 4.2), one of the main questions for this analysis was whether 
FLT3/TKDs were clinically distinct from or associated with a similar phenotype to 
FLT3/ITDs. There were a number of similarities observed between the two types of  
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mutation. For example, like FLT3/ITDs, FLT3/TKDs were associated with a leucocytosis 
at presentation. Furthermore, both mutations were infrequent in cases with complex 
cytogenetics or t(8;21), although the latter was not significant for FLT3/TKDs. The inverse 
correlation between the concurrent presence of both types of mutation could also be 
interpreted as suggesting that they confer similar biological effects to the cell and there is 
little advantage, therefore, for the 2 mutations to occur together.  
 
A number of observations, however, suggest that the two different types of FLT3 mutation 
are clinically distinct. Firstly, they were associated with different underlying genetic events, 
and this had been noted in some, but not all, previously reported cohorts (Table 4.3). For 
example, with regards to cytogenetic subgroups, an increased frequency of FLT3/TKD 
mutations was noted in cases with inv(16), unlike FLT3/ITDs which were uncommon in 
this subgroup. Other cohorts have not examined sufficient numbers of FLT3/TKD
+ patients 
to demonstrate such associations, although some have observed a trend for increased 
numbers of FLT3/TKD mutants associated with inv(16) (Care et al, 2003, Libura et al, 
2003, Thiede et al, 2002). It has also been suggested that cases of FLT3/TKD
+ with inv(16) 
are restricted to those with variant CBFbeta-MYH11 fusion transcripts (Libura et al, 2003), 
although this data was not available in our analysis. A second difference between ITDs and 
TKDs in our cohort was in the reduced frequency with which FLT3/TKDs were detected in 
secondary compared to de novo AML, which was not observed for FLT3/ITDs. Other 
cohorts, however, have observed a lower frequency of FLT3/ITDs in patients with 
secondary AML (Table 4.1).  Finally, FLT3/ITDs have been shown in a number of studies 
to be found at a very high incidence in t(6;9) translocated cases of AML (42/55 cases, 
76.4%) whereas no FLT3/TKD mutations were detected in 51 patients screened (Thiede et 
al, 2007).  
 
The different cooperating genetic events associated with FLT3/ITDs and FLT3/TKDs may 
be a consequence of distinct mechanisms underlying the formation of each type of 
mutation, perhaps reflecting variable susceptibilities of the target cell of transformation to 
different types of DNA damage. Alternatively, the two types of mutation may lead to 
distinct intracellular events downstream of the activated receptor, with consequences for 
cellular phenotype and cooperation with other genetic events. The distinct patterns of gene 
expression that have been reported in primary leukaemic samples containing FLT3/ITDs  
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and TKD mutations (Neben et al, 2005) would support both explanations. It is, however, 
noteworthy that in vitro analysis in a cell model system transfected with the different types 
of mutant found that differential signaling was induced by the two mutations (Choudhary et 
al, 2005b). Moreover, in a mouse model transplanting retrovirally-transduced BM 
progenitors, the phenotype differed significantly according to the type of mutation 
transplanted (Grundler et al, 2005). Mice transplanted with a FLT3/ITD developed a lethal 
oligoclonal myeloproliferative disorder, those with an FLT3/TKD an oligoclonal 
lymphoproliferative disorder. The signalling events resulting from the two types of 
mutation are discussed in more detail in Chapter 7.  
 
It is possible, therefore, that the differential association of ITDs and TKDs with inv(16) 
cases relates to differences in cooperating biological pathways. However, despite the rare 
association between FLT3/ITDs and inv(16) in patients with AML, it is interesting that 
FLT3/ITDs have recently been shown to cooperate with inv(16) to generate a leukaemic 
phenotype in a mouse model (Kim et al, 2007). 
 
The most striking difference between FLT3/ITDs and FLT3/TKDs in our cohort of patients 
was the opposing impact on clinical outcome; the 10 year OS for FLT3/TKD
+ patients was 
51% compared to 24% for FLT3/ITD
+ patients (Figure 4.1B). This association of 
FLT3/TKD mutations with improved long-term survival was unexpected, but the effect was 
robust and remained significant in a multivariate analysis. It is likely to be attributable to a 
reduced RR in FLT3/TKD
+ patients (CIR at 10 years = 37% compared to 62% in 
FLT3/ITD
+ patients) (Figure 4.1A). There was no association of a FLT3/TKD mutation, 
nor a FLT3/ITD (Kottaridis et al, 2001) with attainment of CR. This suggests that any 
leukaemic progenitors which remain post induction chemotherapy may be more chemo-
sensitive if they are FLT3/TKD
+ and, therefore, more likely to be eradicated. These results 
are in contrast to those of previous studies. A recent meta-analysis of the major studies 
concluded that FLT3/TKD mutations are associated with inferior DFS, although there was 
no significant evidence of TKD mutation adversely affecting OS (Yanada et al, 2005). The 
differences from our study may relate to heterogeneity of patient inclusion criteria, 
treatment schedules, length of follow up or the play of chance owing to the relatively small 
number of mutant-positive patients in previous studies. The clinical outcome data in the 
present study was based on 127 mutant-positive, uniformly treated patients with  
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comprehensive clinical follow-up data compared with a total of 83 heterogeneously treated 
patients in the meta-analysis. 
 
The finding of different clinical outcome for two types of mutation in the same protein is 
surprising and raises some interesting biologic question regarding the mechanism(s) 
underlying this difference. Both types of FLT3 mutation lead to constitutive activation of 
the receptor in in vitro studies (Kiyoi et al, 1998, Yamamoto et al, 2001) and are thought to 
lead to loss of auto-inhibition of the kinase activity. Mutations in the TKD are thought to 
alter the configuration of the activation loop in a manner similar to that of ligand-induced 
conformational changes, allowing increased access of ATP and substrates to the kinase, 
whereas the tandem duplications are thought to disrupt the interaction between the JM 
domain and the activation loop which normally stabilises the kinase in its inactive 
configuration (Gilliland and Griffin 2002b, Griffith et al, 2004). The consequence of these 
different mechanisms may be quantitatively and/or qualitatively quite variable, for 
example, they may lead to altered substrate specificities downstream of the kinase 
(Songyang et al, 1995). Precisely how this may influence outcome is unclear. It is also 
possible that the difference in clinical outcome observed between the two mutant types is 
not a consequence of differential downstream signaling events but instead reflects the type 
of mutagenic event giving rise to the FLT3 mutation or the inherent susceptibility of 
different leukaemic stem cells to different types of DNA damage. 
 
As the genetic and epigenetic events that underlie AML become understood in more detail, 
there is a drive towards developing a molecular classification for this disease. For example, 
the current WHO classification of AML includes distinct subgroups on the basis of 
karyotype abnormalities such as t(15;17) and inv(16) (Harris et al, 1999). This 
classification may be relevant to the study of FLT3 mutations as there is some evidence the 
clinical impact of FLT3/ITDs may differ between APL and non-APL cases of AML (Gale 
et al, 2005b). In the present analysis we tested for heterogeneity of the prognostic impact of 
FLT3/TKD mutations between different cytogenetic groups. Whilst no heterogeneity was 
detected, even with over 1000 patients studied, the present analysis was inadequately 
powered to detect such differences. There was a suggestion that the presence of a 
FLT3/TKD mutation conferred a favourable prognosis within the inv(16) subgroup, 
although this did not reach statistical significance (OR 0.48, CI = 0.22 – 1.07, P=.1, Figure  
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4.2B). Such a subgroup analysis needs to include other cooperating mutations within this 
group of patients such as FLT3/ITDs, RAS and c-Kit mutations. Determining the 
prognostic impact of FLT3 mutations in CBF leukaemias will therefore require 
considerable expansion of the present cohort of patients to adequately address this question. 
 
As discussed in chapter 1, 40-50% of young adult patients with AML have an NK and there 
is particular interest in the use of molecular markers to stratify patients with NK AML into 
different risk categories (Mrozek et al, 2007). Understanding how these different mutations 
interact to impact the clinical phenotype is of considerable importance for this 
classification. Collecting sufficient numbers of patients for a robust analysis is the major 
limitation in such studies with regards to the less frequent genetic events such as MLL-
PTDs, CEBP/α, PTPN-11, AML-1 and WT-1 mutations (see chapter 1). A more frequent 
interaction does occur between FLT3 mutations and the recently described mutations of the 
nuclear chaperone protein NPM1 (Falini et al, 2005, Falini et al, 2007). In the NK group of 
patients, both FLT3/ITDs and FLT3/TKDs are associated with NPM1 mutations in the 
majority of cases. A recent analysis of the cohort of patients used in the studies presented 
here demonstrated that FLT3/ITDs are associated with an adverse prognosis in both NPM1
+ 
and NPM1
- patients (Gale et al, 2007). Likewise, the favourable prognosis associated with 
NPM1 mutants was independent of FLT3/ITD status. An analysis of the interaction 
between FLT3/TKD mutations and NPM1 mutations is warranted as it is possible that the 
observed favourable prognostic impact of FLT3/TKD mutations relates to the frequent 
presence of NPM1 mutations in FLT3/TKD+ patients. However, a recent study has 
suggested that the presence of a FLT3/TKD confers additional favourable prognostic 
impact in patients with a NPM1 mutation, although this was of borderline significance 
(Bacher et al, 2008).  
 
The results presented in this chapter have important implications for the treatment of 
patients carrying FLT3 mutations, particularly as there are new opportunities for the 
specific treatment of AML patients with aberrant FLT3 signaling using small molecule 
inhibitors targeting FLT3 (see chapter 6). Several FLT3 inhibitors are now available and 
are being assessed in combination with conventional chemotherapy in phase 3 clinical 
trials. If the different types of FLT3 receptor mutants have different downstream effects, 
then the effects of FLT3 inhibitors might also differ. Furthermore, in some centres, patients  
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with FLT3/ITDs are being considered for allogeneic transplantation in first remission 
(Litzow 2005), but in the absence of other poor prognostic factors, this might not be 
appropriate in patients with FLT3/TKDs.   
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5  16BUCHAPTER 5: THE IMPACT OF FLT3/TKD MUTANT LEVEL ON 
CLINICAL CHARACTERISTICS AND OUTCOME OF YOUNG 
ADULTS WITH AML 
 
5.1  40BUIntroduction 
 
Analysis of FLT3/ITD mutations has shown that the relative level of mutant and WT alleles 
varies widely in AML (Gale et al, 2007). Futhermore, FLT3/ITD mutant level has been 
shown to correlate with clinical characteristics and outcome (see below). Interestingly, 
FLT3/TKD mutation screening by dHPLC also revealed marked variability in the amount 
of heteroduplex that was present in FLT3/TKD
+ cases (see Chapter 3), most likely 
reflecting similar variability of FLT3/TKD mutant levels. However, the clinical analysis 
described in the previous chapter stratified patients solely according to the presence or 
absence of a FLT3/TKD mutation. It is possible that heterogeneity within the group of 
FLT3/TKD
+ patients may influence their clinical characteristics and prognosis. Therefore, 
in view of the biological and clinical significance of FLT3/ITD mutant level, the relative 
mutant level in FLT3/TKD
+ cases is also worthy of further exploration. 
 
5.1.1  130BBiological basis for different FLT3/ITD mutant levels 
Quantification of mutant level in FLT3/ITD
+ cases of AML has shown a very wide range of 
mutant level from 1% of total FLT3 alleles to greater than 90%. Study of the distribution of 
different mutant levels in our cohort of FLT3/ITD
+ patients showed that they could be 
classified into three main groups (Gale et al, 2007). These are defined here as low level 
mutants accounting for 1-24% of FLT3 alleles, high level mutants with 25 to 50% mutant 
alleles and very high level mutants with greater than 50% mutant alleles.  
 
The high level mutants are likely to represent cases where the majority of cells being 
heterozygous for the mutation. A low level of mutation, however, suggests that less than 
half the cells used to make the gDNA sample were heterozygous for the mutation. There  
are two possible explanations for this observation (Figure 5.1). Whilst it is possible that 
contamination by non-leukaemic cells in the gDNA sample has diluted the number of FLT3 
mutant alleles, both clonality analysis and study of NPM1 mutation level suggested that, in  
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Figure 5.1: Possible explanations for a low level mutation accounting for 20% of 
alleles.  
 
the majority of low level cases, this explanation was unlikely (Gale et al, 2007). It appears 
therefore, that in a proportion of cases with a low mutant level, FLT3/ITDs are only present 
in a minority of the leukaemic blasts.  
 
Whilst AML in young adults is a clonal disorder originally derived from a single cell, it is 
also clear that a number of different hits are required for the development of AML (see 
Chapter 1). The accumulation of different genetic events is likely to be temporally 
separated as it is improbable that these hits would occur simultaneously in the same cell. A 
clonal population of AML blast cells may, therefore, actually consist of a heterogeneous 
mix of various subclones with different genetic damage. Some of these genetic events are  
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likely to be essential for the development of the leukaemia. However, it is also possible that 
some of these hits are not essential for the development of the leukaemia but may 
nevertheless influence the leukaemic phenotype, for example by conferring a selective 
advantage to a subclone of cells (see Figure 5.2). Consequently, study of the mutant level 
may provide valuable insights into this phenomenon as hits that are present in the majority 
of blast cells are likely to have occurred as an early or primary event in leukaemogenesis 
and those that are only present in a minority of the cells were acquired as a late or 
secondary event. 
 
A very high mutant level (greater than 50%) suggests that, at least in a proportion of the 
cells, the WT allele has been lost. As shown in Figure 5.3 there are two possible 
explanations for this. Firstly, the FLT3/WT allele may be deleted. Secondly, the WT allele 
may be lost due to mitotic recombination event leading to a homozygous FLT3/ITD. Early 
studies using microsatellite analysis showed that loss of the FLT3/WT allele was due to 
loss of heterozygosity at the FLT3 locus (Whitman et al, 2001), and that deletion of this 
region on chromosome 13 was not apparent by FISH (Thiede et al, 2002). Subsequently, 
genome wide single nucleotide polymorphism arrays have provided strong evidence that a 
mitotic recombination event is, indeed, the most likely explanation for cases with a very 
high mutant level (Fitzgibbon et al, 2005, Raghavan et al, 2005).  
 
5.1.2  131BClinical impact of FLT3/ITD mutant level 
A number of studies have examined the clinical impact of different FLT3/ITD mutant 
levels (see Table 5.1). Given the heterogeneity of the patients included in these studies, as 
well as different methods of analysis of the mutant level, direct comparison is difficult. 
However, there are a number of findings that are consistent between these studies. Patients 
with a very high level of mutation, consistent with loss of the WT allele, are associated 
with a higher WBC and a particularly adverse prognosis. The first study to report this 
(Whitman et al, 2001) observed loss of the FLT3/WT allele in 8 of 23 FLT3/ITD
+ cases in 
a cohort of 85 young adults with NK AML. The DFS at 1 year was 71% for FLT3/WT 
patients, 51% for those with a heterozygous FLT3/ITD and 17% for patients with an ITD 
and loss of the FLT3/WT allele. This observation has been confirmed in larger cohorts of 
adult (Gale et al, 2007, Thiede et al, 2002) and paediatric AML (Meshinchi et al, 2006).   
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Figure 5.2: Diagrammatic representation of early and late mutations in 
leukaemogenesis. In this example, mutations A and B would be quantified as high level 
mutants and mutation C as a low level mutant.  
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Figure 5.3: Possible explanations for high level FLT3 mutants 
 
The prognostic impact of low level mutations is less clear. The study from UCL suggested 
that patients with a low level FLT3/ITD mutation had an adverse outcome that was similar 
to those with an high level of mutation (Gale et al, 2007). However, other studies have 
suggested that lower level FLT3/ITD mutants may have a clinical outcome not dissimilar to 
FLT3/WT patients and the adverse prognosis associated with ITDs relates only to those 
with high level mutants (Meshinchi et al, 2006, Thiede et al, 2002, Whitman et al, 2001). 
However, as shown in Table 5.1, these studies used different ‘cut-offs’ for low and high 
level mutants. 
 
5.1.3  132BPaired presentation and relapse studies of FLT3/ITD mutations 
Further insights into the biology of FLT3/ITDs have been gained though the study of paired 
samples from presentation and first relapse (Kottaridis et al, 2002, Nakano et al, 1999, 
Schnittger et al, 2004, Shih et al, 2002). These studies have shown that FLT3/ITDs are lost 
at relapse in approximately one quarter of cases. This is important as it limits the utility of 
FLT3/ITDs as a molecular marker for MRD analysis. This provides further evidence that, 
at least in a proportion of cases, FLT3/ITDs occur as a late event in leukaemogenesis. In 
cases where the mutant is retained at relapse, the mutant level is often increased, either  
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from a low to high level or from high to very high level. This suggests that the subclone of 
leukaemic cells carrying a heterozygous ITD or homozygous ITD had a proliferative 
advantage and/or increased chemoresistance compared to FLT3/WT or heterozygous 
FLT3/ITD
+ cells respectively. 
 
 
Table 5.1: Association of FLT3/ITD Level with Clinical Characteristics and Outcome 
in non-APL AML 
Reference 
No. 
(inclusion 
criteria) 
No. 
Mutants 
(%) 
Cut-Off 
for high 
level 
No. high 
level 
Mutants 
Clinical 
characteristics 
Clinical 
outcome 
Multivariate 
(Whitman 
et al, 
2001) 
82 (NK, 
<60 yrs) 
23 
(28%) 
Visual 
estimation 
ITD>WT 
8 of 23 
(35%) 
Higher WBC 
(P=.01) 
Reduced 
DFS 
(P=.03) 
and OS 
(P=.008) 
NR 
(Thiede et 
al, 2002) 
254 (de 
novo, 
intermediate 
risk, 
<60yrs) 
59 
(23%) 
>44% 29 
(49%) 
Higher WBC 
and BM blasts 
(NR) 
Reduced 
DFS 
(P=.004) 
and OS 
(P=.006) 
Reduced 
DFS and OS 
(P<.01) 
(Jilani et 
al, 2003) 
85 (18-85 
years) 
18 
(21%) 
Visual 
estimation 
ITD>WT 
5 of 18 
(28%) 
Higher WBC 
(NR) 
Reduced 
OS (NR) 
NR 
(Meshinchi 
et al, 
2006) 
630 (de 
novo, 0.5-
19 years) 
77 
(12%) 
>29% 54 
(70%) 
NS Reduced 
PFS 
(P=.001) 
Reduced 
PFS 
(P<.001) 
(Gale et al, 
2007) 
1425 (non 
APL, young 
adults) 
354 
(26%) 
>50% 53 
(15%) 
Higher WBC 
(P<.001) 
Increased 
RR 
(P<.001) 
Reduced 
DFS and 
OS 
(P<.001)  
Increased 
RR (P<.001) 
and Reduced 
OS (P<.001) 
NR indicates not reported and PFS, progression free survival. 
 
 
In view of the biological and clinical information gained from these studies of FLT3/ITD 
mutant level, it is possible that additional insights would also be gained by the study of 
FLT3/TKD mutation level. FLT3/TKD mutant level has been previously studied in a small 
cohort of patients, revealing marked heterogeneity in the relative mutant level between 1%  
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and 71% (Shih et al, 2004). However, this was a small study including only 13 FLT3/TKD
+ 
patients at diagnosis, precluding any detailed study of clinical characteristics or outcome. In 
order to address this issue, FLT3/TKD mutant level was quantified in the cohort of 
FLT3/TKD
+ patients described in Chapter 4 and results correlated with clinical 
characteristics, outcome and, where possible, mutation status at relapse. 
 
5.2  41BUMethods 
 
5.2.1  133BCharacteristics of the cohort studied 
The FLT3/TKD mutant level was studied in 127 FLT3/TKD
+ patients from the cohort of 
1107 non-APL AML patients. Treatment schedules, definition of end-points and statistical 
methods used are detailed in chapter 4. 
 
5.2.2  134BQuantification of FLT3/TKD mutants by semi-quantitative PCR and 
denaturing polyacrylamide gel electrophoresis 
The relative level of mutant was quantified using semi-quantitative PCR and restriction 
enzyme digestion. The mutant identification method described in section 3.2.4 was 
modified by reducing the cycle number to 25 and end-labelling primers 20F or 20R2 with 
γ-[
32P]-ATP (3000 Ci/mmol, Amersham Pharmacia Biotech, Little Chalfont, UK). Samples 
were digested according to the known mutation (Table 3.3) and electrophoresed through 
denaturing polyacrylamide gels (7 M urea, 6% polyacrylamide cross-linker ratio 37.5:1, 1 x 
Tris-borate-EDTA). The gels were transferred to 3MM Chr chromatography paper, dried 
and exposed to a Fuji BAS-IIIs imager plate overnight. The plates were visualised using a 
Molecular Dynamics Typhoon PhosphorImager and quantified using ImageQuant 5.2 
software (Molecular Dynamics) (Figure 5.4). The level of mutant FLT3 is expressed as a 
percentage of the total signal.   
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Figure 5.4: Analysis of the level of 9 D835V mutations using a radiolabelled 20F 
primer and HincII digestion. 
 
5.2.3  135BQuantification of FLT3/TKD mutants by fragment analysis 
The quantification of FLT3/TKD mutant level was also optimised for fragment analysis. 
The relative level of mutant was quantified using PCR as described in chapter 3, but with a 
fluorescently labeled primer and reduced cycle number (30 cycles) followed by fragment 
analysis on the CEQ8000 DNA Genetic Analysis System. A new primer (20R4: 5’-
GCCCAAGGACAGATGTGATGC-3’), 171 bp further downstream of codon 835 than 
20R, was used in order to generate longer PCR products for optimal analysis using this 
technique. For deletions and insertions, undigested PCR products were analyzed; for other 
mutations, products were first digested with either a mutation-specific restriction enzyme 
(Figure 5.5) or EcoRV. The level of mutant FLT3 is expressed as a percentage of the total 
signal. A small number of mutant samples (n=6) were quantified using both techniques in 
order to confirm that comparable results were obtained.  
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Figure 5.5: Anaysis of two D835Y mutants by fragment analysis after ClaI digestion. 
(A) A high level mutant accounting for 50% of total FLT3 alleles and, (B) a low level 
mutant accounting for 10% of total FLT3 alleles. 
 
 
5.3  42BUResults 
 
5.3.1  136BDistribution of mutant level  
The relative mutant level as a percentage of total FLT3 alleles was quantified in 115 known 
FLT3/TKD
+ samples using labelled PCR products and size separation, after mutation-
specific or EcoRV restriction enzyme digestion if required. The distribution of the mutant 
level is shown in Figure 5.6. Quantification was not performed in 12 cases, either because a 
mutation-specific restriction digest was not available (4 cases), the mutation had not been 
identified (3 cases) or due to lack of material (5 cases), and therefore these samples were 
scored by visual estimation of the dHPLC chromatogram. Mutants were arbitrarily 
classified as high level if the mutant level was greater than the median of 25%, or low level 
when less than or equal to this. Of note, only two patients (2% of all FLT3/TKD mutants) 
showed clear evidence of biallelic mutation or loss of WT alleles, with 88% and 93% 
mutant level respectively. Nine other FLT3/TKD mutants had levels of between 51 and 
70%, thus only 11 cases (9%) had a mutant level >50%. This is a lower frequency of very 
high level mutations than for FLT3/ITDs where these account for approximately 15% of all 
mutants (Gale et al, 2007). Therefore, for FLT3/TKDs, there was an insufficient number of  
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patients with a mutant level >50% for analysis as a separate category and they were 
included with the high level cases.  
 
Of the total cohort of 127 mutant-positive cases, a high level of mutant was present in 62 
(49%), i.e. 6% of all patients in the cohort, and the median mutant level was 43% (range, 
26% - 93%). A low level of mutant was present in 65 cases (51%), i.e. 6% of all patients, 
with a median level of 6% (range, 1%-25%). In the five cases with two mutants, four had 
one major mutant of high level plus a minor mutant of very low level (approximately 2% of 
total), in the remaining case both mutants were lower level (less than 25% of total), this 
latter case was classified as a low level mutant.  
 
5.3.2  137BClinical characteristics according to FLT3/TKD mutant level 
Low level FLT3/TKD
+ patients had a similar WBC to FLT3/WT patients with median 
WBCs of 23 x 10
9/L and 24 x 10
9/L respectively. High level mutants, however, were 
associated with a high WBC (median 49 x 10
9/L; P=.002). There was no evidence of 
heterogeneity between high and low level FLT3/TKD mutants for trial, age, sex, 
performance status, cytogenetic category, de novo versus secondary AML or FAB type. 
 
Figure 5.6. Distribution of the relative FLT3/TKD mutant level in 115 cases. 
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5.3.3  138BDistribution of FLT3/TKD and FLT3/ITD mutations according to mutant level 
Analysis according to the presence or absence of a mutation showed a weak negative 
correlation between the presence of a FLT3/ITD and a FLT3/TKD mutation (see Chapter 
4). Analysis according to the level of mutation, however, showed a highly significant 
negative correlation between the presence of a high level FLT3/ITD and a high level 
FLT3/TKD mutation (Table 5.2, P<.001). In fact, there were no cases where a high level 
FLT3/ITD and FLT3/TKD were present in the same sample.  
 
 
Table 5.2: Distribution of FLT3/TKD and FLT3/ITD mutations according to 
mutant level 
  ITD WT  ITD Low  ITD High  ITD V.High  Total 
TKD WT  724 (88%)  72 (80%)  138 (95%)  46 (94%)  980 
TKD Low  42 (5%)  13 (14%)  7 (5%)  3 (6%)  65 
TKD High  57 (7%)  5 (6%)  0  0  62 
Total  823 90  145 49  1107 
For this analysis, an identical cut off was used for FLT3/ITDs and FLT3/TKDs. Low 
level mutants less than or equal to 25%, high level mutants 26-50% and very high level 
mutants (ITDs only) greater than 50%.  
 
 
5.3.4  139BClinical outcome according to FLT3/TKD mutant level 
Proportional hazards regression analysis found significant evidence for a trend for higher 
FLT3/TKD levels to be associated with better survival (P=.008), however, there was no 
natural cut-off of mutant FLT3/TKD level that acted as an independent predictor of 
outcome. In view of this, for the analysis of clinical outcome, the median mutant level of 
25% was again used as a cut off. In the total cohort of 1107 non-APL AML patients, 
including FLT3/ITD
+ cases, there was no evidence of any impact of FLT3/TKDmutant 
level on the rate of CR, ID or RD (Table 5.3). Patients with a high level FLT3/TKD mutant, 
however, had an improved CIR and OS compared to patients with a lower level of 
mutation, whose outcome was not dissimilar to that of FLT3/TKD
- patients (Table 5.3). 
The CIR at 10 years was 50% for WT patients, 50% for patients with a lower level 
FLT3/TKD mutant and 37% for patients with a higher level mutant (Figure 5.7A). The OS 
at 10 years was 33%, 37% and 59% respectively (Figure 5.7B). This improved OS  
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remained significant in a cox multivariate analysis (OR = 0.74, 95% CI = 0.61-0.91, 
P=.004), although the difference was only of borderline significance for CIR (OR = 0.80, 
95% CI = 0.64-1.00, P=.05). 
 
 
Figure 5.7: Clinical outcome for non-APL AML patients stratified according to 
FLT3/TKD mutant level. (A) CIR and (B) OS. High level mutations, more than 25% of 
FLT3 alleles; low level mutations, 25% of FLT3 alleles or less. 
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5.3.5  140BPaired presentation and relapse samples from FLT3/TKD
+ patients 
DNA samples at the time of relapse were available from 9 of the 51 FLT3/TKD
+ cases who 
relapsed. Four cases with low mutant level (2 D835Y, 1 Δ836 and 1 unknown) and two 
cases with high mutant level (2 D835Y) all lost their mutation at relapse. Three high mutant 
level cases relapsed with the same mutation (2 D835Y, 1 ∆836) at a similar level.  
 
5.4  43BUDiscussion 
 
Analysis of FLT3/ITD mutant level has provided important biological insights into the 
pathogenesis of AML. Furthermore, stratification according to FLT3/ITD mutant level has 
helped to refine the prognostic information gained from mutation screening for detection of 
the presence or absence of the mutation alone. At the time of this analysis, however, similar 
studies had not been carried out for FLT3/TKD
+ mutations.  
 
 
Table 5.3: Clinical outcome in FLT3/TKD
– and FLT3/TKD
+ non-APL AML patients 
 
TKD 
WT 
TKD
 
low 
TKD
high 
OR (CI) 
Adjusted result: OR 
(CI) 
Initial Response         
      CR  84% 83% 94% 0.72  (0.49-1.06);  P .07  0.74 (0.44-1.29); P.3 
      ID  6% 6% 2% 0.65  (0.33-1.28)  P.17 0.57  (0.22-1.47);  P.2 
      RD  10% 11% 5%  0.78  (0.49-1.24);  P.3   0.87 (0.48-1.57); P.6 
Outcome at 5 years          
      CIR  48% 50% 30%  0.78  (0.64-0.94);  P.01 0.80  (0.64-1.00);  P.05 
      DFS  35% 35% 60% 0.77  (0.65-0.91);  P.003 0.78  (0.64-0.95);  P.01 
      OS  37% 37% 71% 0.74  (0.63-0.87);  P.004 0.74  (0.61-0.91);  P.004 
P values relating to TKD
- versus TKD
+ analysis are for Mantel-Haenszel test for initial 
response and log-rank test for long term outcomes. P values relating to TKD
- versus TKD 
low versus TKD high analysis were determined using logistic regression analysis. 
Adjusted results show results of multivariate analyses adjusted for significant variables in 
forward selection regression model. 
 
 
The data presented in this chapter reports on FLT3/TKD mutant level in 127 FLT3/TKD
+ 
non-APL AML cases. The distribution of mutant levels was different to that of FLT3/ITDs. 
Cases with a very high level of mutation were less common for FLT3/TKD mutations (9%)  
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than for FLT3/ITDs (approximately 15%). Furthermore, only 2 (2%) cases had 
FLT3/TKDs mutant levels greater than 75% compared with 8% for FLT3/ITDs. 
Conversely, low level mutants were more frequent for FLT3/TKDs, accounting for 
approximately 50% of mutant positive patients compared with 29% of FLT3/ITDs. Very 
low level mutants, accounting for less than 5% of FLT3 alleles, suggesting that the 
mutation is present in less than 10% of cells, accounted for 22 of 127 FLT3/TKD mutants 
(17% of all mutants) compared with approximately 6% of FLT3/ITDs. As higher mutant 
levels are likely to correlate with mutations that are acquired as earlier events in 
leukaemogenesis, these data would suggest that FLT3/TKDs occur more frequently as late 
or secondary events compared with FLT3/ITDs. 
 
These data differ from previous studies of FLT3/TKD mutant level. In a small cohort of 13 
cases where FLT3/TKD mutant level was measured, 5 (38%) very high level mutants were 
present, with mutant levels between 54% and 71% (Shih et al, 2004). This study, however, 
did confirm the frequent presence of low level FLT3/TKD mutants, accounting for 6 of the 
13 cases (46%). In another study, published subsequent to the present analysis, mutant level 
was quantified in 14 FLT3/TKD
+ young adults with NK, de novo AML (Whitman et al, 
2008). The authors reported that the mutant level ranged from 54% to 100%, with 8 
patients having 100% of the FLT3 alleles mutated, suggesting that loss of the FLT3/WT 
allele is much more common for FLT3/TKDs than FLT3/ITDs in their cohort. The 
explanation for such a striking difference is not clear and is unlikely to be due to 
methodology as the authors report that they used an identical method to that used in the 
present analysis. 
 
Stratification of our cohort according to mutant level and clinical characteristics at 
presentation showed that high level mutants were associated with a high WBC at 
presentation, whereas low level mutants had a WBC that was similar to that of FLT3/WT 
patients. These findings are similar to those reported for FLT3/ITDs (Gale et al, 2007). It is 
possible, therefore, that if a mutation is only present in a subclone of the leukaemic cells, 
this is not sufficient to lead to a leucocytosis for the population as a whole. There was also 
a highly significant inverse relationship between the presence of a high level FLT3/TKD 
and high level FLT3/ITD mutation, which never occurred together. Therefore, although 
FLT3/ITD and FLT3/TKD ‘dual mutant’ cases can be detected, at a biological level these  
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data would suggest that the two different mutations are unlikely to occur in the same 
leukaemic cell.  This may relate to different mechanisms of mutagenesis for FLT3/ITDs 
and FLT3/TKDs. Alternatively, it may be that a leukaemic cell carrying one type of FLT3 
mutation does not gain any additional proliferative advantage by acquiring the different 
type of mutation and is, therefore, not selected for. 
 
Clinical outcome was also correlated with the level of the FLT3/TKD mutation, an analysis 
not made in previous studies. Favourable outcome was associated with FLT3/TKD
+ 
patients with a high level of mutant. For example, patients with a high level mutant had an 
OS at 10 years of 59% compared to 37% in patients with a lower level mutant and 33% in 
patients without an FLT3/TKD mutation (Figure 5.7B). This difference remained 
significant in multivariate analysis (P=.004). This suggests that quantitative differences in 
the level of mutation, reflecting the proportion of leukaemic cells that carry the mutation, 
may be biologically important for the leukaemic population as a whole, for example, in 
determining the response to therapeutic agents. The only other study to have addressed this 
issue failed to demonstrate any significant association between FLT3/TKD mutant level 
and outcome (Whitman et al, 2008), although as noted above and in chapter 4, this study 
only included small numbers of FLT3/TKD
+ patients with a markedly different distribution 
of mutant levels compared with the present analysis. It is also noteworthy that the clinical 
significance of mutant level is different for FLT3/ITDs and FLT3/TKDs in our cohort 
(Gale et al, 2007). Whilst low level FLT3/ITDs retained an adverse prognostic impact 
compared with FLT3/WT patients, low level FLT3/TKD cases could not be distinguished 
from FLT3/WT patients. Conversely, both high level FLT3/ITD
+ and FLT3/TKD
+ patients 
had highly significant and opposite impacts on CIR, DFS and OS. 
 
As discussed above, mutant levels may reflect the stage at which the mutation was 
acquired, with lower level mutants occurring only as a secondary event in an already 
transformed cell, whereas higher level mutants are more likely to be earlier events in the 
transformation process. It is noteworthy, therefore, that the relatively favourable prognosis 
of young adult patients with FLT3/TKD
+ AML is, in a large part, attributable to a reduction 
in the RR of mutant-positive patients who have entered CR. The opposite is the case for 
FLT3/ITDs. As relapse is thought to be caused by residual LSCs which are capable of 
repopulating the BM with a complete leukaemic hierarchy, stratification of patients  
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according to the mutant level may, therefore, correlate with presence of the mutation within 
the LSC population. Of relevance to this, it has been shown that FLT3/ITDs are present in 
the CD34+/CD38- population which is enriched for LSCs (Levis et al, 2005a). 
Furthermore, another study used colony assays to demonstrate that the presence of 
FLT3/ITDs in this CD34+/CD38- population of cells is heterogeneous, and in some cases 
the FLT3/ITD is absent in this population of cells. Presence of a FLT3/ITD in this 
progenitor population correlated both with higher mutant level and also adverse outcome in 
paediatric AML patients (Pollard et al, 2006). 
 
Studies of samples at presentation and relapse provided further biological insights into the 
differences between FLT3/ITDs and FLT3/TKDs. There were 9 FLT3/TKD
+ patients 
where mutation status was available at relapse. Of 5 patients with a high level of mutation, 
3 relapsed with the same mutation at a similar level. However, the other 2 high level 
mutants and all 4 patients with a lower level of mutation lost the mutation at relapse. This 
instability has been noted in an earlier study that showed FLT3/TKD mutations were lost at 
relapse in 8 of 13 (62%) cases studied (Shih et al, 2004). Furthermore, subsequent to the 
present analysis, another study also reported that of 13 FLT3/TKD
+ cases at diagnosis, the 
mutation was lost at relapse in 9 (69%) of these (Bacher et al, 2008). This indicates that, 
although a FLT3/TKD mutation may contribute to the leukaemic phenotype, in many cases, 
it is not an essential requirement for the leukaemic clone (Figure 5.2). This supports the 
above evidence from the mutant level analysis that FLT3/TKDs are frequently late events 
in leukaemogenesis. In contrast, loss of FLT3/ITD mutations at relapse is less frequent than 
for FLT3/TKDs (Kottaridis et al, 2002, Schnittger et al, 2004, Shih et al, 2002). 
Furthermore, FLT3/ITD mutant level often increases at relapse whereas this is not the case 
for FLT3/TKDs (Shih et al, 2004), suggesting that FLT3/ITD
+ cases may be more 
chemoresistant than FLT3/TKD
+ cases. 
 
The studies described in this chapter provide further insights into the biological differences 
between FLT3/ITDs and FLT3/TKDs. Distribution of mutant level complemented by 
presentation/relapse studies suggest that FLT3/TKDs are more frequently acquired as late 
or secondary events in leukaemogenesis than are FLT3/ITDs. This does not explain the 
differences observed in the clinical outcome associated with the two types of mutation, 
however, with high level FLT3/TKD mutations being associated with a particularly  
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favourable prognosis compared with the markedly adverse prognosis of high level 
FLT3/ITDs. Dissecting out the factors that determine these differences may provide 
valuable insights into the mechanisms of chemoresistance in AML.  
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6  17BUCHAPTER 6: STUDIES OF THE CYTOTOXIC EFFECT OF FLT3 
INHIBITORS AND CYTARABINE ON PRIMARY AML BLAST 
CELLS 
 
6.1  44BUIntroduction 
 
Studies to identify and characterise molecular defects in AML are partly driven by the goal 
of improving outcome for patients with this disease. The first way this may be achieved is 
through the identification of prognostic factors, thereby allowing the development of a 
more robust prognostic index in AML. It is hoped that this will, in turn, refine prognostic 
stratification of patients with AML to allow more accurate risk-adapted therapy. The 
second, and more direct potential benefit, is the identification of molecular targets for novel 
therapeutic approaches. FLT3 has emerged as an important candidate molecular marker for 
both these approaches. In view of the markedly increased RR associated with FLT3/ITDs, 
it is particularly important to determine whether treatment can be modified for this poor 
prognostic group of patients in order to improve their outcome. Interest in the optimal 
therapeutic strategy for patients with FLT3 mutations has mainly focused on two areas:  
 
•  Can the adverse outcome associated with FLT3/ITDs in AML be overcome using 
conventional therapeutic approaches? 
 
•  Do FLT3 inhibitors have therapeutic efficacy in patients with FLT3 mutated AML? 
 
6.1.1  141BCan conventional therapeutic strategies be used to overcome the adverse 
prognosis associated with FLT3/ITDs? 
There is no doubt that the combination of high dose chemoradiotherapy and graft-versus-
leukaemia effect associated with allogeneic stem cell transplantation (SCT) dramatically 
reduces the RR in AML. However, this does not translate into a survival advantage in most 
studies because of the significant toxicity associated with the procedure (Burnett 2002b). 
Using conventional cytogenetic risk stratification, a recent study has suggested that patients 
in an intermediate or adverse cytogenetic risk group benefited from allogeneic SCT 
whereas those with favourable cytogenetics did not (Cornelissen et al, 2007). It is also  
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possible that FLT3/ITD
+ patients would benefit from allogeneic SCT and should therefore 
be selected for transplant. The corollary of this would be that FLT3/ITD
- patients with an 
intermediate karyotype may not benefit from allogeneic SCT. This question was addressed 
in a study of 170 young adults with AML who received a Cy/TBI conditioned sibling 
allograft as part of the UK MRC AML 10 and 12 trials, 35 of whom were FLT3/ITD
+ (Gale 
et al, 2005a). Allograft recipients had a 5 year RR which was comparable between 
FLT3/ITD
+ (31%) and FLT3/ITD
- patients (25%) as opposed to 76% and 53% for those 
treated with chemotherapy alone. Although this suggests that the adverse RR associated 
with FLT3/ITDs was overcome by the allograft, because of the relatively small numbers of 
patients studied, the confidence intervals were wide and this apparent effect was not 
significant. The OS was 44% and 58% for FLT3/ITD
+ and FLT3/WT patients respectively. 
Importantly, there was no evidence of any heterogeneity of effect of an allograft on relapse 
or survival when stratified according to FLT3/ITD status. Recent evidence suggests that the 
combination of NPM1 and FLT3/ITD mutation status may help to refine the process of 
patient selection for allogeneic transplantation (Schlenk et al, 2008), although these data 
will need to be validated in other studies. 
 
Notwithstanding the lack of clear evidence, some centres are currently selecting FLT3/ITD 
mutant positive patients for allogeneic SCT. It has also been suggested that a similar 
strategy should apply to FLT3/TKD mutant positive patients as their prognostic impact was 
thought to be similar to that of FLT3/ITDs (Litzow 2005, Yanada et al, 2005). The data 
presented in chapters 4 and 5, however, suggest that this approach would be inappropriate 
in patients with FLT3/TKD mutations as the risks of the procedure may outweigh the 
benefits. It could even be proposed that patients with a high level FLT3/TKD mutation 
should be excluded from receiving an allogeneic transplant in view of their favourable 
prognosis. However, given the difficulty associated with providing statistically significant 
evidence for FLT3/ITDs (which are relatively frequent in AML), it would be extremely 
difficult to produce robust data to support this course of action for FLT3/TKDs. This is 
exemplified by the fact that in the total cohort of 1107 non-APL AML patients screened for 
FLT3/TKD mutations, only 17 of the 127 mutant-positive patients received an allograft. To 
demonstrate any survival advantage for high level FLT3/TKD mutant positive patients 
treated with chemotherapy alone compared to those who received an allograft in first CR 
would require a cohort of many thousands of patients.  
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6.1.2  142BTargeted therapies for human malignancies 
Modification of conventional chemotherapeutic approaches with SCT is not the only 
approach for improving outcome for patients with leukaemia. The introduction of tyrosine 
kinase inhibitors has led to the development of many so called ‘targeted therapies’ against 
oncogenic tyrosine kinases (Krause and Van Etten 2005). The remarkable success of 
imatinib in the treatment of chronic myeloid leukaemia (CML) (Druker et al, 2001) has 
served as a paradigm for this approach. CML is characterised by the t(9;22) Philadelphia 
chromosome which leads to the production of a bcr-abl fusion protein, with consequent 
constitutive activation of the abl tyrosine kinase. Imatinib is an abl kinase inhibitor which 
was shown be cytotoxic to bcr-abl expressing cell lines and primary CML leukaemic cells 
in vitro (Druker et al, 1996). Initial clinical trials of imatinib were in chronic phase CML 
patients who had failed therapy with interferon-α. Single agent therapy with imatinib was 
remarkably effective and induced a complete haematological remission in 53 of 54 patients 
when used at doses of 300mg per day or more. Furthermore, major cytogenetic responses 
occurred in 17 of 54 patients in this early study (Druker et al, 2001). Larger randomised 
studies subsequently demonstrated superiority of imatinib for the first line therapy of 
chronic phase CML compared to interferon-α with or without cytarabine. The complete 
cytogenetic response rate at 18 months in the two treatment groups was 76.2% and 14.5% 
respectively (O'Brien et al, 2003). This has led to a significant reduction in the number of 
patients receiving an allogeneic transplant in this disorder (Giralt et al, 2007). 
 
6.1.3  143BFLT3 inhibitors 
In view of the success of imatinib, there has been a great deal of interest in the development 
of other small molecule inhibitors to target dysregulated tyrosine kinases in other 
malignancies (Krause and Van Etten 2005). There are a number of reasons why FLT3 is an 
attractive therapeutic target for such an approach. Firstly, constitutive activation of FLT3 is 
a frequent occurrence in AML due to the approximately one quarter of young adults with 
AML that have ITDs within the juxtamembrane domain, and the 7-22% of patients with 
mutations within the TKD (See chapter 3). Furthermore, activation of WT FLT3 may also 
occur as a result of autocrine stimulation by FLT3-ligand (Zheng et al, 2004b), over-
expression of FLT3 (Armstrong et al, 2003, Dicker et al, 2007) or by inactivating 
mutations of c-cbl (Caligiuri et al, 2007, Sargin et al, 2007). Targeting FLT3 in AML has  
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generated particular enthusiasm in view of the poor prognosis associated with FLT3/ITDs 
(Kottaridis et al, 2001).  
 
The first inhibitor of FLT3 function to be described was herbimycin A. Rather than directly 
inhibiting the FLT3 kinase, herbimicyn A inhibits the molecular chaperone Hsp-90, thereby 
interfering with FLT3/ITD protein folding. This agent was shown to inhibit the growth of 
transformed 32Dcl3 cells (Zhao et al, 2000), an effect that intriguingly appears to be 
specific to FLT3/ITDs and not FLT3/WT (Minami et al, 2002, Zhao et al, 2000). The first 
direct inhibitors of the FLT3 tyrosine kinase to be discovered were the bicyclic 
quinoxalines AG1295 (Levis et al, 2001) and AG1296 (Tse et al, 2001). Both were initially 
decribed as inhibitors of PDGFRβ, a closely related class 3 RTK. These agents compete 
with ATP for the ATP binding pocket, and inhibit the FLT3 kinase with an IC50 of 
approximately 300 nM. AG1296 was shown to inhibit the factor independent proliferation 
of Ba/F3 cells (Tse et al, 2001) and AG1295 was shown to be specifically cytotoxic against 
FLT3/ITD
+ AML blast cells in vitro (Levis et al, 2001). These inhibitors however have a 
very low bioavailability due to their hydrophobicity and therefore have little potential as 
clinical agents.  
 
Drug discovery screening programmes in the pharmaceutical industry have now identified a 
wide array of different small molecule inhibitors of FLT3 from a number of different 
chemical classes (Knapper 2007) and with variable specificity for the FLT3 kinase (Table 
6.1). Many of these inhibitors are still at the preclinical stage, however, a number of these 
agents have progressed to more advanced stages of clinical development and these are 
summarised in Table 6.2. Inevitably, these phase 1/2 studies have been primarily conducted 
in patients with relapsed or refractory disease. Importantly, the agents have generally been 
well tolerated at doses which achieved serum concentrations of the drug sufficient to inhibit 
FLT3 phosphorylation in vitro. Despite the high-risk patients enrolled, clinical responses 
have been observed and are generally characterised by reductions in the WBC, with some 
cases clearing the BM to <5% blasts. These responses have occurred in both FLT3 mutant 
and FLT3/WT patients. However, it should be noted that, at the present time, no CRs have 
been induced using a FLT3 inhibitor as monotherapy. Furthermore, the clinical responses 
that have been seen have been transient, with progression of the disease within weeks.   
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Table 6.1: Inhibitors of the FLT3 tyrosine kinase 
Name Chemical  Class  IC50 
FLT3 
Other kinases  Stage of 
Development 
Reference 
ABT-869  Urea derivative  4nM  KIT, KDR, PDGFR  Phase I  (Zhou et al, 
2008) 
AG1295 Quinoxaline  300nM  PDGFR,  KIT  Preclinical  (Levis et al, 
2001) 
AG1296  Quinoxaline  300 nM  PDGFR, KIT  Preclinical  (Tse et al, 
2001) 
AGL2043  Quinoxaline  100 nM  PDGFR, KIT  Preclinical  (Gazit et al, 
2003) 
AS602868 Anilinopyrimidine  678  nM  IKK2  Preclinical (Griessinger 
et al, 2007) 
BAY 43-9006 
(Sorafenib) 
Bi-aryl urea  <50nM  B-RAF, VEGFR, 
PDGFR 
Preclinical (Zhang et al, 
2008) 
CEP701 
(lestaurtinib) 
Indolocarbazole  2 nM  TRKA, VEGFR  Phase III  (Levis et al, 
2002) 
CHIR-258 
(TKI258) 
Amino-benzimidalzole-
quinolinone 
10 nM  KIT, FMS, FGFR, 
VEGFR, 
PDGFR 
Phase I  (Trudel et al, 
2005) 
D64406 Bis-indolyl-1-methanone  300  nM  PDGFR, KIT  Preclinical  (Teller et al, 
2002) 
FI-700  Not reported  20 nM  KIT, FMS, LIN  Preclinical  (Kiyoi et al, 
2007) 
Go6976 Indolocarbazole    JAK2,  PKC  Preclinical  (Grandage et 
al, 2006) 
GTP-14564 Cyclopenta[a]inden  300  nM  KIT, FMS, PDGFR  Preclinical  (Murata et al, 
2003) 
Herbimycin A  Benzoquinoid ansamycin  100 nM PDGFR,  EGFR  Preclinical  (Zhao et al, 
2000) 
IMC-EB10 Monoclonal  Antibody  N/A  NR  Preclinical (Piloto et al, 
2005) 
IMC-NC7 Monoclonal  Antibody  N/A NR  Preclinical  (Piloto et al, 
2005) 
Ki23819 Quinoline-urea  10  nM  NR  Preclinical  (Komeno et 
al, 2005) 
KRN383 Quinoline-urea  3  nM  NR  Preclinical  (Nishiyama et 
al, 2006) 
KW-2449  NR  6 nM  KIT, Aurora  Phase I  (Pratz et al, 
2009) 
LS-104 Hydroxystyryl–
acrylonitrile compound 
4 μM  ABL, JAK2  Phase I  (Kasper et al, 
2008) 
MLN518  Piperazinyl quinazoline  30 nM  KIT, PDGFR  Phase II  (Kelly et al, 
2002c) 
NVP-AST487  N,N'-diphenyl urea  120 nM  RET, c-Kit, ABL  Preclinical  (Weisberg et 
al, 2008) 
PKC412  Indolocarbazole  10 nM  KIT, KDR, PKC, 
PDGFR 
Phase III  (Weisberg et 
al, 2002) 
SU5416 3-Substituted  indolinone  100  nM  KIT, VEGFR  Phase II  (Yee et al, 
2002) 
SU5614  3-Substituted indolinone  10 nM  KIT, FMS  Preclinical  (Yee et al, 
2002) 
SU11248 
(sunitinib) 
3-Substituted 
indolinoneindolinone 
50 nM  KIT, PDGFR, 
VEGFR 
Phase I  (O'Farrell et 
al, 2003) 
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Table 6.2: Clinical trials of FLT3 inhibitors in patients with AML 
Trial Agent  No. FLT3 
WT/ITD/TKD 
Median Age
(range)  Disease Status  Significant clinical 
benefit  CR  Time to Progression 
in responders 
(Giles et al, 
2003)  SU5416  33 (unknown 
mutation status) 
64 
(23 – 76)  U + R + Rf  3/33  
(1 TKD +ve)  0  Event free survival  
3-6.5 months 
(O'Farrell et al, 
2003)  SU11248  24/3/2  67 (19-82)  U + R + Rf  5/29 (2 ITDs, 3 
WT)  0 NA 
(Fiedler et al, 
2003)  SU5416  28/7/NA 
7 unknown 
65  
(27-79)  U + R + Rf  8/42  
(0/7 FLT3/ITD)  0 Median  1.6  months 
(Smith et al, 
2004) 
Lestaurtinib 
(CEP701)  0/14/0  61.5  
(18-74)  R + Rf  5/14  0  2 weeks to 3 months 
(Fiedler et al, 
2005)  SU11248 10/2/2  70.5 
 (54-80)  U + Rf  6/14 
(4/4 mutant FLT3)  0  Median  2 cycles (6 
weeks per cycle) 
(Stone et al, 
2005b)  PKC412 0/18/2  62 
 (29-78)  R + Rf  14/20  0  Median 13 weeks 
(De Angelo et al, 
2006) 
Tandutinib 
(MLN518)  30/8/1  70.5  U + R + Rf  2/39  
(2/8 FLT3/ITDs)  0  44 days and 2 months 
(Knapper et al, 
2006a) 
Lestaurtinib 
(CEP701)  22/2/3  73  
(67 – 82)  U  8/27  
(3/5 mutant FLT3)  0  Median 28 days 
U indicates untreated patients not fit for conventional chemotherapy, R relapsed patients, Rf refractory patients, NA not available. 
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Two indolocarbazole compounds, lestaurtinib and PKC412, originally derived  from the 
alkaloid K-252a (a fermentation product of Nonomurea longicatena) are competitive 
inhibitors of the FLT3 kinase and are of particular interest as they have both shown some 
efficacy as single agents in AML. Both have progressed to ongoing multi-centre phase 3 
trials in AML. Lestaurtinib, originally known as CEP701, is a potent and relatively specific 
inhibitor of the FLT3 kinase with an IC50 of approximately 2nM (Levis et al, 2002), as 
opposed to IC50s of over 500 nM for other class 3 RTKs. It was originally identified as an 
inhibitor of TrkA (IC50 3 nM), a member of the nerve growth factor receptor subfamily 
(non-class III RTK). It has been shown to have a cytotoxic effect against AML blasts in 
vitro, particularly cases which are FLT3/ITD
+ compared to FLT3/WT cases, and has also 
been shown to prolong survival in a mouse model of FLT3/ITDs (Brown et al, 2004, 
Knapper et al, 2006b, Levis et al, 2002). In clinical trials, lestaurtinib has good oral 
bioavailability and is well tolerated, with gastrointestinal side effects being the most 
common toxicity. One phase 1/2 study assessed the efficacy of CEP701 in 14 relapsed or 
refractory FLT3/ITD
+ AML patients. Transient responses were seen in 5 patients, including 
one patient in whom the BM blast percentage reduced to <5% (Smith et al, 2004). A 
second phase 2 trial of lestaurtinib in elderly patients with untreated AML demonstrated 
transient responses in 3 of 5 patients with a FLT3 mutation and 5 of 22 patients with 
FLT3/WT (Knapper et al, 2006a). Importantly, both of these trials demonstrated that a 
patient was highly likely to demonstrate a clinical response if their blast cells were sensitive 
to lestaurtinib inhibition in vitro and if plasma levels of lestaurtinib sufficient for in vitro 
FLT3 inhibition were achieved. 
 
PKC412 is another orally bioavailable indolocarbazole which inhibits FLT3 with an IC50 
of approximately 10nM. This agent was originally described as an inhibitor of protein 
kinase C and is less selective against FLT3 than lestaurtinib, with significant inhibitory 
activity against PDGFRβ and c-Kit. It was shown to inhibit the growth and cause apoptosis 
of FLT3 transformed Ba/F3 cells, and prolong survival in mice transplanted with BM cells 
oncoretrovirally transduced with a FLT3/ITD (Weisberg et al, 2002). In a phase 2 study of 
20 patients with FLT3 mutated relapsed/refractory AML, 14 patients demonstrated a 
significant reduction in WBC, with 2 cases clearing BM blasts to <5%. Again, responses 
were transient, with a median duration of 13 weeks (Stone et al, 2005b). Interestingly,  
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much of the clinical activity of PKC412 appears to relate to a metabolite (CGP52541) 
rather than PKC412 itself (Levis et al, 2006). 
 
Despite the lack of durable remissions, the demonstration of a biological effect of FLT3 
inhibition in preclinical and clinical studies of FLT3/ITD mutants has been sufficiently 
encouraging for these agents to be taken forward into larger clinical trials. Since several 
studies have shown that FLT3/ITD
+ AML blast cells are more sensitive to FLT3 inhibitors 
than FLT3/WT cases, both in vitro and in vivo (Brown et al, 2004, Knapper 2007, Knapper 
et al, 2006b, Levis et al, 2002), a number of these trials only include FLT3 mutant-positive 
cases, defined as either FLT3/ITD
+ or FLT3/TKD
+. As demonstrated in chapters 3 and 4 
however, in the cohort studied here, FLT3/TKD mutations are biologically distinct from 
FLT3/ITDs and are an independent predictor of favourable outcome in AML. Moreover, as 
described in chapter 5, whilst high levels of a FLT3/ITD mutation are associated with a 
particularly adverse prognosis (Gale et al, 2007, Thiede et al, 2002, Whitman et al, 2001), 
the opposite is the case for FLT3/TKDs. These data raise the possibility that the in vitro and 
in vivo effects of FLT3 inhibitors will also differ according to the mechanism of FLT3 
activation. Whether FLT3/TKD
+ cases are more sensitive to FLT3 inhibition than 
FLT3/WT cases, however, is unclear. This question is important as some clinical trials of 
FLT3 inhibitors include FLT3/TKD
+ patients but exclude FLT3/WT cases. The only study 
to address this issue in adult AML examined the in vitro effects of lestaurtinib on 
FLT3/TKD
+ cases and suggested that they respond similarly to FLT3/ITD
+ cases (Knapper 
et al, 2006b), although only 6 FLT3/TKD
+ cases were studied. A study in paediatric AML, 
however, suggested that FLT3/ITD
+ and FLT3/TKD
+ cases differ in their response to 
lestaurtinib (Brown et al, 2004). 
 
To determine whether the clinical and biological differences between FLT3/ITDs and 
FLT3/TKDs influence the response to FLT3 inhibitors, the in vitro effects of lestaurtinib 
and PKC412 on primary AML blast cells, both alone and in combination with cytarabine, 
were studied. Results were correlated with FLT3 mutation status and mutant level.  
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6.2  45BUMaterials and Methods 
 
6.2.1  144BPatients 
Patient details are shown in Table 6.3. Mononuclear cells from the peripheral blood or bone 
marrow of patients with newly diagnosed (n=31) or relapsed (n=5) AML were purified 
using Ficoll-Hypaque centrifugation (Chapter 2.1.7). Where possible, cells were used fresh 
(n=22), otherwise they were stored in liquid nitrogen until required (n=14). Cryopreserved 
cells were thawed (Chapter 2.1.8) and live cells were purified using Ficoll-Hypaque 
centrifugation. At the time of analysis, all samples had 90% or more viable cells as 
determined by trypan blue exclusion (Chapter 2.1.9). Informed consent for all tissue 
collection was provided according to the Declaration of Helsinki. 
 
6.2.2  145BReagents 
Lestaurtinib and PKC412 were stored as stock solutions at concentrations of 4mM in 
DMSO at -20°C. A working solution of 100μM was made up prior to each experiment by 
dilution in RPMI. Cytarabine was stored as a 100mg/ml stock solution at 4°C. 
 
6.2.3  146BDetection and Identification of FLT3 Mutations 
FLT3/TKD mutations were detected, identified and quantified as previously described in 
chapters 3 and 4. FLT3/ITD status and mutant level were known from previous work in the 
department (Gale et al, 2005a).  
 
6.2.4  147BMTS Assays 
Purified cells were resuspended in 96 well plates at 2 x 10
5/100μl in RPMI containing 10% 
fetal calf serum (R10) in the presence or absence of cytarabine (100, 10, 1 or 0.1μg/ml), 
lestaurtinib or PKC412 (100, 50, 20, 10 or 5nM) or, when enough cells were available, at 
least six different combinations of lestaurtinib and cytarabine. Each condition was plated in 
triplicate. Cells were incubated at 37°C, 5% CO2 in a humidified incubator. After 48 hours, 
20 μl of MTS tetrazolium compound (Promega, Southampton, UK) was added to each well 
and absorbance read at 490nm after 4 hours. The effects of cytarabine and lestaurtinib as 
single agents were expressed as a percentage of optical density (OD) relative to untreated 
cells (±standard error of the mean [SEM]).  
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6.2.5  148BSequential incubation with lestaurtinib and cytarabine 
In 10 cases where adequate numbers of cells were available, 4 x 10
6 cells were incubated in 
R10 at 2 x 10
6/ml in the presence of either nothing, 1 μg/ml cytarabine, 20nM lestaurtinib 
or a combination of the two. After 48 hours the cells from each of the 4 conditions were 
then washed twice in R10, split into 4 aliquots and re-suspended in each of the same 4 
conditions without adjustment for cell number, making a total of 16 different conditions. 
The cells were incubated for a further 48 hours; cell viability was then assessed using the 
MTS assay as above. The results were expressed as the optical density relative to cells 
cultured in R10 only for 96 hours.  
 
6.2.6  149BData Analysis and Statistical Interpretation 
P-values are for the student T-test between two groups. The relationship between mutant 
level and cytotoxicity was calculated using Spearman’s Rank Correlation. The median dose 
effect (Dm) was calculated using Calcusyn software. Evidence of synergy between 
cytarabine and lestaurtinib was assessed using the combination index (CI) of Chou and 
Talalay (Chou and Talalay 1984) (Calcusyn software). A CI of less than 1 indicates 
evidence of a synergistic interaction. 
 
6.3  46BUResults 
 
6.3.1  150BComparison of the cytotoxic effect of PKC412 and lestaurtinib on primary 
AML blast cells 
The cytotoxic effect of both PKC412 and lestaurtinib was tested on a small cohort of blast 
cells from 7 patients with AML. Of these 7 patients, 3 were FLT3/WT, 3 were FLT3/ITD
+ 
and 1 was FLT3/TKD
+. The median age was 44 years (range 21 – 61). The in vitro 
cytotoxic effect of lestaurtinib was greater than that of PKC412 at all concentrations tested 
(Figure 6.1). For example, at a concentration of 50nM, the mean %OD for lestaurtinib was 
63.9±8.5% (SEM) compared to 88.2±6.8% for PKC412 (P=0.05). In view of the lack of in 
vitro dose response for PKC412, subsequent experiments were performed with lestaurtinib 
only.  
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Figure 6.1: Cytotoxic dose-response to lestaurtinib and PKC412 of blast cells from 7 
patients with AML. Error bars represent standard error of the mean. 
 
 
6.3.2  151BCharacteristic of the whole cohort of patients studied 
Of the 36 cases examined for the cytotoxic effect of lestaurtinib, 14 were FLT3/WT, 11 
were FLT3/ITD
+ with a median mutant level of 45% of total FLT3 alleles (range 17%-
93%), and 11 were FLT3/TKD
+ (Table 6.3). The mutation was identified in 10 FLT3/TKD
+ 
cases, 3 were D835Y, 3 Δ836, and a single case each of D835V, N841I, D839G and a 12 
base pair insertion, with mutant levels varying between 22% and 50% of total FLT3 alleles. 
The one uncharacterised FLT3/TKD mutation was present at a low level, approximately 
5% of FLT3 alleles.  
 
6.3.3  152BThe cytotoxic effect of cytarabine on primary AML blast cells with different 
FLT3 mutation status  
Overall, there was no difference in the cytotoxic effect of cytarabine between FLT3/ITD
+, 
FLT3/TKD
+ and FLT3/WT blast cells (Figure 6.2A). At a concentration of 10 μg/ml 
cytarabine, the mean  %OD for these three groups was 45±5%, 43±7% and 50±6% 
respectively (Figure 6.2B). However, in FLT3/ITD
+ cases, there was a moderate correlation 
between increasing mutant level and an increased resistance to cytarabine-induced 
cytotoxicity (r
2=0.48, P=.04) which was not apparent in FLT3/TKD
+ cases (Figure 6.2D).  
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Table 6.3: Clinical and demographic characteristics of patients 
stratified by FLT3 mutation status. 
 FLT3/WT  FLT3/ITD+ve  FLT3/TKD+ve 
Number  14 11  11 
Sex (M/F)  12/2 8/3  3/8 
Median Age in years (Range)  49 (17-77)  56 (21-67)  44 (24-73) 
Disease Stage      
         Presentation  12 9  10 
         Relapse  2 2  1 
Cytogenetics      
       Favorable  5 1  2 
       Intermediate  6 8  8 
       Adverse  2 0  0 
       Unknown  1 2  1 
FLT3 Mutation      
       Median Mutant Level (%) 
             (Range)  N/A  45 (17-93)  43 (5-50) 
 
 
 
6.3.4  153BThe cytotoxic effect of lestaurtinib on primary AML blast cells with different 
FLT3 mutation status 
Lestaurtinib induced increased cytotoxicity in FLT3/ITD
+ compared to FLT3/WT blasts 
(Figure 6.3A). FLT3/TKD
+ blast cells, however, responded similarly to FLT3/WT cells at 
all concentrations tested. At 5nM lestaurtinib, there was a highly significant difference 
between FLT3/ITD
+ cells compared to FLT3/TKD
+ (P=.006) and FLT3/WT (P=.004) cells, 
with a mean %OD of 70±6%, 92±2% and 93±3% respectively (Figure 6.3B). There was no 
correlation between FLT3/ITD or FLT3/TKD mutant level and sensitivity to lestaurtinib 
(Figures 6.3C and 6.3D). It is noteworthy, however, that the two very high level 
FLT3/ITD
+ cases (83% and 93% mutant) were quite sensitive to lestaurtinib (%OD at 5nM 
lestaurtinib, 54% and 65% respectively compared to the median of 70%) but were relatively 
resistant to cytarabine (%OD at 10µg/ml cytarabine, 60% and 62% respectively compared 
to the median of 45%) (Figures 6.2C and 6.3C). 
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Figure 6.2: Cytotoxic responses to cytarabine stratified according to FLT3 mutation 
status. (A) Dose response to cytarabine, (B) Scatter plot of individual responses to 10 
μg/ml cytarabine, (C) Relationship between response to 10 μg/ml cytarabine and FLT3/ITD 
mutant level, (D) Relationship between response to 10 μg/ml cytarabine and FLT3/TKD 
mutant level. Error bars represent standard error of the mean. 
 
 
6.3.5  154BThe cytotoxic effect of a combination of cytarabine and lestaurtinib on primary 
AML blast cells with different FLT3 mutation status 
The cytotoxic effect of combinations of lestaurtinib and cytarabine was studied in 33 cases, 
14 FLT3/WT, 9 FLT3/TKD
+ and 10 FLT3/ITD
+. The cytotoxic effect of lestaurtinib was 
synergistic with that of cytarabine at the majority of combinations used. The median CI 
(with 25
th-75
th percentiles) was 0.47 (0.27 – 1.1) for FLT3/WT cells, 0.59 (0.23 – 1.49) for 
FLT3/TKD
+ cells and 0.35 (0.24 – 0.7) for FLT3/ITD
+ cells respectively (Figure 6.4),   
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Figure 6.3: Cytotoxic responses to lestaurtinib stratified according to FLT3 mutation 
status. (A) Dose response to lestaurtinib, (B) Scatter plot of individual responses to 5nM 
lestaurtinib, (C) Relationship between response to 5nM lestaurtinib and FLT3/ITD mutant 
level, (D) Relationship between response to 5nM lestaurtinib and FLT3/TKD mutant level. 
Error bars represent standard error of the mean.indicating that the highest degree of synergy 
was in FLT3/ITD
+ samples, although the differences between the three groups were not 
statistically significant. 
 
 
6.3.6  155BSequential incubation of primary AML cells with cytarabine and lestaurtinib 
The impact of sequential administration of cytarabine and lestaurtinib on their cytotoxic 
effect was studied in 10 cases. The results were adequate for interpretation in 6 of the 10 
cases studied. In the other 4 cases the MTS colour change of the control cells was 
inadequate for analysis (<0.2 mean optical density). Of the 6 cases studied, 2 were 
FLT3/WT, 2 were FLT3/ITD
+ and 2 were FLT3/TKD
+. The results of the sequential 
administration experiments are shown in Figure 6.5 and Table 6.4. Blast cells treated 
initially with lestaurtinib then cytarabine had a mean %OD of 56±9% versus 46±7% for  
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Figure 6.4: Scatter plot of the cytotoxic effect of lestaurtinib in combination with 
cytarabine. The combination index (CI) for the six different combinations of the two drugs 
is plotted for each sample and stratified according to FLT3 mutation status. A CI of 1, 
shown by the dashed line, is consistent with an additive effect when the two agents are 
combined. A CI of less than 1 indicates evidence of a synergistic interaction and a CI of 
greater than 1 indicates an antagonistic interaction. Error bars represent the median and 25
th 
- 75
th percentiles for each group. 
 
 
cells treated in the opposite sequence. The mean ratio of %OD for blast cells treated 
initially with cytarabine then lestaurtinib versus the opposite sequence was 0.82 (i.e. 46/56), 
representing an increased cell kill for cells cultured in cytarabine first. This may suggest 
that lestaurtinib is having an inhibitory effect on the cytotoxic effect of cytarabine. 
However, blast cells cultured in cytarabine followed by R10 had a %OD of 57±10% versus 
74±9% for those treated in the opposite sequence with a ratio of 0.77. This demonstrates 
that the cell kill was always greater when cells were cultured in cytarabine for the first 48 
hours compared to the second 48 hours, irrespective of the presence of lestaurtinib. This 
effect was not apparent with lestaurtinib; following incubation with lestaurtinib alone for 
the first 48 hours and then R10 for the second 48 hours the %OD was 74±9% versus  
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77±6% for blast cells incubated in the opposite sequence (ratio 0.96). The greatest 
cytotoxic effect was achieved by continuous incubation with a combination of cytarabine 
and lestaurtinib for the whole 96 hours. 
 
Figure 6.5: The impact of different sequences of administration of lestaurtinib on 
blast cells from 6 patients with AML. N indicates incubation in R10 only; L, 20 nM 
lestaurtinib only; C, 1 μg/ml cytarabine only; and B, both 1 μg/ml cytarabine and 20 nM 
lestaurtinib. Error bars represent the SEM. 
 
 
Table 6.4: Sequential culture of blast cells in cytarabine and lestaurtinib. The 
percentage optical density is shown for each of the 16 different culture conditions after 96 
hours of incubation. 
                                 First 48 Hours    
Second 48 Hours  Nil  Lestaurtinib  Cytarabine  Both 
Nil  100±0 74±9 57±10 40±10 
Lestaurtinib  77±6 60±9 46±7 35±8 
Cytarabine  74±9 56±9 46±7 36±8 
Both  65±7 48±8 40±6 32±7 
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6.4  47BUDiscussion 
 
As small molecule inhibitors that target FLT3 progress to more advanced clinical trials, it is 
becoming increasingly important to determine which patients might benefit from receiving 
them as part of their therapy. In vitro studies have shown that FLT3/ITD
+ blast cells are 
more sensitive to lestaurtinib-induced cytotoxicity than FLT3/WT cases (Brown et al, 
2004, Knapper et al, 2006b, Levis et al, 2002), however, although both types of mutation 
lead to constitutively activated receptors, the situation in FLT3/TKD
+ blast cells is less 
clear. Relatively few samples from such cases have been studied due to the low frequency 
of these mutations, and whilst one study reported the same response to lestaurtinib as 
FLT3/ITD
+ blasts, in another study they showed a reduced response, similar to FLT3/WT 
blasts (Brown et al, 2004, Knapper et al, 2006b). This is an important issue to clarify as an 
in vitro cytotoxic response closely correlates with clinical response in patients where 
adequate serum concentrations of the drug are achieved (Knapper et al, 2006a, Smith et al, 
2004). The studies presented within this chapter therefore focussed on FLT3/TKD
+ cases 
and found that the response to lestaurtinib of blast cells from 11 such cases was 
significantly less than that of FLT3/ITD
+ cells but similar to FLT3/WT cells at all 
concentrations tested.  
 
There are a number of possible explanations for the differential response of ITD and TKD 
mutations to FLT3 inhibition. It is possible that the impact of the mutation on protein 
conformation influences interaction with lestaurtinib. In FLT3/ITDs, the insertion of 
additional amino acids is thought to disrupt the juxtamembrane domain that normally 
stabilises all the structural components involved in holding the kinase in an inactive 
conformation (Gilliland and Griffin 2002a, Griffith et al, 2004). In FLT3/TKD mutations, 
however, the amino acid substitutions or deletions directly disturb the activation loop and 
the conformational change is more comparable to that induced by ligand stimulation of the 
WT receptor. FLT3/ITDs may, therefore, have a more powerful effect on protein unfolding 
than FLT3/TKD mutations and consequently lead to greater accessibility to lestaurtinib. 
However, in a cell line model, it has previously been reported that the two types of 
mutation have similar IC50s for lestaurtinib (Levis et al, 2002), suggesting that this is not 
the reason for the difference. Furthermore, point mutations leading to resistance to FLT3  
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inhibition by indolocarbazoles occur in the ATP binding pocket in the first kinase domain 
and not the second kinase domain (Cools et al, 2004, Heidel et al, 2006).  
 
An alternative explanation for the differential sensitivity of FLT3/ITD
+ and FLT3/TKD
+ 
blast cells to FLT3 inhibition may be that FLT3/ITD
+ blast cells are more dependent on 
FLT3 signalling for survival than FLT3/TKD
+ cells and are therefore more likely to die 
when FLT3 is inhibited. This may relate to differential events that occur downstream of the 
two types of mutation, for example, studies have indicated that, unlike FLT3/ITDs, 
FLT3/TKD mutations lead to signalling events that are very similar to those caused by 
ligand activation of the WT receptor (Choudhary et al, 2005b, Grundler et al, 2005). It 
should be noted, however, that response to lestaurtinib was not totally absent in either 
FLT3/TKD
+ or FLT3/WT cases, particularly at the higher drug concentrations used, just 
less than that observed in FLT3/ITD
+ cases. This suggests that, in at least a proportion of 
these cases, FLT3 signalling is an important contributor to leukaemia cell survival.  
 
The level of a FLT3 mutation has been shown to add important prognostic information to 
the detection of the presence of a mutation alone, and higher mutant levels correlate with a 
significantly poorer outcome in FLT3/ITD
+ cases (Gale et al, 2007, Meshinchi et al, 2006, 
Thiede et al, 2002, Whitman et al, 2001), and an improved outcome in FLT3/TKD
+ cases 
(Mead et al, 2007). The relationship between mutant level and response to cytarabine and 
lestaurtinib was therefore examined. Previous studies have suggested that higher level 
FLT3/ITDs may be more sensitive to the effects of FLT3 inhibitors than lower level 
mutants (Brown et al, 2004, Knapper et al, 2006b). The data presented in this chapter 
demonstrated that there was a weak correlation between increasing lestaurtinib sensitivity 
and higher FLT3/ITD mutant level, but this was not statistically significant. However, there 
was evidence of a significant inverse relationship between cytarabine-induced cytotoxicity 
and FLT3/ITD mutant level. In particular, two cases had a FLT3/ITD mutant level that was 
consistent with loss of the FLT3/WT allele through mitotic recombination (Raghavan et al, 
2005). It is noteworthy that these cases showed relative resistance to cytarabine but 
remained highly sensitive to lestaurtinib-induced cytotoxicity. This has important 
implications for treatment of such cases as they have a particularly adverse prognosis, with 
a very high relapse rate, and are good candidates for more experimental therapies. 
Furthermore, studies of paired presentation/relapse samples have shown that in FLT3/ITD
+  
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cases, mutant levels are often increased at relapse, probably because the ITD-carrying 
leukaemic stem cells have increased chemo-resistance and are therefore selected for 
(Kottaridis et al, 2002, Schnittger et al, 2004, Shih et al, 2002). Sensitivity to targeted 
FLT3 inhibition may therefore be especially beneficial in such cases. There was no 
evidence of any relationship between FLT3/TKD mutant level and sensitivity to either 
cytarabine or lestaurtinib. 
 
The modest clinical responses seen in clinical trials of FLT3 inhibitors (Table 6.2) may, at 
least in part, reflect the poor risk patients entered into these trials. Nevertheless, significant 
responses were seen, and given the molecular heterogeneity of AML in comparison to 
chronic phase CML, expectations for the efficacy of single agent FLT3 inhibitors need to 
be adjusted accordingly. Unfortunately however, all trials using FLT3 inhibitors as 
monotherapy have shown that resistance rapidly occurs in responding patients (Table 6.2). 
This may relate to new mutations in the kinase domain (Heidel et al, 2006), or the 
activation of downstream signalling by other mechanisms, thereby bypassing FLT3 (Piloto 
et al, 2006). Furthermore, in some cases, a FLT3 mutation is probably a secondary event 
occurring late in leukaemogenesis, with the FLT3 mutant(s) only being present in a 
subpopulation of leukaemic cells (Kottaridis et al, 2002). It is possible that in these cases 
there will be a rapid outgrowth of FLT3/WT leukaemic clones, resistant to the effects of 
FLT3 inhibition. Finally, the main cause of treatment failure in AML is relapse caused by 
residual leukaemic stem cells which survive induction and consolidation chemotherapy. To 
be successful in improving outcome, FLT3 inhibitors will need to be efficacious in 
targeting this small population of cells rather than simply reducing the bulk of the 
leukaemia. Encouragingly, there is some data that lestaurtinib can prevent the engraftment 
of FLT3/ITD mutated AML blast cells in a mouse model, suggesting that this inhibitor may 
indeed have the desired effect (Levis et al, 2005a). 
 
In view of the limited clinical responses seen with lestaurtinib monotherapy (Knapper et al, 
2006a, Smith et al, 2004), it is likely that any therapeutic role for lestaurtinib will be in 
combination with conventional chemotherapy. The data presented in this chapter 
demonstrates that the level of cell kill induced by lestaurtinib was synergistic with 
cytarabine, regardless of mutational status, and the degree of synergy observed was not 
statistically different between the 3 groups.   
139
 
One concern with regards to the combination of FLT3 inhibitors with conventional 
chemotherapy agents is that inhibition of FLT3 is likely to slow down cell proliferation in 
AML blasts with activated FLT3, thereby reducing the efficacy of cell-cycle dependent 
chemotherapeutic agents such as cytarabine. Studies using cell line models have suggested 
that the sequence of administration of lestaurtinib in combination with conventional 
chemotherapy is important to achieve a synergistic effect of the two drugs (Levis et al, 
2004). In these experiments, lestaurtinib pre-treatment of Ba/F3 cells transduced with a 
FLT3/ITD led to relative resistance to the effects of cytarabine. However, these results 
should be interpreted with caution for a number of reasons. Firstly, a cell line model system 
is biologically very different from primary AML cells and the impact of sequential 
administration of lestaurtinib and cytarabine on primary AML cells was not addressed. 
Studying the impact of the sequential incubation of lestaurtinib and cytarabine on primary 
AML cells in vitro is complicated by the decrease in viability with time of primary AML 
cells in liquid culture. Interpretation of such in vitro studies is therefore inevitably limited 
as it relies on a comparison between a control population of cells with inexorably declining 
viability and the impact of in vitro agents on the rate of this decline. Whilst this is clearly 
far removed from the in vivo treatment of AML in patients, it may nevertheless produce 
data that are more relevant than murine cell line studies. A further limitation of the above 
study relates to the longer period of exposure of the lestaurtinib pretreated Ba/F3 cells to 
lestaurtinib (72 hours versus 48 hours) which would lead to a reduced viability of the 
control cells. As these data were expressed as percentage cell viability relative to the 
control cells, artificial skewing of the curves and potential misinterpretation of the 
combination index could result.  
 
In the work presented in this chapter, the impact of sequential administration of cytarabine 
and lestaurtinib was studied in 6 primary AML cases. The cytotoxic impact of cytarabine 
followed by lestaurtinib treatment was slightly greater than the two drugs in the opposite 
sequence (%OD, 46% versus 56%). This would support a possible antagonistic interaction 
of the two drugs when lestaurtinib is used first. However, the cytotoxic impact of 
cytarabine as a single agent was less when given in the second 48 hours compared to the 
first (%OD, 74% versus 57%), suggesting that the above effect does not relate to 
lestaurtinib. It may be that the blast cells which survive longer in liquid culture are less  
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sensitive to cytarabine-induced toxicity. Furthermore, pre-treatment of blast cells with 
lestaurtinib for the first 48 hours followed by a combination of cytarabine and lestaurtinib 
induced increased cytotoxicity compared to blast cells cultured in R10 alone for the first 48 
hours followed by a combination of the two agents (%OD, 48% versus 65%). There is no 
evidence from these experiments, therefore, that pre-treatment with lestaurtinib reduces the 
cytotoxic effect of cytarabine on AML blast cells in vitro. This is an important question to 
adequately answer as it may be that concurrent administration of FLT3 inhibitors and 
chemotherapy may be beneficial, as inhibition of anti-apoptotic pathways may be more 
important in vivo than any possible detrimental impact because of an anti-proliferative 
effect. This may be particularly relevant for the leukaemic stem cell population, which are 
likely to be more quiescent the bulk population of leukaemic cells.  
 
Clinical studies are currently underway combining FLT3 inhibitors with conventional 
chemotherapy. One trial randomised patients with relapsed, FLT3 mutated AML to 
lestaurtinib with conventional chemotherapy or chemotherapy alone (Levis et al, 2005b). In 
this trial lestaurtinib and cytarabine were not administered concurrently. Of 17 patients 
randomised to receive lestaurtinib and chemotherapy, 10 achieved a response (5 CR) 
compared to 4 of 17 randomised to receive chemotherapy alone (2 CR). Another study 
combined PKC412 with conventional chemotherapy in patients with untreated AML, 
regardless of FLT3 mutation status (Stone et al, 2005a). Despite some problems with 
tolerability at a high dose level, with a dose reduction, the regime was well tolerated. An 
update of this trial (Stone et al, 2006) reported a CR rate of 69% in 26 FLT3/WT patients 
compared to 92% in 12 FLT3 mutated patients, with 7 of these 12 patients remaining in CR 
after a follow up of 3-15 months. These results are sufficiently encouraging, at least in 
FLT3 mutated patients, for these agents to be incorporated into larger, randomised trials of 
AML. For example, the UK MRC AML 15 trial has an amendment randomising FLT3 
mutant-positive patients to receive lestaurtinib or not, in combination with conventional 
chemotherapy.  
 
In conclusion, the data presented in this chapter suggests that in clinical trials of FLT3 
inhibitors in adult AML, FLT3/TKD
+ cases should not be differentiated from FLT3/WT 
cases. It should be emphasised that this does not imply that lestaurtinib should be restricted 
to FLT3/ITD
+ cases, as an alternative approach would be for all patients to receive a FLT3  
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inhibitor, with the presence of a FLT3/ITD being used merely as a risk stratification 
variable. Nevertheless, it is encouraging that the cytotoxic effects of FLT3 inhibition appear 
to be most marked in the patient group where conventional chemotherapeutic approaches 
are most likely to fail. 
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7  18BUCHAPTER 7: EXOGENOUS EXPRESSION OF FLT3 MUTANTS 
IN CELL LINE MODELS AND HUMAN PRIMARY 
HAEMATOPOIETIC STEM CELLS 
 
7.1  48BUIntroduction 
 
Following the observation that FLT3 is frequently mutated in AML, there has been 
considerable interest in developing experimental systems in order to understand the 
functional consequences of these mutations at a cellular level. These studies may provide 
insight(s) into mechanisms of leukaemogenesis and explain the adverse prognosis 
associated with FLT3/ITDs. If the latter is directly related to signalling events that arise as a 
result of mutation of this receptor, then characterising the downstream events may aid in 
understanding mechanisms of chemoresistance in AML and, more importantly, how to 
overcome them. Furthermore, if the different prognostic impact of FLT3/ITDs and 
FLT3/TKD mutations relates to differential signalling events, then direct comparison of the 
cellular consequences of these two mutations may also be relevant.  
 
7.1.1  156BThe role of FLT3 in normal haematopoiesis 
The role of FLT3 in the growth and differentiation of normal haematopoietic cells has been 
widely studied. When used alone, FL was only a weak stimulator of CD34+ BM cells in 
vitro. When it was used in combination with other growth factors, however, FL 
synergistically enhanced the growth of primitive HSCs and more committed HPCs (Rusten 
et al, 1996), leading to a marked increase in the number of granulocyte-monocytic colonies 
formed in methylcellulose assays. A specific role in the differentiation of HSCs to B-
lymphocyte progenitors has been suggested by in vitro studies (Veiby et al, 1996) as well 
as by in vivo mouse knockout studies of FLT3 (Mackarehtschian et al, 1995) or FL (Buza-
Vidas et al, 2007). FL also appears to stimulate the proliferation and differentiation of early 
T-cells (Moore and Zlotnik 1997), and is a potent stimulator of dendritic cell development 
both in vitro and in vivo, leading to interest in its use to improve anti-tumour dendritic cell 
vaccination strategies (Dong et al, 2002). However, FL does not stimulate erythropoiesis or 
megakaryopoiesis (Ratajczak et al, 1995, Ratajczak et al, 1996), an observation that is  
143
consistent with the lack of expression of FLT3 on megakaryocytic and erythroid 
progenitors (Adolfsson et al, 2005). 
 
7.1.2  157BSignalling events downstream of FLT3/WT activation 
Several groups had examined the intracellular signalling consequences of activating 
FLT3/WT before the identification of FLT3/ITDs in AML. As FL had not yet been 
discovered when these initial experiments took place, the first studies used chimeric 
molecules containing the extracellular domain of the CSF-1 receptor (c-FMS) fused to the 
transmembrane and cytoplasmic domains of murine Flt3. CSF-1 stimulation of Ba/F3 cells 
transduced with the chimeric receptor induced receptor dimerisation and 
autophosphorylation, led to IL-3 independent growth and tyrosine-phosphorylation of RAS 
GTPase-activating protein (GAP), phospholipase C-γ1 (PLCγ1), Vav, Fyn, Shc (SH2-
containing sequence protein), src family tyrosine kinases and the p85 subunit of 
phosphatidyl inositol-3 kinase (PI3K) (Casteran et al, 1994, Dosil et al, 1993).  In co-
precipitation assays it was shown that FLT3 directly associated with Grb2, PLCγ1, the p85 
subunit of PI3K, Shc and Src family tyrosine kinases. Furthermore, it was also observed 
that phosphorylation of p85 and Shc by FLT3 was cell-type-specific and differed between 
NIH 3T3 cells and Ba/F3 cells (Dosil et al, 1993).  
 
The cloning of human FL in 1993 (see chapter 3) allowed the more direct study of FLT3 
signalling pathways (Lavagna-Sevenier et al, 1998a, Lavagna-Sevenier et al, 1998b, 
Marchetto et al, 1999, Zhang and Broxmeyer 1999, Zhang and Broxmeyer 2000, Zhang et 
al, 1999). These studies mostly recapitulated the earlier observations using the chimeric 
receptor, with some notable differences. For example, human FLT3 does not bind directly 
to the p85 subunit of PI3K but rather activates PI3K by forming a complex with 
intermediaries such as GRB2, GAB2, SHIP, SHP2, CBL and CBLB. Through the 
phosphorylation of these intermediary proteins a number of key signalling pathways are 
activated including the PI3K pathway (Zhang and Broxmeyer 1999), the mitogen activated 
protein kinase (MAPK) pathway (Zhang et al, 1999) and signal transducers and activators 
of transcription such as STAT5A (Zhang et al, 2000), the latter by a JAK (Janus kinase) 
independent mechanism. Activation of the FLT3 kinase also leads to phosphorylation of 
SHIP (SH2-domain containing inositol phosphatase), which results in negative regulation 
of RAS and PI3K signalling (Marchetto et al, 1999).   
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7.1.3  158BTransduction of FLT3/ITDs in cell line models 
FLT3/ITD induced ligand-independent activation of FLT3 was reported when plasmid 
constructs containing FLT3/WT or 5 different FLT3/ITDs were expressed in Cos7 cells 
(Kiyoi et al, 1998). Using immunoblotting, with or without immunoprecipitation, it was 
shown that FLT3/WT protein was not tyrosine phosphorylated in the absence of FL but 
addition of FL led to dimerisation and phosphorylation. FLT3/ITDs, however, were 
dimerised and tyrosine phosphorylated in the absence of FL, although in some cases the 
addition of FL further increased the level of tyrosine phosphorylation. It was also noted that 
the duplicated sequence of 51 different FLT3/ITDs almost always involved a tyrosine rich 
region between residues 589 and 599 (tyrosines at positions 589, 591, 597 and 599). 
However, by substituting tyrosine residues 589 or 591 to phenylalanine, it was shown that 
these tyrosine residues were not essential for FLT3/ITD-induced FL-independent 
activation. A further study demonstrated that FLT3/ITDs were capable of dimerising with 
and activating the FLT3/WT protein, even when the FLT3/ITD lacked a TKD domain and 
therefore had no intrinsic kinase activity (Kiyoi et al, 2002). 
 
The downstream effects of FLT3/ITDs were investigated by introducing full-length WT 
and ITD forms of human FLT3 into the IL-3 dependent 32D and Ba/F3 murine cell lines by 
electroporation (Hayakawa et al, 2000). Upon deprivation of IL-3, the ITD-transduced cells 
continued proliferating whereas the WT-transduced cells showed weak proliferation in the 
presence of FL and rapidly died in the absence of cytokines. Both the ITD and FL-
stimulated FLT3/WT led to phosphorylation of ERK1 (extracellular signal-regulated 
kinase) and ERK2, part of the MAPK signalling pathway. Intriguingly, however, whilst the 
ITD-transduced cells showed phosphorylation of STAT5A with associated DNA binding, 
this was absent in FL-stimulated WT-transduced cells. These findings were confirmed by 
another study (Mizuki et al, 2000), which also found that FLT3/ITDs retained dependence 
on FL stimulation for the phosphorylation of MAPK and AKT (protein kinase B), a key 
serine-threonine kinase. However, a different study showed that STAT5A was strongly 
activated by FL stimulation of FLT3/WT (Zhang et al, 2000). The explanation for these 
differences is unclear.  
 
Subsequent studies have focused on anti-apoptotic pathways activated by FLT3/ITDs.  An 
initial report demonstrated strong activation of protein kinase A (PKA) and ribosomal S6  
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kinase 1 (RSK1) in FLT3/ITD transformed Ba/F3 cells (Yang et al, 2005), equivalent to FL 
stimulation of FLT3/WT transformed cells. PKA and RSK1 activation in turn led to 
phosphorylation of the Bcl-2 family member BAD at serine112, thereby leading to an 
inhibition of apoptosis. Phosphorylation of BAD may also occur through an alternative 
pathway through upregulation of Pim-1 by FLT3/ITDs (Kim et al, 2005, Kim et al, 2006). 
However, another study demonstrated that in FLT3/WT-transduced 32D cells, anti-
apoptotic pathways induced by FL stimulation were dependent on BAD phosphorylation 
for cell survival whereas FLT3/ITD-transduced cells maintained anti-apoptotic signalling 
by upregulating Bcl-XL (an anti-apoptotic Bcl2 family member), even when BAD was 
dephosphorylated (Minami et al, 2003). A subsequent report showed that transduction of 
32D cells with a FLT3/ITD led to very strong cytokine-independent phosphorylation and 
activation of AKT and consequent phosphorylation and inactivation of the proapoptotic 
protein Foxo3a (Brandts et al, 2005, Scheijen et al, 2004). Conversely, FL stimulation of 
FLT3/WT-transduced 32D cells only led to weak activation of AKT. Proliferation and 
viability of ITD-transformed 32D cells could be markedly reduced by cotransfection with 
double negative forms of AKT. Finally, other studies have shown an apparent cooperation 
of Wingless-type (Wnt) signalling pathways with FLT3/ITD signalling, with FLT3/ITDs 
inducing an increased expression of Frizzled-4, a receptor for Wnt ligands, and high-β-
catenin protein levels in 32D cells transfected with a FLT3/ITD compared to ligand 
stimulated FLT3/WT cells (Tickenbrock et al, 2005).  
 
7.1.4  159BCorrelation of signalling studies in cell line models with primary AML blast 
cells 
Studies of signalling pathways in murine haematopoietic cell lines may not, however, 
reflect the impact of FLT3/ITDs in primary leukaemic cells. Indeed, correlation of cell line 
studies with the activation of signalling pathways in primary AML blast cells has produced 
mixed results. One study failed to show any correlation between constitutive activation of 
FLT3 in primary AML blasts and the presence of a FLT3/ITD (Fenski et al, 2000). This 
study included 32 cases of AML, 4 of which were FLT3/ITD
+. FLT3 protein was detectable 
by immunoprecipitation in 27 cases, and in 18 of these cases the FLT3 was 
autophosphorylated following 5 minutes stimulation with 100ng/ml FL (Fenski et al, 2000). 
There were only 3 cases which displayed ligand-independent autophosphorylation of FLT3 
and only 1 of these cases had a FLT3/ITD. Three other cases were FLT3/ITD-positive but  
146
only demonstrated FLT3 autophosphorylation in the presence of FL. In another study, 
however, all 12 cases studied (5 WT FLT3, 6 ITDs and 1 TKD) showed ligand-independent 
phosphorylation of FLT3 (Knapper et al, 2006b).  
 
In terms of downstream signalling pathways, correlation with FLT3 status has also 
generally yielded mixed results. One study demonstrated STAT5 activation by Western blot 
analysis in 3 of 14 cases without a FLT3/ITD compared with 4 of 8 FLT3/ITD
+ patients 
(Spiekermann et al, 2003). Furthermore, a study using a T-cell factor/lymphoid enhancer 
factor (TCF/LEF) reporter assay showed a borderline association between the presence of a 
FLT3/ITD and increased Wnt signalling in primary blast cells from 25 cases of AML 
(Simon et al, 2005). However, other studies observed either no correlation (Grandage et al, 
2005), or an apparent negative correlation (Tamburini et al, 2007), between the presence of 
FLT3 mutations and PI3K activation.  
 
These studies highlight the difficulty of studying signalling events in primary cells ex vivo 
that may have been cryopreserved and lack the growth factor stimulation they would 
normally receive in vivo. It is very difficult to know how closely these studies reflect the in 
vivo signalling consequences that arise as a result of FLT3 mutation when cells are within 
the bone marrow microenvironment. 
 
7.1.5  160BTransduction of FLT3/TKDs in cell line models 
The potential that mutations in the TKD of FLT3 could be constitutively activating was 
first demonstrated before the mutations were described in AML. Activating mutations in c-
Kit were known to be located within the second TKD (Furitsu et al, 1993) and the authors 
therefore hypothesised that equivalent point mutations may also activate the FLT3 kinase. 
They transfected 32D cells with murine D838V FLT3, the equivalent to human D835V, 
and showed this led to autophosphorylation of FLT3 and factor independent growth (Fenski 
et al, 2000). Subsequently, FLT3/TKD mutations were detected in AML patients and a 32D 
cell model was used to demonstrate that a number of these mutations (D835Y, D835V, 
D835H, D835E, D835N and I836L+D) led to FLT3 autophosphorylation and proliferation 
in the absence of cytokines (Yamamoto et al, 2001).  
  
147
Signalling events downstream of FLT3/TKD mutations (D835Y, Δ836 and I836M+R) were 
reported in Ba/F3, 32D and HEK293 cells (Grundler et al, 2003) and compared with 
FLT3/WT and a FLT3/ITD. This study showed that TKD mutants induced factor-
independent growth of Ba/F3 cells, autophosphorylation of FLT3 and significant 
phosphorylation of STAT5, equivalent to that of the FLT3/ITD. FL stimulated FLT3/WT 
cells did not show any STAT5 phosphorylation. This study therefore suggested that both 
ITDs and TKDs lead to similar signalling events in the absence of cytokines, although 
FLT3/ITD-transduced cells did proliferate more quickly than FLT3/TKD-transduced cells.  
 
A subsequent report, however, suggested that there are important differences in the 
signalling events activated by the different FLT3 mutations (Choudhary et al, 2005b). They 
found that expression of a FLT3 ITD or TKD (D835Y) in 32D cells led to strong cytokine-
independent autophosphorylation of FLT3 but that TKDs induced less pronounced 
autonomous growth than ITDs. Furthermore, FLT3/ITD-transduced 32D cells were able to 
form colonies in semi-solid media in the absence of cytokines, unlike FLT3/TKD-
transduced cells or FL-stimulated FLT3/WT cells. FLT3/ITD cells were also more resistant 
radiation-induced apoptosis than FLT3/TKD cells as assessed by measuring cell viability 
after exposure to 5 Gy γ irradiation in the absence of cytokines. FLT3/ITD, TKD or FL-
stimulated WT cells all had similar degrees of phosphorylated Shc and AKT. The 
FLT3/TKD and FL-stimulated WT 32D cells had less strongly activated ERK1 and 2 than 
FLT3/ITDs. Most strikingly, the FLT3/ITD cells strongly phosphorylated STAT5, had 
increased Pim-2 and CIS expression (both downstream targets of activated STAT5) and 
demonstrated suppression of C/EBPα and PU.1 expression, changes that were not apparent 
in FLT3/TKD and FL-stimulated WT 32D cells. 
 
7.1.6  161BThe impact of mutant FLT3 on haematopoietic cell differentiation 
In addition to the above survival and proliferative signals, studies have also examined the 
impact of a FLT3/ITD on myeloid differentiation. In a G-CSF-induced model of cell 
differentiation in 32Dcl3 cells, transduction with a FLT3/ITD led to a block in 
differentiation, unlike FL-stimulation of FLT3/WT transduced cells (Zheng et al, 2002). It 
is possible that this relates to a FLT3/ITD-induced reduction in the level of expression of 
C/EBPε (Zheng et al, 2002) and C/EBPα (Mizuki et al, 2003, Zheng et al, 2004a), or  
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inhibition of C/EBPα by phosphorylation (Radomska et al, 2006). Alternatively, 
suppression of other myeloid transcription factors by FLT3/ITDs, such as PU.1, may 
contribute to this differentiation block (Mizuki et al, 2003, Zheng et al, 2004a). Another 
study has suggested that FLT3/ITD-induced suppression of RGS2, a regulator of G-protein 
signalling, is important for the myeloid differentiation block (Schwable et al, 2005). 
 
No studies have addressed the impact of FLT3/TKDs on cellular differentiation, although it 
is interesting to note that FLT3/TKDs, unlike ITDs, do not suppress C/EBPα or PU.1 
expression (Choudhary et al, 2005b), and also lead to an increased expression of the tumour 
suppressor TSC-22 (transforming growth factor-β stimulated clone-22) which in turn 
promotes, rather than blocks, myeloid differentiation (Lu et al, 2007). 
 
7.1.7  162BTransduction of FLT3 mutations into normal murine haematopoietic cells 
The in vivo impact of FLT3/ITDs on murine haematopoiesis has been studied by 
transplanting mouse BM cells oncoretrovirally transduced with a FLT3/ITD into lethally 
irradiated syngeneic recipient mice. This led to the development of a lethal 
myeloproliferative disease with a latency of approximately 40-50 days (Kelly et al, 2002b). 
An ITD alone was insufficient to generate an overt leukaemic phenotype. This finding has 
been confirmed in other studies using a similar oncoretroviral transduction approach 
(Grundler et al, 2005). Furthermore, transgenic mice with the FLT3/ITD expressed either 
under a vav promoter or 'knocked-in' to the murine FLT3 locus (Lee et al, 2007, Lee et al, 
2005) also display a similar phenotype. However, mice transplanted with BM cells from 
PML-RARA transgenic mice that were oncoretrovirally transduced with a FLT3/ITD did 
develop a leukaemia-like syndrome with many similar features to APL, a marked reduction 
in the latency time of disease onset and complete penetrance (Kelly et al, 2002a). This 
would suggest that these two different genetic events cooperate to cause leukaemia. Similar 
results have been obtained with combinations of FLT3/ITDs and the core binding factor-
β/smooth muscle myosin heavy chain (CBFβ-SMMHC) fusion gene (Kim et al, 2007) as 
well as the AML1-ETO fusion gene (Schessl et al, 2005). 
 
The impact of FLT3/TKDs (D835Y and I836M+R) has also been examined in a murine 
transplantation model and compared with a FLT3/ITD (Grundler et al, 2005). In freshly  
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harvested BM cells, all mutant-transduced cells had activated AKT, ERK1 and STAT5. In 
BM cells starved for 4 hours, however, FLT3/ITD-transduced cells demonstrated stronger 
phosphorylation of STAT5 and ERK than FLT3/TKD-transduced cells. Phosphorylation of 
AKT was similar between the ITD and TKDs. Mice transplanted with FLT3/TKD-
transduced BM, however, developed B and T-cell lymphoproliferative disorders with a 
longer latency, in contrast to the ITD-induced MPD with a latency of approximately 50 
days. 
 
7.1.8  163BTransduction of FLT3 mutations into normal human haematopoietic cells in 
vitro 
Given the key role of FLT3 mutations in the pathogenesis of AML, and the potential 
limitations of murine models of human leukaemogenesis, studies of the impact of FLT3 
mutations in human haematopoietic cells are of considerable importance. It is surprising 
therefore, that only a limited number of studies have been reported on human HSCs 
transduced with FLT3/ITDs. One study used oncoretrovirally transduced umbilical cord 
blood (UCB) CD34+ cells with a GFP-tagged vector or FLT3/ITD (Chung et al, 2005). The 
ITD-transduced cells demonstrated increased proliferation in stromal co-culture assays, as 
demonstrated by a 4-fold increase in the GFP-positive fraction of ITD-transduced cells, but 
no change in the GFP-positive fraction of vector-transduced cells over the course of 5 
weeks. Interestingly, these cells showed a dramatic reduction in monocytic markers and an 
increase in erythroid lineage markers. Furthermore, using in vitro progenitor assays, an 
increase in erythroid colonies was also reported, although this was surprising in view of the 
lack of any role for FL in stimulating erythroid colonies (see above). However, given that 
FLT3 was expressed non-physiologically under the control of a constitutive promoter, 
caution is required in the interpretation of these results. In an additional experiment, 
STAT5A was shown to be activated in the FLT3/ITD- but not FLT3/WT-transduced cells. 
Similar results were observed in another study using an oncoretroviral transduction 
approach (Moore et al, 2007), which also showed that transduction of UCB CD34+ cells 
with a constitutively activated form of STAT5A led to a similar phenotype as FLT3/ITD 
transduction. A subsequent study used a lentiviral vector approach to transduce UCB 
CD34+ cells, which has the advantage of being cell-cycle independent and therefore not 
requiring cytokine pre-stimulation. This study again demonstrated an increased 
proliferation in FLT3/ITD-transduced cells compared to vector-transduced cells in liquid  
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and semi-solid cultures in the presence of SCF and thrombopoietin, a reduction in 
monocytic differentiation but a relative increase in erythroid markers during liquid culture 
(Li et al, 2007). Of note, all these studies used GFP-vector transduced cells rather than 
FLT3/WT-transduced cells as a control. No studies have transduced human CD34+ cells 
with FLT3/TKD mutations. 
 
7.1.9  164BAims 
The work in this Chapter aimed to compare the functional impact of FLT3/ITDs and 
FLT3/TKDs at a cellular level in terms of proliferation and differentiation. To achieve this, 
lentiviral vectors were developed in order to express FLT3/WT and the different mutant 
forms of FLT3 in both murine and human cell lines and in primary HSCs. 
 
7.2  49BUMaterials and methods 
 
7.2.1  165BCloning of FLT3 into an MSCV lentiviral vector 
The parental plasmid constructs containing full length FLT3 with a D835Y mutation and a 
FLT3/ITD were kindly provided by Professor A. Khwaja (Department of Haematology, 
UCL). The ITD was a 57 bp duplication with a 3 bp insertion within the juxtamembrane 
domain of FLT3 and contained 4 tyrosine residues within the duplicated segment, residues 
589, 591, 597 and 599 (Figure 7.1). 
 
The plasmids required for lentiviral production were a kind gift from Dr Nathwani, 
Department of Haematology, UCL. The third generation, self-inactivating vector plasmid 
had a GFP gene downstream of an internal ribosomal entry site (IRES) expressed under the 
regulation of a murine stem cell virus promoter. This vector plasmid had BsrGI restriction 
enzyme digest sites just 3’ of GFP and 5’ of the IRES as shown in Figure 7.2A. The 
FLT3/ITD and FLT3/TKD plasmids had BsrGI restriction enzyme digestion sites upstream 
of FLT3 and 3’ of GFP as shown in Figure 7.2B. To subclone the TKD and ITD sequences 
including the IRES-GFP into the lentiviral plasmid, approximately 1 μg of each plasmid 
DNA was digested with BsrGI in a 20 μl reaction for 4 hours at 37°C according to the 
manufacturer’s recommended conditions. Digested products were separated by 1% agarose 
gel electrophoresis and the required band was cut out of the gel and purified using  
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Figure 7.1: Duplicated segment of the juxtamembrane domain of the FLT3/ITD vector 
showing the inserted 20 amino acid sequence that resulted from a 57 bp tandem duplication 
and 3 bp insertion. 
 
 
QIAquick Gel Extraction Kit (Qiagen, Crawley, West Sussex, UK). The purified and 
digested plasmid and FLT3-IRES-GFP insert were then ligated at 1:1, 1:3 and 1:5 molar 
ratios (plasmid:insert) using Promega T4 DNA Ligase (Promega, Southampton, UK) 
according to the manufacturer’s recommended conditions. Ligated products were 
transformed into DH5α competent bacteria by adding 5 μl of the ligation reaction to 50 μl 
of DH5α competent bacteria and incubating on ice for 30 minutes. The cells were then 
heat-shocked at 37°C for 30 seconds and returned to ice for 2 minutes. Following this, 200 
μl of SOC medium was added and the cells incubated on a shaker for 60-90 minutes at 
37°C. Cells were then spread onto LB-agar plates with carbenicillin added to 50 μg/ml final 
concentration and incubated overnight at 37°C. Colonies were plucked the next day, 
transferred to 5 mls of LB medium containing carbenicillin and grown overnight. Bacterial 
cells were then pelleted and plasmid DNA extracted using QIAprep Miniprep kit (Qiagen, 
Crawley, West Sussex, UK). Insertion of FLT3 in the correct orientation was confirmed by 
EcoRV and HincII digestion. Forward orientation insertion of the FLT3/ITD resulted in 4   
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Figure 7.2: Plasmids used for FLT3 cloning. (A) The lentiviral-vector plasmid used with 
BsrGI sites marked. (B) The section  of the plasmid containing FLT3 upstream of an IRES-
GFP cassette with flanking BsrGI sites marked. (C) The resulting FLT3 plasmid with the 
sites of the ITD or TKD mutation marked. The AscI and SphI sites used to generate 
FLT3/WT are shown.  
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 bands at 5304, 2672, 2220 and 1574 bp whereas for the D835Y, only 3 bands were present 
at 7916, 2220 and 1574 bp. FLT3/WT was not available in a plasmid and was therefore 
generated using SphI and AscI restriction enzyme digestion sites (shown in Figure 7.2C) in 
order to cut, gel extract and religate the WT segments of the FLT3/TKD and FLT3/ITD 
constructs. Thus 4 different plasmids were developed: 
•  Vector: GFP only 
•  WT: GFP-tagged FLT3/WT 
•  TKD: GFP-tagged D835Y FLT3/TKD 
•  ITD: GFP-tagged FLT3/ITD 
DNA of the constructs and plasmids required for electroporation and lentivirus production 
was generated using Qiagen Megaprep kits (Qiagen, Crawley, West Sussex, UK). 
 
7.2.2  166BHaemopoietic cell lines 
32D clone 3 (32Dcl3) cells, a growth factor dependent murine myeloid cell line 
(Greenberger et al, 1983), and Ba/F3 cells, an IL3 dependent murine bone marrow derived 
pro-B cell line (Palacios and Steinmetz 1985) were grown in RPMI containing 10% fetal 
calf serum (R10) and 1% antibiotic/antimycotic solution (Sigma-Aldrich) in the presence of 
10 nM murine IL3 (mIL3) in 5% CO2 in a humidified incubator at 37°C. Cells were 
maintained at a density of approximately 1 x 10
5/ml and were split 3 times per week.  
 
The NB4 (Lanotte et al, 1991) cell line, derived from a case of human APL, was grown in 
R10 and 1% antibiotic/antimycotic solution without the addition of IL3. This cell line is 
FLT3/WT (Quentmeier et al, 2003), which was confirmed by direct sequencing of gDNA. 
 
7.2.3  167BElectroporation of plasmid constructs into 32Dcl3 cells 
32Dcl3 cells were transduced with the above plasmids by electroporation. Cells were 
resuspended in R10 at a density of 1-2 x 10
5/ml and cultured overnight. The next day, they 
were washed, resuspended at a density of 20-40 x10
6/ml in 0.5 ml of phenol red-free 
medium containing 10% FCS, 10% WEHI-conditioned medium and 20 μg of one of the 
plasmids, and electroporated at 250 V and 960 mF. They were left for 5 minutes to recover 
and then resuspended in 15-20 ml of R10 and returned to the incubator. The following day, 
live cells were harvested by Ficoll-Hypaque centrifugation and cultured in 10 nM mIL3.  
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After 1 week, GFP-positive cells were selected by fluorescence activated cell sorting 
(FACS) on an EPICS, Beckman-Coulter flow cytometer under sterile conditions.  
 
7.2.4  168BLentiviral production 
Third generation self-inactivating lentivirus was produced using a previously described 4-
plasmid transient transfection method (Hanawa et al, 2002). 293T cells were seeded onto 
10cm tissue culture plates at a density of approximately 0.3 x 10
6/ml in 10 mls of DMEM 
containing 10% fetal calf serum (D10) and 1% antibiotic/antimycotic solution and placed in 
5% CO2 in a humidified incubator at 37°C. After 24 hours, the cells were approximately 
90% confluent. For each plate, a mixture of 10 μg of the required plasmid, 7.5 μg of 
packaging plasmid (KGP1.1R), 2 μg of helper plasmid (RTR2), 2 μg of envelope plasmid 
(VSVG) and 50 μl of 2.5M CaCl2 was made up to 500 μl with water. This was slowly 
mixed with an equal volume of 2 x HEPES-buffered saline whilst vortexing and then 
immediately mixed with 9mls of D10. The medium was removed from each 10cm plate and 
replaced with 10mls of the plasmid/D10 medium. The cells were then returned to the 
incubator. 
 
After 24 hours, transduction was assessed using microscopy under UV light to detect GFP-
expressing cells. The cells were then washed twice with 10 mls of PBS and fresh D10 
medium added. After a further 24 hours of culture, the medium was harvested from each 
plate and filtered through a 0.2 μm filter. The lentiviral rich-medium was used fresh where 
possible, otherwise it was stored at –40°C. 
 
In order to concentrate virus preparations for CD34+ cell transductions, viral supernatants 
were spun at 50000 g (27000 rpm) for 90 minutes at 4°C. The supernatant was then 
carefully decanted off under sterile conditions and 50 μl of X-vivo10 medium (Cambrex) 
added per tube. After 30 minutes the virus was fully resuspended by pipetting, transferred 
to a sterile eppendorf tube, then spun for 10 minutes at 1000 g (4000 rpm) to remove any 
cell debris. The supernatant was used fresh or aliquoted to cryovials and stored at –80°C. 
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7.2.5  169BBiological titre of lentiviral supernatants 
Using a six well plate, HeLa cells were plated at a concentration of 1 x 10
4 cells per well in 
2 mls of D10. After 24 hours, the medium was replaced with 1 ml fresh D10 containing 5 
μl, 50 μl or 500 μl of viral supernatant and 2 μl of 1000x polybrene (final concentration 4 
μg/ml) and culture continued for 48 hours. The % GFP of HeLa cells was then measured by 
flow cytometry and the estimated titre of the virus calculated as follows: 
 
Viral titre = % GFP x 100,000 x dilution factor 
Dilution factor = 1000/volume of viral supernatant added (μl) 
 
7.2.6  170BLentiviral transduction of haemopoietic cell lines 
To transduce cell lines, cells were incubated in a 6 well plate at a density of 5 x 10
4/ml in 
either R10 (Ba/F3) or D10 (NB4) in the presence of 4 μg/ml polybrene and the specific 
viral supernatants at a multiplicity of infection (MOI) of 10 viral particles per cell for NB4 
cells and 2 for Ba/F3 cells. After 24 hours the cells were washed and the medium replaced 
with R10, with the addition of 10 nM mIL3 for Ba/F3 cells. After a further 48 hours the 
cells were assessed for GFP positivity and GFP-positive cells selected by FACS. 
 
7.2.7  171BAssessment of cell proliferation 
To assess cell survival and proliferation, 32Dcl3 cells were washed and resuspended in R10 
at a density of 1 x 10
5/ml in the presence of cytokines and/or lestaurtinib as indicated. Cell 
number and viability were measured every 24 hours using trypan blue exclusion. Cell 
number was re-adjusted following each cell count to 1 x 10
5/ml in R10.  
 
Proliferation rate of the other cell lines was assessed using propidium iodide staining 
(Chapter 2.1.10) and flow cytometry. Cells were washed and re-suspended at a density of 5 
x 10
4/ml in R10 containing appropriate concentrations of cytokines and/or lestaurtinib as 
indicated. Cell number and viability were assessed every 2-4 days (depending on the rate of 
proliferation of the cells) by staining the cells with propidium iodide (see Chapter 2) and 
calculating the number of live cells relative to a known concentration of calibration beads. 
An example of this is shown in Figure 7.3. Cell density was re-adjusted following each cell   
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Figure 7.3: Assessment of cell number and viability using flow cytometry with 
propidium iodide staining and calibration beads. (A) The beads were added at a known 
density (x beads/ml) and quantified in gate R4 using a side scatter (SS) versus forward 
scatter (FS) plot. Ba/F3-TKD cells of unknown density (y cells/ml) were quantified by 
gating the cells on a SS/FS plot (gate R1) and (B) then assessing viability of the gated cells 
according to strength of PI staining (viable cells gated in R5). The density of viable cells 
was calculated as y = x(R5/R4). (C) The Ba/F3-TKD cells were also gated to a histogram 
showing the relative GFP fluorescence (untransduced Ba/F3 control). 
 
 
count to 5 x 10
4/ml. The doubling time for each cell line was calculated using logistic 
regression and results are presented as R
2 and standard error of the mean (SEM).  
 
7.2.8  172BCytotoxicity assays 
The effect of lestaurtinib was assessed by incubating cells at a density of 4 x 10
5/ml in the 
presence of varying concentrations of the cytotoxic agent in a total volume of 100μl R10 or  
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D10 in 96 well plates. After 48 hours, 20 μl of MTS tetrazolium compound (CellTitre 96
® 
AQueous one solution cell proliferation assay reagent, Promega, UK) was added to each well 
and after a further 4 hours the absorbance at 490nm was measured and corrected for 
background absorbance in wells containing medium only. P-values are for the student T-
test between two groups. 
 
7.2.9  173BDetection of proteins by immunoblotting 
Ba/F3 cells were washed twice in PBS and cultured for 24 hours in R10 containing 10 nM 
mIL3 for Ba/F3-vector cells, 20 ng/ml FL for Ba/F3-WT cells and R10 only for Ba/F3-
TKD and ITD cells. Cells were then exposed to 0, 5 or 50 nM lestaurtinib for 6 hours. Cells 
were pelleted by centrifugation at 800 g  (1500 rpm) for 5 minutes at 4°C, washed in ice 
cold PBS, mixed with 45μl lysis buffer per 1 x 10
6 cells and placed on ice for 30 minutes. 
The lysates were then clarified at 20000 g (13000 rpm) for 10 minutes at 4°C. The 
supernatant was aspirated, mixed with an appropriate volume of 5x loading buffer, boiled 
for 5 minutes and then used immediately or stored at -20°C until required. The lysates were 
run on SDS-PAGE gels and transferred to a nitrocellulose membrane as described in 
Chapter 2.  
 
Membranes were incubated in the indicated primary antibody, at the manufacturers’ 
recommended concentration, made up in 3% BSA, 0.1% PBS/Tween-20. All primary 
antibodies were incubated with the membrane overnight at 4°C. The primary antibody was 
removed, the membrane washed 3 times in 0.1% PBS/Tween-20 and then incubated with 
the appropriate horseradish peroxidase-linked secondary antibody diluted 1:10000 in 2% 
milk, 0.1% PBS/Tween-20 for 1 hour at room temperature. The membrane was then 
washed 3 times and protein bands detected by chemiluminesence (ECL or ECL-plus for 
phospho-specific antibodies) according to manufacturers’ recommended guidelines. The 
membrane was then exposed to autoradiography film. 
 
7.2.10  174BAssessment of intracellular phospho-proteins by flow cytometry 
Ba/F3 cells were washed and incubated in the presence or absence of mIL3 and FL as for 
the immunoblotting. After 24 hours, lestaurtinib was added to a concentration of 10 nM as 
indicated and cells incubated for a further 6 hours. Approximately 1 x 10
6 cells were then  
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washed in ice cold PBS containing 1% BSA and resuspended in 250 μl 
Fixation/Permeabilisation solution (Bdbiosciences) for 20 minutes at 4°C. The cells were 
then washed twice in 1ml of 1x Perm/Wash™ buffer (Bdbiosciences.com), resuspended in 
50μl of 1x Perm/Wash™ buffer containing 1 μl of the primary antibody and incubated at 
4°C for 30 minutes in the dark. The cells were then washed and resuspended in 50μl of 1x 
Perm/Wash™ buffer containing 5 μl of the goat anti-mouse IgG antibody conjugated to 
allophycocyanin (APC) and incubated at 4°C for 30 minutes in the dark. The cells were 
then washed twice, resuspended in PBS containing 1% BSA and kept on ice until flow 
cytometric analysis. Control cells were treated in an identical fashion with the exception 
that the primary antibody was not added. 
 
7.2.11  175BNB4 Cell Differentiation Experiments 
Transduced NB4 cells were incubated at a density of 2 x 10
5/ml in R10 in the presence or 
absence of 0.037μM, 0.111μM, 0.333μM or 1μM ATRA with or without 10 nM 
lestaurtinib for 4 days. The level of differentiation was assessed by flow cytometry using an 
APC-conjugated anti-CD11b antibody. Approximately 5 x 10
5 cells were washed twice in 
ice cold PBS and incubated with the antibody according to the manufacturer’s 
recommended conditions (BD Pharmingen). Cells were washed twice with ice cold PBS 
prior to flow cytometric analysis. Results are expressed as the median fluoresent intensity 
(MFI) of APC. 
 
7.2.12  176BPrimary CD34+ Cells 
Local ethical approval for the use of ‘left-over’ peripheral blood stem cell harvest samples 
was obtained prior to these studies. All studies were carried out following appropriate, 
generic informed consent for the use of these cells for research studies. CD34 cells were 
selected from peripheral blood stem cell harvests by a double round of magnetic cell sorting 
(MACS® cell separation columns and reagsents, Miltenyi Biotec) according to 
manufacturers recommended protocol. Following this the percentage of CD34 +ve cells 
was >95% as measured by flow cytometry using a phycoerythrin conjugated anti-CD34 
antibody (BD Pharmingen). Cells were either cropreserved until required or were re-
suspended at a density of 1 x 10
6/ml in Stem Pro-34 SFM medium containing 20ng/ml 
SCF, 20 ng/ml FL, 45 ng/ml TPO and 10 ng/ml IL3 and placed in 5% CO2 in a humidified  
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incubator at 37°C until lentiviral transduction later the same day. If frozen CD34+ cells 
were used they were thawed and cultured overnight in the above cytokines prior to viral 
transduction. 
 
Approximately 2 x 10
5 cells were incubated in the minimum possible volume of 
concentrated lentiviral medium to provide a MOI of 50. Polybrene was not used as this led 
to a high level of cell death. The mix was incubated overnight in 5% CO2 in a humidified 
incubator at 37°C then washed, resuspended in Stem Pro-34 containing the above cytokines 
and cultured for 72 hours. Following this, the cells were washed and cultured in Stem Pro-
34 in the absence of cytokines for 24 hours. The cell density and percentage of GFP 
positive cells were then measured by flow cytometry (day 0). The number of viable cells 
was measured every 2-3 days for a total of 2 weeks by propidium iodide staining relative to 
a known concentration of calibration beads.  
 
Following 7 and 14 days in the above cytokine free Stem Pro-34 liquid culture medium, the 
volume of medium estimated to contain 250 viable cells was added to 0.5 mls of 
methycellulose in the presence of 20ng/ml SCF, 20ng/ml FL, 20 ng/ml GM-CSF and 
50ng/ml G-CSF and placed in 5% CO2 in a humidified incubator at 37°C. The number of 
colonies was counted after 1 and 2 weeks. 
 
7.3  50BUResults 
 
7.3.1  177BConfirmation of FLT3 expression using the cloned plasmid constructs 
In order to confirm that the plasmid constructs containing the different forms of FLT3 led 
to expression of the FLT3 protein, they were transiently transfected into 293T cells using 
calcium phosphate. Transduction efficiency was over 90% for all 4 plasmids as assessed by 
GFP positivity by flow cytometry. Cell lysates were made and immunoblotting for FLT3 
revealed very high levels of expression in the WT, TKD and ITD-transduced cells but 
absence of FLT3 protein in the vector-transduced cells (Figure 7.4).  
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Figure 7.4: Detection of FLT3 protein (135 kDa) by immunoblotting in 293T cells 
transduced with the different FLT3 constructs. 
 
 
7.3.2  178BExpression of FLT3 in haemopoietic cell lines 
Following electroporation of 32Dcl3 cells, transduction efficiency was only 1-2% and two 
rounds of FACS sorting were therefore required in order to obtain a highly selected 
population of GFP-positive cells. Ba/F3 cells were transduced with lentiviral supernatants 
with an MOI of 2 as higher MOIs led to high levels of cell death. The transduction 
efficiency varied between 8% and 62%. Both 32Dcl3 and Ba/F3 cells were maintained in 
10nM mIL3 until the start of each experiment. NB4 cells were transduced with lentiviral 
supernatants with an MOI of 10. High levels of transduction were achieved, between 78% 
and 99% as assessed by the percentage of GFP positive cells. 
 
In each case, cells were selected according to approximately equal GFP fluorescent 
intensity as the level of GFP should directly correlate with expression of FLT3. This was 
confirmed by immunoblotting with anti-FLT3 antibody (Figure 7.5). As has been noted by   
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Figure 7.5: Western blotting studies to show expression of FLT3 protein in transduced 
cell lines. (A) 32Dcl3 cells; (B) Ba/F3 cells; and (C) NB4 cells. P indicates parental 
(untransduced) cells. Blots were probed with antibodies as specified. 
 
 
others, the larger, glycosylated FLT3 band is weaker for FLT3/ITD and to a certain extent 
FLT3/TKD than for FLT3/WT (Choudhary et al, 2005b). 
 
7.3.3  179BImpact of transduced FLT3 expression on the proliferation of haemopoietic 
cell lines 
32Dcl3-vector cells proliferated rapidly in the presence of mIL3 whereas in the absence of 
cytokines the cells failed to proliferate and died within 3 to 4 days (Figures 7.6A, 7.7 and 
Table 7.1). The addition of FL did not increase survival of 32D-vector cells in the absence 
of mIL3 (Figure 7.7). Proliferation in the presence of mIL3 was not significantly impacted 
by the addition of 20 nM lestaurtinib.  
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Figure 7.6: Proliferation rates of transduced 32Dcl3 cells. (A) 32Dcl3-vector, (B) 
32Dcl3-WT, (C) 32Dcl3-WT + FL, (D) 32Dcl3-TKD, (E) 32Dcl3-ITD and (F) a 
comparison of 32Dcl3-vector + IL3, 32Dcl3-WT + FL, 32Dcl3-TKD + nil and 32Dcl3-ITD 
+ nil. Cells were grown in the presence of 10 ng/ml murine IL3 (IL3), 20 nM lestaurtinib 
(L) and 20 ng/ml FLT3 ligand (FL). 
  
163
 
Table 7.1  Proliferation rates of transduced cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DT indicates doubling time; SEM, standard error of the mean for the doubling time; R2, the coefficient of determination for 
the logistic regression used to calculate the doubling time; L, lestaurtinib 20 nM; IL3, 10 ng/ml murine IL3; FL, 20 ng/ml 
FLT3 ligand; and N/A not applicable
    32Dcl3     Ba/F3     NB4  
  DT (hours)  SEM  R2  DT (hours) SEM  R2 DT  (hours) SEM R2 
Vector  N/A N/A  N/A  N/A  N/A  N/A 31.2  1.1  0.98
Vector + IL3  12.1 0.5  0.99  15.7  1.1  0.96  N/A  N/A  N/A 
Vector + IL3 + L  12.5 0.5  0.99  17.5  1.2  0.95  N/A  N/A  N/A 
WT  51.6  2.6  0.85 35.3  3.0  0.75 31.4  1.0  0.98
WT + IL3  12.3 0.4  0.99  13.8  0.6  0.99  N/A  N/A  N/A 
WT + IL3 + L  N/A N/A  N/A  14.5  0.8 0.98  N/A  N/A  N/A 
WT + FL  20.5 1.0  0.99  22.6  1.7  0.91  N/A  N/A  N/A 
WT + FL + IL3  14.1 0.56  0.99  14.4  0.8  0.98  N/A  N/A  N/A 
WT + FL + IL3 + L  11.4 0.8  0.99  14.6  0.8  0.98  N/A  N/A  N/A 
TKD  16.0  0.6  0.98 18.7  1.1  0.96 31.1  1.1  0.98
TKD + IL3  13.8 0.8  0.98  15.0  0.9  0.97  N/A  N/A  N/A 
TKD + IL3 + L  17.9 1.3  0.98  15.9  1.2  0.95  N/A  N/A  N/A 
ITD  12.4  0.6  0.99 14.4  0.9  0.97 30.7  1.0  0.98
ITD + IL3  18.4 0.7  0.98  14.8  0.8  0.97  N/A  N/A  N/A 
ITD + IL3 + L  12.8 0.8  0.99  14.2  0.8  0.98  N/A  N/A  N/A  
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Figure 7.7: Impact of the addition of 20 ng/ml FL on the proliferation of 32Dcl3 
transduced cells over 72 hours. 
 
 
32Dcl3-WT cells proliferated at a similar rate to vector-transduced cells in the presence 
of mIL3 (Figures 7.6B, Table 7.1). In the absence of mIL3, FLT3/WT transduced cells 
retained viability but proliferated at a markedly reduced rate which was inhibited with 
the addition of 20nM lestaurtinib.  
 
Addition of 20 ng/ml FL increased the proliferation rate of FLT3/WT transduced cells 
(Figure 7.6C, Table 7.1), however, this was still slower than that induced by mIL3. The 
FL-induced 32Dcl3-WT proliferation was inhibited by the addition of 20nM 
lestaurtinib. The presence of mIL3 in addition to FL significantly increased the 
proliferation of FLT3/WT transduced cells to the rate observed with mIL3 stimulated  
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vector-transduced cells and, surprisingly, the addition of 20nM lestaurtinib increased 
this rate of proliferation further. 
 
In the absence of cytokines, 32Dcl3-TKD cells did proliferate, albeit at a slower rate 
compared with mIL3 stimulated 32Dcl3-vector cells (Figure 7.6D and Table 7.1), but 
nevertheless at an increased rate compared with 32Dcl3-WT cells grown in the presence 
of FL. The cytokine-free proliferation of 32Dcl3-TKD cells was inhibited in the 
presence of 20nM lestaurtinib. Addition of mIL3 to 32Dcl3-TKD cells led to a 
considerable increase in the rate of proliferation to a similar rate to that seen with 
32Dcl3-vector cells but the proliferation was slower if 20nM lestaurtinib was present. 
The addition of 20 ng/ml FL to 32Dcl3-TKD cells led to a minor increase in the rate of 
proliferation (Figure 7.7).  
 
32Dcl3-ITD cells also proliferated rapidly in the absence of cytokines (Figures 7.6E and 
Table 7.1) at a similar rate to mIL3-stimulated 32Dcl3-vector cells and significantly 
faster than cytokine free 32Dcl3-TKD cells. For example, the doubling time of 32Dcl3-
ITD cells was 12.4 hours compared to 16 hours for 32Dcl3-TKD cells. The cytokine-
free proliferation of 32Dcl3-ITD cells was also inhibited in the presence of 20nM 
lestaurtinib. Surprisingly, addition of mIL3 slowed the proliferation rate of 32Dcl3-ITD 
cells, an effect that was reversed with the addition of 20 nM lestaurtinib. The addition of 
20 ng/ml FL to 32Dcl3-ITD cells led to a minor increase in the rate of proliferation 
(Figure 7.7). 
 
As shown in Figure 7.8A-F, the results observed with transduced Ba/F3 cells were 
similar to those seen with 32Dcl3 cells. The addition of mIL3 to FL stimulated Ba/F3-
WT and cytokine free Ba/F3-ITD cells, however, had no significant impact on the rate 
of cell growth. 
 
As opposed to the marked effect of mutant FLT3 expression on the proliferation of 
mIL3-dependent murine cell lines, transduction of NB4 cells with WT or mutant FLT3 
had no impact on the proliferation rate of this factor-independent, human cell line 
(Figure 7.9, Table 7.1).  
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Figure 7.8: Proliferation rates of transduced Ba/F3 cells. (A) Ba/F3-vector, (B) 
Ba/F3-WT without FL, (C) Ba/F3-WT with 20 ng/ml FL, (D) Ba/F3-TKD, (E) Ba/F3-
ITD and (F)a comparison of Ba/F3-vector + IL3, Ba/F3-WT + FL, Ba/F3-TKD + nil 
and Ba/F3-ITD + nil. IL3 indicates that cells were grown in the presence of 10 ng/ml 
murine IL3; L indicates that cells were grown in the presence of 20 nM lestaurtinib. 
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Figure 7.9: Proliferation rates of NB4 and cells transduced with the different 
constructs. 
 
 
7.3.4  180BEffect of cytotoxic agents on FLT3 expressing cell lines 
MTS assays of 32Dcl3 cells transduced with a TKD or an ITD and incubated for 48 
hours with lestaurtinib showed a dose-dependent cytotoxic effect (Figure 7.10A). 
However, at lower concentrations of lestaurtinib, 32Dcl3-TKD cells were more 
sensitive than 32Dcl3-ITD cells. For example, at 1nM lestaurtinib, the mean %OD was 
62% for 32D-TKDs and 95% for 32D-ITD cells (Figure 7.10A, P=.03). The addition of 
5 nM FL had little impact on the cytotoxic effect of lestaurtinib on 32Dcl3-ITD cells 
(Figure 7.10B) or 32Dcl3-TKD cells (Figure 7.10C).  
 
Increased sensitivity to lestaurtinib-induced cytotoxicity was also seen with Ba/F3-TKD 
cells in comparison with Ba/F3-ITD cells (Figure 7.10D). Lestaurtinib at lower 
concentrations had little impact on Ba/F3-vector cells grown in the presence of IL3, 
although at a concentration of 25 nM the %OD was reduced to 81% suggesting that 
higher concentrations of lestaurtinib may also impact on IL3 signalling.  
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Figure 7.10: Cytotoxic effect of lestaurtinib on FLT3 transduced 32Dcl3 and Ba/F3 
cells. (A) dose response of lestaurtinib in 32D-ITD and 32D-TKD cells; (B) impact of 
20 ng/ml FL on the cytotoxic effect of lestaurtinib for 32D-ITDs and (C) 32D-TKDs; 
and (D) dose response of lestaurtinib in Ba/F3-vector cells grown in the presence of 10 
ng/ml murine IL3 and cytokine-free Ba/F3-ITD and Ba/F3-TKD cells.   
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It is possible that the difference in %OD observed between TKD and ITD-transduced 
32Dcl3 and Ba/F3 cells was due to a difference in the proliferation rate, rather than a 
cytotoxic effect. The percentage of dead cells following incubation in lestaurtinib for 24  
hours was therefore assessed using propidium iodide staining. Ba/F3-vector cells grown 
in mIL-3 were not affected by the addition of lestaurtinib (Figure 7.11). With 10 nM 
lestaurtinib, the percentage of cell death was lower for Ba/F3-ITD cells than Ba/F3-
TKD cells at 57% and 71% respectively (repeated in triplicate, P=.04), consistent with a 
more marked cytotoxic effect on Ba/F3-TKD cells compared with Ba/F3-ITD cells. 
 
 
Figure 7.11: The impact of lestaurtinib on Ba/F3 transduced cells assessed by 
propidium iodide staining after 24 hours. 
 
 
7.3.5  181BSignalling events in transduced Ba/F3 cells 
The different proliferative rates arising from cells transduced with WT or mutant FLT3 
suggest that signalling may differ between the different forms of FLT3. Therefore, the 
signalling pathways activated by the different FLT3 mutants or by mIL3 stimulation 
were investigated by immunoblotting and flow cytometry. 
 
Ba/F3-vector cells grown in the presence of 10 ng/ml mIL3 showed marked activation 
of ERK, AKT and STAT5 that were not affected by the addition of up to 50nM 
lestaurtinib (Figure 7.12). Ba/F3-WT cells stimulated with FL showed activation of 
ERK and AKT but not STAT5. The ERK and AKT activation were inhibited by the  
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addition of 5nM lestaurtinib. Ba/F3-TKD cells showed weak STAT5 activation but 
strong activation of AKT, both of which were inhibited by lestaurtinib. In Ba/F3-ITD 
cells STAT5 was strongly activated, along with ERK and AKT. This activation was  
 
Figure 7.12: Immunoblotting of phospho-signalling proteins in transduced Ba/F3 
cells. Cells were incubated for 24 hours in the presence or absence of 10 nM mIL3 or 20 
ng/ml FL as indicated. Cells were then exposed to 0, 5 or 50 nM lestaurtinib for 6 hours 
following which cell lysates were made. Blots were probed with antibodies as specified.  
 
 
inhibited by 5 nM of lestaurtinib, although, at this concentration, some residual AKT 
activation was seen which was reduced by 50 nM of lestaurtinib. 
 
Intracellular signalling was also assessed by immunostaining and flow cytometry of 
fixed and permeabilised cells which allowed quantification of the relative level of 
activation of these signalling proteins. Median fluorescence intensity (MFI) was 
expressed relative to control cells where the primary antibody was not added. Three 
independent experiments were performed, a representative example for phospho-
STAT5 is shown in Figure 7.13 and the mean MFI for all 3 experiments is shown in 
Figure 7.14A. Ba/F3-vector cells grown in the presence of mIL3 showed strong 
pSTAT5 fluoresence relative to control which was slightly reduced by pre-incubation of 
cells for 6 hours with 10 nM lestaurtinib and markedly reduced when cells were grown  
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in the absence of mIL3 for 24 hours. Ba/F3-WT cells incubated with 20ng/ml FL and 
Ba/F3-TKD cells showed only weak pSTAT5 fluorescence relative to control. This was 
further reduced by the addition of lestuartinib. Ba/F3-ITD cells, however, showed  
 
 
Figure 7.13: Assessment of intracellular phospho-STAT5 by flow cytometry of 
fixed and permeabilised transduced Ba/F3 cells. (A) Ba/F3-vector cells grown in the 
presence of 10 nM mIL3 unless labelled as otherwise (green histogram only); (B) 
Ba/F3-WT cells grown in the presence of 20 ng/ml FL; (C) cytokine-free Ba/F3-TKD 
cells; and (D) cytokine-free Ba/F3-ITD cells. 
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Figure 7.14: Results of 3 independent experiments on intracellular phospho-
signalling proteins in transduced Ba/F3 cells. (A) phospho-STAT5; (B) phospho-
MAPK; and (C) phospho-S6. The median fluorescence intensity (MFI) is expressed as a 
ratio of the MFI relative to control cells which were not incubated with the primary 
antibody. All y axes are on a logarithmic scale. 
 
 
strong pSTAT5 fluorescence which was markedly reduced by pre-incubation with 
lestaurtinib.  
 
Similar experiments were performed to assess the level of pMAPK and phospho-S6 
(Figure 7.14B and C). Phospho-S6 was used as this is downstream of AKT, and 
therefore indicates AKT activation, as pAKT itself is difficult to detect by flow 
cytometry due to low levels of fluorescence intensity. No significant difference in the 
activation of pMAPK or phospho-S6 was seen between Ba/F3-vector cells grown in the  
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presence of 10 nM mIL3, Ba/F3-WT cells grown in the presence of 20 ng/ml FL or 
cytokine free, Ba/F3-TKD or Ba/F3-ITD cells. The impact of the addition of lestaurtinib 
was not tested in these experiments. 
 
7.3.6  182BThe impact of FLT3 expression on ATRA-induced differentiation of NB4 
cells 
To examine the impact of FLT3 mutants on haematopoietic cell differentiation, ATRA-
induced expression of CD11b was examined in the promyelocytic leukaemia cell line, 
NB4. Incubation of NB4-vector cells with ATRA for four days led to an ATRA-
concentration dependent increase in CD11b expression (Figure 7.15A, E). NB4-WT and 
NB4-TKD cells showed an increase in CD11b expression relative to NB4-vector cells at 
intermediate concentrations of ATRA (Figure 7.15 B, C, E). Conversely, NB4-ITD cells 
showed less CD11b expression at the lower ATRA concentrations (Figure 7.15D, E). 
This effect was overcome at a higher concentration of ATRA (1 μM). By arbitrarily 
setting a gate at 2% in untreated cells, the relative proportion of NB4 cells that 
differentiated in response to ATRA could be quantified. In the experiment shown in 
Figure 7.15, 0.11 μM ATRA induced differentiation in 66%, 76%, 84% and 53% of 
vector, WT, TKD and ITD-transduced cells respectively. Similar results were obtained 
in 3 independent experiments. 
 
The difference between the 4 cell lines was most marked at 0.11 μM ATRA. In order to 
determine whether the differences in CD11b expression were reproducible, 3 
independent experiments were performed using 0.11 μM ATRA. In addition, the impact 
of lestaurtinib on the level of ATRA-induced CD11b expression was examined. A 
concentration of 10 nM lestaurtinib was used as this had a minimal impact on cell 
viability in all NB4 lines. Figure 7.16A shows the mean MFI for each condition. Due to 
marked variation in the MFI between experiments, the SEMs are considerable and 
consequently the differences are not significant. Therefore, to compare the different 
FLT3-transduced cell lines, results were expressed as a ratio of CD11b MFI relative to 
that of NB4-vector cells for each condition (Figure 7.16B). In this analysis, NB4-TKD 
cells consistently showed increased CD11b expression in response to ATRA relative to 
NB4-vector cells whereas NB4-ITD cells showed reduced CD11b expression. 
Lestaurtinib inhibited the relative increase in ATRA-induced CD11b expression in 
NB4-TKD cells and increased CD11b expression in NB4-ITD cells. Therefore, in the   
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Figure 7.15: ATRA-induced CD11b expression in transduced NB4 cells. (A) NB4-
vector; (B) NB4-WT; (C) NB4-TKD; (D) NB4-ITD; and (E) dose response relationship 
between ATRA concentration and median fluorescent intensity of CD11b. 
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Figure 7.16: ATRA-induced CD11b expression in transduced NB4 cells and the 
impact of lestaurtinib. (A) Mean and SEM of MFI; (B) results expressed as the 
relative MFI compared to vector transduced cells. Data shown is the result of 3 
independent experiments. 
 
 
presence of lestaurtinib, all 4 cell lines responded similarly to ATRA in terms of CD11b 
expression, suggesting that the observed differences are FLT3- dependent. 
 
7.3.7  183BLentiviral transduction of primary CD34+ cells 
In view of the limitations of transformed cell line models for the study of FLT3 
mutations, a lentiviral vector system was developed for transduction of CD34+ 
haematopoietic stem cells. This required considerable optimisation before significant 
transduction efficiencies were achieved. The necessary titres of virus required for the  
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transductions were easily obtained for the ‘empty vector’, but viral production was far 
less efficient for the FLT3 constructs. Furthermore, the use of polybrene and/or 
retronectin was associated with considerable cell death in the FLT3-transduced CD34+ 
cells. Even following optimisation and with an MOI of 50, transduction efficiency for 
the FLT3-containing constructs was poor. In 3 independent experiments, for CD34-
vector transductions the %GFP-positive cells at 72 hours were 29%, 40% and 49% 
respectively. For CD34-WT the transduction was only 6%, 17% and 8%, for CD34-
TKD 10%, 11% and 5%, and for CD34-ITD 7%, 7% and 6% respectively.  
 
In order to assess the impact of FLT3 expression on the survival and/or proliferation of 
CD34+ cells grown in cytokine-free liquid culture, following the initial 72 hours in 
cytokines, unsorted cells were washed and cultured in cytokine-free liquid culture. The 
total number of viable cells and the proportion that were GFP-positive were counted 
every 1-2 days over the course of a 2 week period using flow cytometry and propidium 
iodide staining with calibration beads as described in section 7.2.12. In the absence of 
cytokines, all CD34+ cells showed a rapid decline in viability, irrespective of the 
construct they had been transduced with, and there was no evidence, therefore, that 
mutant FLT3 led to factor-independent proliferation of CD34+ cells (Figure 7.17A). 
The percentage of GFP-positive cells, however, did increase over the two week period 
for all the FLT3-transduced cells (Figure 7.17B). For example, over 3 independent 
experiments, after 7 days of culture, the proportion of GFP+ cells increased from 10% 
to 30% for FLT3/WT transduced cells, 9% to 29% for FLT3/TKD cells and 7% to 25% 
for FLT3/ITD cells. However, the proportion of GFP-expressing cells also increased for 
CD34-vector cells from 39% to 49%, suggesting that these findings may, at least partly, 
relate to an increase in auto-fluorescence. 
  
7.3.8  184BColony assays of transduced CD34+ cells 
Following 14 days in cytokine-free liquid culture, 250 unsorted CD34+ cells transduced 
with the different constructs were added to 0.5 mls of methycellulose in the presence of 
20ng/ml SCF, 20ng/ml FL, 20 ng/ml GM-CSF and 50ng/ml G-CSF and placed in 5% 
CO2 in a humidified incubator at 37°C. The number of colonies was counted after 2 
weeks. Each colony assay was performed in triplicate and the results presented are the 
mean numbers of colonies from 3 independent experiments. Of the initial 2x10
5 
transduced CD34+ cells, the estimated number of colony forming cells remaining after 
2 weeks in cytokine-free liquid culture was 74±24 for vector-transduced cells (Figure  
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7.17C). This was not different for FLT3/WT- (114±35, P.4) or TKD-transduced cells 
(124±46, P.4) but was markedly increased for FLT3/ITD-transduced cells (642±222, 
P.03). 
 
 
 
Figure 7.17: Transduction of CD34+ cells with vector or FLT3 contructs. (A) 
Relative numbers of viable transduced CD34 cells in cytokine free liquid culture; (B) 
Proportion of GFP expressing cells over 2 weeks in cytokine free liquid cultue; and (C) 
numbers of colony forming units remaining after cytokine free liquid culture for 14 
days.  
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7.4  51BUDiscussion 
 
A number of studies of AML patients have observed clinical and biological differences 
between AML patients with FLT3/TKD mutations and FLT3/ITDs (reviewed in 
Chapters 4, 5 and 6). The data described in chapters 4, 5 and 6 adds to the accumulating 
evidence of important differences between the 2 mutations. It remains unclear, however, 
whether these differences directly relate to differential signalling events downstream of 
the mutations or to an association of these different mutation with other biological 
variables such as different cytogenetic abnormalities or mutations, in which case, the 
functional effects of the two mutations would be expected to be the same. In order to 
explore possible signalling differences between FLT3/TKD mutations and FLT3/ITDs, 
a number of cell model systems were developed whereby different FLT3 constructs 
were introduced into the 32Dcl3, Ba/F3, NB4 cell lines and primary human CD34+ 
peripheral blood mobilised cells. This allowed direct comparison in the same cellular 
context of the impact of the 2 mutations on cell survival, proliferation and 
differentiation, as well as in vitro sensitivity to therapeutic agents.  
 
In the initial experiments, the impact of the expression of the different FLT3 mutations 
on the growth of 32Dcl3 and Ba/F3 cell lines was assessed. These cell lines are 
normally dependent on the presence of mIL3 for cell survival and proliferation. In the 
absence of mIL3, vector-transduced cells failed to proliferate and died within a few 
days (Figures 7.6 and 7.8). Expression of both the FLT3/ITD and FLT3/TKD mutation 
led to factor-independent growth of both cell lines. FLT3/ITD-transduced cells, 
however, proliferated at a more rapid rate than FLT3/TKD-transduced cells. This 
difference was unlikely to be due to quantitative differences in the amount of FLT3 
protein present in the cells as they were selected according to the level of GFP 
expression, which should be proportional to FLT3 expression, and equivalent 
expression of FLT3 protein was confirmed by immunoblotting (Figure 7.5). Surface 
expression of FLT3 was not used to select cells with equivalent FLT3 expression as 
there is evidence that FLT3/ITDs are able to signal when located intracellularly as well 
as when at the cell surface (Koch et al, 2008). Furthermore, Koch et al also showed that 
overexpressed FLT3/WT accumulated within the endoplasmic reticulum of COS7 cells 
rather than at the cell surface. The present data, therefore, suggest that FLT3/ITDs 
confer a stronger proliferative drive, at least in the context of these murine cell model  
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systems. These results are consistent with previous reports (Choudhary et al, 2005b, 
Grundler et al, 2003).  
 
Mutation of FLT3 is not the only possible mechanism of aberrant FLT3 signalling. For 
example, there are several lines of evidence that FLT3/WT protein is expressed at high 
levels in some cases of AML (Armstrong et al, 2003, Caligiuri et al, 2007, Dicker et al, 
2007, Sargin et al, 2007, Zheng et al, 2004b). However, the biological significance of 
FLT3/WT overexpression is unclear as it has not been shown to lead to constitutive 
FLT3 signalling. Of note, the present data show that in both 32Dcl3 and Ba/F3 cells, 
expression of FLT3/WT alone was sufficient to lead to cell survival in the absence of 
cytokines, although these cells only proliferated at a very slow rate (Figures 7.6, 7.7 and 
7.8). The addition of FL to these cells led to a marked increase in the rate of 
proliferation to a level close to that of FLT3/TKD-transduced cells. The observation that 
FLT3/WT overexpression, with or without FL, is capable of conferring a survival and 
proliferative signal is important as this may, therefore, contribute significantly to cell 
survival and proliferative signalling in AML, particularly if FL is co-expressed (Zheng 
et al, 2004b). This may also be important with regards to the potential use of FLT3 
inhibitors in patients with FLT3/WT as discussed in Chapter 6. 
 
In view of the marked impact of FL on the proliferation rate of FLT3/WT transduced 
cells, it is also possible that FL may influence the proliferative signals induced by FLT3 
mutations. The impact of the addition of FL to 32cl3D-TKD and 32cl3D-ITD cells was 
therefore examined. FL only led to marginal increase in the proliferation rate of 
FLT3/TKD-transduced 32Dcl3 cells and was insufficient to induce a proliferation rate 
equivalent to that of FLT3/ITD transduced cells. The distinct proliferation signal from 
the two mutations is not, therefore, accounted for by a differential response to FL. 
 
The dependence of cell proliferation on signalling through FLT3 in these model systems 
was supported by the impact of FLT3 inhibition. Lestaurtinib inhibited proliferation of 
FLT3/ITD- and FLT3/TKD-transduced 32Dcl3 and Ba/F3 cells and led to cell death. It 
is interesting, however, that TKD-transduced cells were more sensitive to the cytotoxic 
effects of lestaurtinib than ITD-transduced cells (Figure 7.10). This resulted from 
reduced cell viability and did not simply reflect a different rate of proliferation between 
TKD- and ITD-transduced cells (Figure 7.11). This cytotoxic effect was not abrogated 
by the addition of FL. These data are of particular interest in view of the opposite  
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observation in primary AML samples (Chapter 6) where FLT3/ITD-positive blast cells 
were more sensitive to the cytotoxic effects of lestaurtinib than FLT3/TKD mutant-
positive blast cells. There are a number of possible explanations for these differences. 
First and foremost, primary cells are characterised by multiple genetic alterations that 
have been acquired over a prolonged period of time and they may not, therefore, be 
dependent on one signal for cell survival. Furthermore, as discussed in previous 
chapters, ITDs and TKD mutations may be associated with different genetic 
abnormalities that may also influence the response to FLT3 inhibition. Conversely, 
transduced factor-dependent cell line models are, by definition, dependent on the 
introduced oncogene for survival. Secondly, it may also be that the different FLT3/TKD 
mutations in the primary blast cell cases in Chapter 6 (only 3 of 11 were D835Y) are 
less sensitive to lestaurtinib than the D835Y mutation used in all the experiments 
described in this chapter. Alternatively, if FLT3/ITDs confer a stronger survival and 
proliferative signal than FLT3/TKDs, this may have different implications with regards 
to the sensitivity to the cytotoxic effects of lestaurtinib depending on the cellular 
context. In cell line models such as the 32Dcl3 and Ba/F3 lines used in this chapter, a 
lower concentration of lestaurtinib may be sufficient to reduce the weaker survival and 
proliferative signals induced by a FLT3/TKD to a level that is incompatible with cell 
survival. In contrast to this, the stronger survival and proliferative signals of FLT3/ITDs 
may require higher concentrations of lestaurtinib to lead to the necessary level of 
inhibition to induce cell death. Conversely, as discussed in Chapter 6, in primary cells, 
the stronger survival signals downstream from a FLT3/ITD may increase the 
dependence of the blast cells on this signal for survival. This may, therefore, increase 
sensitivity to the cytotoxic effects of lestaurtinib thus providing indirect evidence for 
‘oncogene addiction’ to FLT3 signalling in AML (Weinstein and Joe 2008). 
 
It is possible that the distinct proliferative impacts and differences in sensitivity to 
therapeutic agents between FLT3 mutations may relate to differential signalling events. 
Published studies are conflicting in this regard. For example, whilst a number of 
previous studies had shown that ITDs induce strong phosphorylation of STAT5A 
(Choudhary et al, 2005a, Choudhary et al, 2005b, Grundler et al, 2005), the impact of 
FLT3/TKD mutations and/or FL-stimulated FLT3/WT on STAT5A activation is 
controversial. Some studies have demonstrated that FLT3/TKD mutations (Grundler et 
al, 2003) and FLT3/WT (Zhang et al, 2000) may also strongly activate STAT5A. 
Others, however, have suggested that FLT3/WT and FLT3/TKDs fail to induce strong  
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STAT5A phosphorylation, both in cell lines (Choudhary et al, 2005b, Hayakawa et al, 
2000, Mizuki et al, 2000) and an animal model (Grundler et al, 2005). Furthermore, one 
study also suggested that FLT3/TKDs less strongly activated ERK1 and 2 compared 
with FLT3/ITDs (Choudhary et al, 2005b).  
 
The transduced Ba/F3 cell lines described in this chapter also provided an opportunity 
to examine the downstream signalling events that occur as a result of the presence of 
different types of FLT3 mutation. Three different signalling pathways, MAPK, PI3K 
and STAT5 were investigated using immunoblotting of cell lysates and intracellular 
flow cytometry of single cells. The study of intracellular signalling events in fixed and 
permeabilised single cells by flow cytometry was a useful technique for these studies as 
it allowed a degree of quantification of signalling differences. A clear difference in the 
degree of activation of STAT5A was observed between Ba/F3-ITDs, which showed 
strong activation of STAT5A, and Ba/F3-TKD or FL-stimulated Ba/F3-WT cells, which 
only demonstrated weak STAT5A activation (Figures 7.12 and 7.13). STAT5A 
activation in mIL3-stimulated Ba/F3-vector cells was not affected by the addition of the 
FLT3 inhibitor, whereas in the FLT3-ITD and TKD-transduced Ba/F3 cells, STAT5A 
activation was fully inhibited by the addition of lestaurtinib. PI3K and MAPK pathway 
activation appeared to be comparable between the two types of mutated FLT3, although 
smaller differences cannot be excluded. Further studies will be required to determine 
whether differential STAT5 activation accounts for the proliferative differences 
between FLT3/ITDs and TKD mutations. 
 
In addition to aberrant cell survival and/or growth, a block in cellular differentiation is 
also a feature of a full leukaemic phenotype. This is often simplified as a two-hit model 
of leukaemogenesis, as discussed in Chapter 1, whereby a type-1 mutation confers a 
proliferative and survival drive and a type-2 mutation leads to a differentiation block 
(Kelly and Gilliland 2002). However, a number of different genetic events can lead to 
both type-1 and type-2 effects. For example, in limited in vitro studies, FLT3/ITDs have 
been shown to lead to a differentiation block in haemopoietic cell line models 
(Schwable et al, 2005, Zheng et al, 2002). The impact of FLT3/TKD mutations on 
differentiation has not been investigated. A model system of ATRA-induced CD11b 
expression was therefore developed in FLT3/WT and FLT3 mutant NB4 cells. As 
anticipated from previous studies, these data demonstrated that transduction of NB4 
cells with a FLT3/ITD led to reduced ATRA-induced differentiation at lower  
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concentrations of ATRA compared to vector trasnduced cells (Figures 7.15 and 7.16). 
In contrast, NB4-WT and NB4-TKD cells demonstrated increased differentiation in 
response to ATRA. This was not related to a difference in the rate of proliferation, 
which was identical between the different transduced cell lines (Figure 7.9). These data 
suggest that there may be important differences in the downstream effects of the 
different mutations on haematopoietic transcription factor expression levels that control 
cellular differentiation. It is interesting to note, therefore, that studies have shown 
FLT3/TKDs, unlike ITDs, do not suppress C/EBPα or PU.1 expression (Choudhary et 
al, 2005b), two transcription factors that are key regulators of myeloid cell 
differentiation. FLT3/TKDs also lead to an increased expression of the tumour 
suppressor TSC-22, which in turn promotes, rather than blocks, myeloid differentiation 
(Lu et al, 2007). The impact of FLT3/ITDs on TSC-22 expression is not known. This 
differential impact of ITDs and TKD mutations on haemopoietic cell differentiation is 
interesting in view of the observations described in Chapter 4 that FLT3/TKD mutations 
and FLT3/ITDs show markedly different associations with other genetic abnormalities. 
For example, FLT3/TKDs are common in cases with the inv(16) cytogenetic 
abnormality whereas FLT3/ITDs are uncommon in this subgroup. This may reflect the 
distinct impact of different FLT3 mutations on haemopoietic cell differentiation and 
therefore their ability to collaborate with other genetic events. 
 
Studies of the impact of FLT3 mutations in immortalised and transformed cell lines can 
provide useful information on signalling events but such cell lines are far removed from 
the impact of FLT3 mutations in primary AML cells in vivo. Therefore, in order to 
study the impact of FLT3 mutations on primary human haematopoietic progenitor cells, 
a lentiviral system for CD34+ cell transduction was developed. However, despite 
numerous attempts at optimisation, transduction efficiencies were low. Nevertheless, 
transduction was sufficient to allow some observations. Firstly, neither the presence of a 
FLT3/ITD nor a FLT3/TKD mutation led to factor-independent proliferation of CD34+ 
cells in cytokine-free liquid culture. Previous studies had shown that expression of 
FLT3/ITD in CD34+cells leads to a proliferative advantage over WT-transduced cells 
using stromal co-culture assays, suggesting that additional signals are required in 
primary cells in addition to those downstream of a FLT3/ITD (Chung et al, 2005, 
Moore et al, 2007). Another study had shown that in a liquid culture system of FLT3-
transduced cells, further cytokines are required such as thrombopoietin and SCF in 
addition to the FLT3 signalling in order to allow cell survival and proliferation (Li et al,  
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2007). Despite the lack of factor-independent proliferation in the absence of other 
cytokines in the present studies, expression of FLT3 did to lead to an increase in the 
percentage of GFP-positive cells with time, although this did not differ between 
FLT3/WT, TKD and ITD-expressing cells. These findings should be interpreted with 
caution, however, in view of the increase in the percentage of GFP-expressing vector-
transduced cells, as they may simply relate to an increase in autofluoresence with time, 
regardless of the presence of a FLT3 mutation. The expression of a FLT3/ITD did lead 
to a significant increase in the number of colony forming units that were able to survive 
for 1 or 2 weeks in cytokine-free liquid culture. It is possible that the different effects of 
FLT3/ITD and FLT3/TKD mutations on cell survival, proliferation and differentiation 
may explain these observations. However, in view of the poor transduction efficiency in 
the experiments described in this chapter, a more reliable system for transduction of 
human CD34+ cells will be required in order to allow more systematic study of the 
impact of FLT3 mutations in primary human cells. 
 
In conclusion, the data presented in this chapter provides a number of a number of lines 
of evidence in multiple cell line and primary cell model systems that FLT3/ITDs lead to 
a stronger survival and proliferative signal than occurs as a result of a FLT3/TKD. In 
these studies, FLT3/TKDs confer similar signalling as that of FL-stimulated FLT3/WT 
cells whereas FLT3/ITD signalling was more akin to that of IL3 stimulated cells. These 
studies also confirmed previous observations that FLT3/ITDs induce a myeloid 
differentiation block. Conversely, however, FLT3/TKDs that appeared to promote 
haematopoietic cell differentiation. Whether these differences occur as a result of the 
observed differential activation of STAT5A by the two mutations remains to be 
established. Furthermore, exactly how these observations relate to the clinical 
differences observed between FLT3/ITDs and FLT3/TKD mutations remains unclear. 
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8  19BUCHAPTER 8: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Despite significant improvements in the treatment of young adults with AML over the 
last few decades, outcome is still unsatisfactory with only approximately 40-50% of 
patients alive and disease-free after 5 years. As described in Chapter 1, risk stratification 
according to cytogenetics and clinical factors allows a degree of risk-adapted therapy in 
current protocols, enabling selection of higher risk patients for more intensive therapy. 
However, these prognostic groups include patients with markedly heterogeneous 
diseases and consequently, in many cases, useful information to guide treatment is not 
available. Improved understanding of the role of molecular abnormalities in AML may 
allow further dissection of these risk groups and more accurate risk stratification. 
Furthermore, this may also provide insights into the biology of AML and improve 
therapeutic strategies in the future. Whilst the presence of a FLT3/ITD is known to 
predict adverse outcome in young adults with AML, the clinical significance of 
FLT3/TKD mutations is unclear. In order to address this issue, the studies described in 
this thesis compared and contrasted the incidence (Chapter 3) and clinical associations 
(Chapters 4 and 5) of FLT3/TKD mutations with those of FLT3/ITDs in a large cohort 
of young adult patients with AML treated on the MRC AML 10 and 12 trials. The 
impact of FLT3 inhibitors according to FLT3 mutations status (Chapter 6) and the 
biological impact of different FLT3 mutations in vitro (Chapter 7) was also assessed. In 
the present Chapter, the main findings of these studies will be briefly summarised and 
possible directions for future studies highlighted. 
 
The dHPLC-based method for the detection of FLT3/TKD mutations (Chapter 3) was 
shown to be a highly sensitive technique, capable of detecting FLT3/TKD mutations 
present in as few as 5% of FLT3 alleles. This technique was also shown to be superior 
to the commonly used EcoRV restriction digest technique as evidenced by 17 cases 
(11% of all mutant-positive cases) that were mutant by dHPLC but WT by EcoRV 
digestion. The dHPLC method also had the advantage that the chromatogram trace 
readily allowed identification of the type of mutation (Figure 3.5). Therefore, a cohort 
of 1339 young adults with AML from the UK MRC AML trials was screened for 
FLT3/TKD mutations using this dHPLC technique. Mutations were detected in 161 
cases (12%).  
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There were a number of significant differences observed when the clinical 
characteristics and outcome of these FLT3/TKD mutant-positive cases was compared 
with FLT3/ITD positive cases (Chapter 4). For example, there was a high incidence of 
FLT3/TKD mutations in patients with inv(16) (13 of 55 patients, 24%, P=.009), a 
cytogenetic group in which FLT3/ITDs are uncommon. Strikingly, the clinical outcome 
of patients with FLT3/TKD mutations and FLT3/ITDs was markedly different, with 
FLT3/TKD mutations associated with a favourable long-term outcome in contrast with 
the adverse outcome associated with FLT3/ITDs. For example, the CIR at 10 years was 
46% for FLT3 WT patients, 37% for FLT3/ITD
-TKD
+ patients, 62% for 
FLT3/ITD
+TKD
- patients and 68% for FLT3/ITD
+TKD
+ patients. OS for these groups 
was 36%, 51%, 24% and 37% respectively (P<.001 for FLT3/ITD
-TKD
+ versus 
FLT3/ITD
+TKD
- patients).  
 
FLT3/TKD mutation screening by dHPLC also revealed marked variability in the 
amount of heteroduplex that was present in FLT3/TKD
+ cases, most likely reflecting 
variability of FLT3/TKD mutant levels. Furthermore, analysis of FLT3/ITD mutations 
has shown that the relative level of mutant and WT alleles varies widely in AML and 
correlates with clinical characteristics and outcome (Gale et al, 2007). Therefore, the 
relative mutant level in FLT3/TKD
+ cases was quantified (Chapter 5). The distribution 
of mutant levels was different to that of FLT3/ITDs. Cases with a very high level of 
mutation (>50% of total FLT3 alleles) were less common for FLT3/TKD mutations 
(9%) than for FLT3/ITDs (approximately 15%). Furthermore, only 2 (2%) cases had 
FLT3/TKD mutant levels greater than 75% compared with 8% for FLT3/ITDs. 
Conversely, low level mutants (≤25% of total FLT3 alleles) were more frequent for 
FLT3/TKDs, accounting for approximately 50% of mutant-positive patients compared 
with 29% of FLT3/ITDs. There was also a highly significant inverse relationship 
between the presence of high level FLT3/TKD and FLT3/ITD mutations, which never 
occurred together (P<.001).  
 
Stratification of the cohort according to FLT3/TKD mutant level and clinical 
characteristics at presentation showed that high level mutants (>25% total FLT3 alleles) 
were associated with a high WBC at presentation, whereas low level mutants had a 
WBC that was similar to that of FLT3/WT patients. The favourable outcome of 
FLT3/TKD mutants described in Chapter 4 was mostly attributable to patients with a 
high level of mutant. Lower level mutant-positive patients had an outcome that was  
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very similar to that of FLT3/WT patients. For example, patients with a high level 
mutant had an OS at 10 years of 59% compared to 37% in patients with a lower level 
mutant and 33% in patients without a FLT3/TKD mutation. This difference remained 
significant in multivariate analysis (P=.004). 
 
The marked differences observed between FLT3/TKD mutations and FLT3/ITDs raised 
the possibility that the in vitro and in vivo effects of FLT3 inhibitors may also differ 
according to the mechanism of FLT3 activation. The in vitro cytotoxic impact of 
lestaurtinib, a FLT3 inhibitor currently in phase III clinical trials, was therefore assessed 
(Chapter 6). Primary leukaemic blast cells from FLT3/ITD-positive patients were more 
sensitive to the cytotoxic effects of lestaurtinib than cells with a FLT3/TKD mutation. 
Interestingly, patients with a very high level FLT3/ITD mutation, associated with a 
particularly adverse prognosis, were particularly sensitive to lestaurtinib induced 
cytotoxicity. There was, however, no difference in the sensitivity of cells to cytarabine 
when stratified according to FLT3 mutation status. The concurrent incubation of 
lestaurtinib with cytarabine led to synergistic cytotoxicity. This synergistic cytotoxic 
effect did not differ when blast cells were incubated with cytarabine and lestaurtinib 
concurrently or sequentially.  
 
In order to explore the possibility that the clinical differences between FLT3/TKD 
mutations and FLT3/ITDs relate directly to differential signalling events, a number of in 
vitro cell model systems were developed (Chapter 7). Different FLT3 constructs were 
introduced into 32Dcl3, Ba/F3, NB4 cell lines and primary human CD34+ peripheral 
blood mobilised cells. In 32Dcl3 and Ba/F3 cells, a FLT3/ITD led to a stronger 
proliferative drive than a FLT3/TKD mutation. In an NB4 cell line model of ATRA-
induced myeloid differentiation, a FLT3/ITD inhibited differentiation unlike a 
FLT3/TKD mutation which increased differentiation. Furthermore, transduction of 
human, CD34+ HSCs with a FLT3/ITD led to increased cytokine-free survival of 
colony forming cells, unlike a FLT3/TKD which did not differ from WT. Signalling 
studies also revealed differences, with a FLT3/ITD leading to stronger STAT5 
activation than a FLT3/TKD mutation or FL stimulation of FLT3/WT. In summary, the 
functional impact of a FLT3/TKD mutation was similar to that of FL-stimulated 
FLT3/WT cells whereas FLT3/ITD signalling was more akin to that of IL3-stimulated 
cells. 
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8.1  52BUFuture directions 
 
The incidence of FLT3/TKD mutations that were detected in the present cohort was 
higher than has been described in most other studies examining different cohorts. Whilst 
it is possible that this was due to the increased sensitivity of the dHPLC technique, as 
well as the detection of mutations that occur outside the EcoRV digest site, it is also 
possible that this difference relates to a high proportion of cases of AML with a high 
presenting WBC that are stored in the MRC AML gDNA bank, hence biasing towards 
inclusion of FLT3/TKD mutant-positive patients. Ongoing studies of AML15 samples, 
using the dHPLC technique will address this question as samples are obtained from a 
very high proportion of all cases and analysis of these samples will, therefore, not be 
subject to a similar bias. Indeed, preliminary results suggest that the incidence of 
FLT3/TKD mutations is lower in these samples. 
 
Whilst the difference in prognosis between FLT3/ITD and FLT3/TKD mutant-positive 
patients was statistically highly significant, the favourable prognosis of FLT3/TKD 
mutant-positive cases of AML in comparison with FLT3/WT cases requires further 
confirmation, as very different observations have been reported for other cohorts 
(Chapter 4). Whilst it is possible that differences between the present and other studies 
could be partly due to the different screening techniques used, it seems unlikely that this 
could wholly account for the contrasting results. An important factor relating to these 
differences may be heterogeneity of patient cohorts studied with regards to inclusion 
criteria, and also treatment protocols. For example, it is noteworthy that cases with a 
favourable inv(16) karyotype were over-represented in the FLT3/TKD mutant-positive 
group in the present cohort, although this was also the case in some, but not all, the 
other cohorts (Chapter 4). However, despite this, when stratified into different 
cytogenetic categories, the favourable prognosis of FLT3/TKD mutations remained 
statistically significant within the intermediate cytogenetic category (Figure 4.2B), 
although, in multivariate analysis the favourable prognosis was only of borderline 
statistical significance. It is also likely that other molecular abnormalities will also 
influence the clinical outcome of the patients studied, particularly within this crucial 
intermediate cytogenetic category, and information on some known interacting 
molecular abnormalities was not available in this analysis. For example, NPM1 and 
CEBPA mutations are frequent in NK patients, are known to coexist with both 
FLT3/TKD mutations and FLT3/ITDs and, importantly, are both associated with a  
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favourable prognosis in AML. It will be important, therefore, to re-analyse the 
FLT3/TKD mutation data when information with regards to these molecular 
abnormalities becomes available. It would be particularly interesting to examine a 
population of NK-AML patients with an NPM1 mutation stratified according to FLT3 
mutation status. Within these groups of patients, the impact of the different FLT3 
mutations could be studied in the absence of a number of some of the other confounding 
variables.  
 
The lack of an adverse outcome associated with FLT3/TKD mutations is of direct 
clinical relevance as some centres are selecting patients for allogeneic transplantation in 
first remission on the basis of the presence of a FLT3/ITD (Litzow 2005). In the 
absence of other poor prognostic factors, this might not be appropriate in patients with 
FLT3/TKDs. The finding of a markedly different clinical outcome associated with 
activating mutations of the same gene also has broader implications for molecular 
screening as these data would suggest that mutations of the same gene should only be 
grouped together with caution and, where possible, after heterogeneity in clinical and 
biological characteristics has been addressed. Dissecting out the specific clinical 
associations of each type of mutation is challenging, particularly in view of the 
relatively low incidence of many mutations as well as the increasing number of different 
mutations being reported. However, the risk of misinterpreting data and consequently 
inappropriately treating patients on the basis of these results must also be taken into 
account. 
 
Assessment of the relative mutant level as described in Chapter 5 not only provides 
additional clinically relevant information but also can further assist in understanding the 
role of these mutations in AML biology. With the advent of genome-wide approaches to 
mutation detection using next generation sequencing technology (Ley et al, 2008), it 
will become increasingly important to dissect mutations that are clinically and/or 
biologically ‘important’ from other mutations. However, determining approaches that 
allow the identification of the ‘important’ mutations is not straightforward. For 
example, mutations may occur in cancer cells as primary events i.e. essential for cancer 
cell propagation, or as secondary events that may contribute to disease phenotype at a 
later stage in oncogenesis. Furthermore, it has been suggested that some mutations may 
be ‘passenger’ rather than ‘driver’ events that do not contribute significantly to 
pathogenesis of the cancer but are incidentally selected for. It should be noted, however,  
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that this does not necessitate that these ‘passenger’ events are biologically insignificant, 
although this has been used as a strategy to differentiate ‘passenger’ from ‘driver’ 
mutations (Frohling et al, 2007). Furthermore, the degree to which the concepts of 
‘primary versus secondary’ and ‘passenger versus driver’ mutations overlap is not clear. 
Measurement of mutant level can contribute significantly to these issues. For example, 
as discussed in Chapter 6, higher mutant levels are likely to correlate with mutations 
that are acquired as earlier events in leukaemogenesis. Conversely, low level mutations 
are likely to be present in only a subclone of the leukaemic cells, and therefore a 
secondary event. The data presented in Chapter 6, therefore, would suggest that 
FLT3/TKDs occur more frequently as late or secondary events compared with 
FLT3/ITDs. Moreover, although FLT3/ITD and FLT3/TKD ‘dual mutant’ cases can be 
detected, at a biological level these data would suggest that the two different mutations 
are unlikely to both occur as early events.   
 
Whether mutant level is helpful in the differentiation of driver versus passenger 
mutations is less clear. On the one hand it could be argued that passenger mutations are 
likely to be high level if they have incidentally occurred in the cell that initially 
undergoes transformation to leukaemia. Alternatively, if leukaemic cells are gradually 
acquiring secondary events at an increasing rate over time due to increasing genomic 
instability, the occurrence of passenger events will also increase. It is, however, difficult 
to design studies to directly address these issues. Whilst it would be biologically 
interesting to observe the natural history of low level mutations over time, as most 
young patients are treated with cytotxic agents at diagnosis, such samples are not 
available. An alternative would be to study the dynamics of engraftment of these low-
level mutants following xenotransplantation. It may be that some, or even the majority, 
of the low-level FLT3/TKD mutations would disappear from the leukaemic clone 
altogether, having occurred as an incidental event in a leukaemic cell without long-term 
self-renewal properties. The presentation/relapse studies (Chapter 5), where all low 
level mutations were lost at relapse, would be consistent with this hypothesis. A related 
study would be to sort leukaemic cells according to the surface expression of different 
antigens and examine the level of mutant within different BM stem cell and progenitor 
subpopulations, e.g. according to CD34, CD38 and FLT3 expression. Determining the 
populations of cells within the BM that contain the mutations, and also those that do 
not, may provide new therapeutic opportunities whereby the LSC could be targeted 
leaving the HSC intact.  
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As the study of mutant level can provide valuable information in addition to mutant 
detection alone, it could be proposed that an assessment of the mutant level is important 
for all mutation detection in cancer, although a prerequisite for this kind of analysis is 
that non-malignant cells only constitute a small proportion of the sample. Furthermore, 
‘cut-off’ mutant levels would need to be standardised before this information could be 
incorporated into clinical protocols. Whether the benefit of such analyses outweight the 
costs incurred by the additional complexity of analysis is likely to differ depending on 
the context.  
 
The differential sensitivity of different FLT3 mutations to lestaurtinib (Chapter 6) is of 
relevance to ongoing clinical studies using FLT3 inhibitors in patients with FLT3-
mutated AML. These data suggest that FLT3/TKD mutant-positive patients should not 
be differentiated from those with FLT3/WT and both groups may benefit from FLT3 
inhibitor therapy. Despite this, many trials currently exclude FLT3/WT patients. 
Clearly, however, the most important issue is the clinical outcome of patients treated 
with FLT3 inhibitors. With a number of large phase III studies currently underway, this 
question should be addressed in the near future. The most effective sequence for 
administration of FLT3 inhibitors in combination with cytotoxic chemotherapeutic 
agents also remains unclear. A widely held view is that the two different classes of 
agent should be used in sequence rather than concurrently, mainly due to results 
obtained from cell line studies (see Chapter 6). This is due to the concern that FLT3 
may be driving proliferation and, therefore, inhibition of FLT3 will reduce the 
proliferation rate of leukaemic blast cells and hence reduce the cytotoxic impact of cell 
cycle-dependent agents. However, the crucial role of FLT3 inhibitors may actually be to 
inhibit anti-apoptotic signalling in the LSC population. These LSCs are thought to be 
relatively resistant to cell cycle-specific agents such as cytarabine due to an inherent 
low rate of proliferation, paralleling their normal HSC counterparts. If this were the case 
then concurrent administration of FLT3 inhibitors with chemotherapy would be the 
most sensible approach, as the benefit of inhibition of anti-apoptotic signalling would 
outweight the risk of inhibiting cell proliferation in an already relatively quiescent cell. 
This issue is worthy of further investigation in appropriate animal models in order to 
maximise the impact of anti-FLT3 therapies against the LSC population. 
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Chapter 7 explored the functional consequences of the different types of FLT3 
mutation. It is possible that the increased proliferative drive and survival signalling that 
were associated with a FLT3/ITD directly relate to the increased chemoresistance 
observed in the FLT3/ITD-positive patient group. In addition to this, the increased 
differentiation of NB4 cells transduced with a FLT3/TKD mutation in contrast to 
impaired differentiation induced by expression of a FLT3/ITD was a novel finding. In 
the light of this, it would be interesting to explore the impact of ATRA on FLT3/TKD 
mutant-positive patients with AML who received this agent as part of the MRC trials as 
it is possible that they may selectively benefit from this therapy. Whether the 
differences between FLT3/ITDs and FLT3/TKD mutations directly related to the 
differential activation of STAT5, however, was not directly addressed in these studies. 
As STAT5 activation has been shown to be associated with impaired myeloid 
differentiation (Wierenga et al, 2006), it would be interesting to explore this further, for 
example, by studying the impact of FLT3 mutations on a STAT5A null background.  
 
It should be noted, however, that viral transduction of cell-lines creates a highly 
artificial system that is, in many ways, far removed from AML pathogenesis. In an 
attempt to partly address these limitations, primary human haematopoietic cells were 
lentivirally transduced with different FLT3 constructs. However, the low transduction 
efficiency precluded more detailed study of these transduced cells beyond the described 
cytokine-free survival studies. This low transduction efficiency may reflect toxicity 
induced by unregulated expression of an activated oncogene in primary human cells. It 
may be, for instance, that the mutations causing AML are required to occur in a 
particular sequence with, for example, an NPM1 mutation being permissive for a cell to 
tolerate the presence of activated FLT3. This is clearly speculative, and in order to 
dissect these, and other, pathogenic mechanisms in AML, it will be essential to develop 
models of AML that more closely recapitulate the role of different mutations, including 
FLT3 mutations, in AML.  
 
Viral transduction of murine haematopoietic cells followed by transplantation into 
recipient mice is a common strategy for the study of the impact of different mutations in 
vivo. It is important, however, to understand the limitations of this approach. First, viral 
transduction studies are complicated by the very high level of expression of the 
transgene which may not reflect the pathophysiological situation. As over-expression of 
FLT3/WT may alone contribute to leukaemogenesis, this is clearly of importance.  
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Second, insertional mutagenesis may contribute to virally transduced murine models of 
FLT3 mutations with unpredictable consequences induced by insertion of the viral 
promoter in close proximity to other oncogenes. Third, as in the majority of cases the 
whole BM compartment is transduced using these approaches, they do not contribute to 
understanding the possible target cell of transformation. Conditional knock-in of FLT3 
mutations at their physiological locus, for example using a Cre-Lox approach, would go 
some way to addressing a number of these pitfalls. As it is essential to understand how 
mutations collaborate, the sequential or concurrent introduction of collaborating 
mutations is also important to study, perhaps using a combination of conditional knock-
in of one mutation followed by viral transduction of another. With regards to 
FLT3/TKD mutations, NPM1 mutations and inv(16) are the most common, known 
collaborating genetic events, and are worthy of further study. Finally, it is possible that 
murine cells will respond to mutations in different ways to human cells. As it has now 
been shown to be possible to recapitulate human leukaemia using viral transduction 
strategies (Barabe et al, 2007), it would be interesting to try to reproduce these findings 
using a combination of different collaborating mutations, e.g. a FLT3 mutation and an 
NPM1 mutation. This would thereby provide a powerful model for the study of AML 
biology and therapy. 
 
8.2  53BUConclusions 
 
In conclusion, this thesis has described the distinct clinical and biological characteristics 
of FLT3/TKD mutations in AML in comparison with FLT3/ITDs. These findings not 
only provide a number of novel avenues for future studies but are also of direct clinical 
relevance to current clinical decision making in patients with AML. As such this work 
represents a significant contribution to current understanding of the role of FLT3 
mutations in AML. 
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